<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004685.pub3" GROUP_ID="SKIN" ID="823002090911193635" MERGED_FROM="" MODIFIED="2016-05-11 10:33:23 +0100" MODIFIED_BY="Laura Prescott" REVIEW_NO="#49" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2016-05-11 10:33:23 +0100" MODIFIED_BY="Laura Prescott">
<TITLE>Systemic antifungal therapy for tinea capitis in children</TITLE>
<CONTACT MODIFIED="2016-05-11 10:33:23 +0100" MODIFIED_BY="Laura Prescott"><PERSON ID="51612545277580292628101201101251" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Min</FIRST_NAME><LAST_NAME>Zhang</LAST_NAME><POSITION>Associate professor</POSITION><EMAIL_1>hxlily@163.com</EMAIL_1><EMAIL_2>lily666@medmail.com.cn</EMAIL_2><ADDRESS><DEPARTMENT>Department of Dermatology &amp; Venereology</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 18980601870</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-05-11 10:33:23 +0100" MODIFIED_BY="Laura Prescott"><PERSON ID="F97E64B782E26AA200FFCE21B8EB0170" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Xiaomei</FIRST_NAME><LAST_NAME>Chen</LAST_NAME><EMAIL_1>chenmeir@sohu.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Dermatology &amp; Venereology</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 898 78601</PHONE_1></ADDRESS><FOOTNOTE>Joint first author</FOOTNOTE></PERSON><PERSON ID="z1409171644516258842565733471990" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Xia</FIRST_NAME><LAST_NAME>Jiang</LAST_NAME><EMAIL_1>summer0701@outlook.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Dermatology &amp; Venereology</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>155 2827 6098</PHONE_1></ADDRESS><FOOTNOTE>Joint first author</FOOTNOTE></PERSON><PERSON ID="19153" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ming</FIRST_NAME><LAST_NAME>Yang</LAST_NAME><POSITION>Attending Physician</POSITION><EMAIL_1>yangmier@gmail.com</EMAIL_1><EMAIL_2>yangmier@126.com</EMAIL_2><MOBILE_PHONE>+86 13981962309</MOBILE_PHONE><ADDRESS><DEPARTMENT>Center of Geriatrics and Gerontology</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Lane</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 8542 3234</PHONE_1><FAX_1>+86 28 8542 2321</FAX_1></ADDRESS></PERSON><PERSON ID="6021" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Urbà</FIRST_NAME><LAST_NAME>González</LAST_NAME><EMAIL_1>ugonzalez@goandfer.es</EMAIL_1><ADDRESS><DEPARTMENT>Unit of Dermatology</DEPARTMENT><ORGANISATION>CL&#314;NICA GO&amp;FER</ORGANISATION><ADDRESS_1>Riera Blanca 6-8, L´Hospitalet</ADDRESS_1><CITY>Barcelona</CITY><ZIP>08903</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 606259718</PHONE_1></ADDRESS></PERSON><PERSON ID="C55601F782E26AA2013849DFAFD68666" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Xiufang</FIRST_NAME><LAST_NAME>Lin</LAST_NAME><POSITION>Attending physician</POSITION><EMAIL_1>sitaning00@163.com</EMAIL_1><EMAIL_2>sitaning@medmail.com.cn</EMAIL_2><ADDRESS><DEPARTMENT>Center of Geriatrics and Gerontology</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 8542 2326</PHONE_1></ADDRESS></PERSON><PERSON ID="z1409171635097533921049766812232" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Xia</FIRST_NAME><LAST_NAME>Hua</LAST_NAME><POSITION>Doctor</POSITION><EMAIL_1>Hua3226@163.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Dermatology &amp; Venereology</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>18382098651</PHONE_1></ADDRESS></PERSON><PERSON ID="C96BD29682E26AA201F33AEF05E7F716" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Siliang</FIRST_NAME><LAST_NAME>Xue</LAST_NAME><POSITION>MSc</POSITION><EMAIL_1>xuesiliang@163.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Dermatology &amp; Venereology</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 139 8226 2622</PHONE_1><PHONE_2>+86 28 8543 7365</PHONE_2><FAX_1>+86 28 8542 2310</FAX_1></ADDRESS></PERSON><PERSON ID="51612545277580292628101201101251" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Min</FIRST_NAME><LAST_NAME>Zhang</LAST_NAME><POSITION>Associate professor</POSITION><EMAIL_1>hxlily@163.com</EMAIL_1><EMAIL_2>lily666@medmail.com.cn</EMAIL_2><ADDRESS><DEPARTMENT>Department of Dermatology &amp; Venereology</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 18980601870</PHONE_1></ADDRESS></PERSON><PERSON ID="828110F882E26AA200E51E67E25FC1CF" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Cathy</FIRST_NAME><LAST_NAME>Bennett</LAST_NAME><POSITION>Visiting Professor</POSITION><EMAIL_1>info@systematicresearch.uk</EMAIL_1><EMAIL_2>cmt.bennett@ntlworld.com</EMAIL_2><ADDRESS><DEPARTMENT>Centre for Technology Enabled Health Research (CTEHR)</DEPARTMENT><ORGANISATION>Coventry University</ORGANISATION><ADDRESS_1>Priory Street</ADDRESS_1><CITY>Coventry</CITY><ZIP>CV1 5FB</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-05-03 16:53:31 +0100" MODIFIED_BY="Laura Prescott ">
<UP_TO_DATE>
<DATE DAY="23" MONTH="11" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="11" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="23" MONTH="11" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-05-04 16:54:58 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-05-04 15:54:56 +0100" MODIFIED_BY="Laura Prescott ">
<DATE DAY="4" MONTH="5" YEAR="2016"/>
<DESCRIPTION>
<P>We included 4 new randomised controlled trials in this update, which changed some of the main results</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2016-05-04 16:54:58 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="5" YEAR="2016"/>
<DESCRIPTION>
<P>The conclusions of the previous version of the review have been altered</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-05-11 10:31:25 +0100" MODIFIED_BY="Laura Prescott ">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-05-11 10:31:25 +0100" MODIFIED_BY="Laura Prescott ">
<DATE DAY="21" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="22" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-21 15:23:53 +0100" MODIFIED_BY="Cathy Bennett">
<DATE DAY="30" MONTH="5" YEAR="2007"/>
<DESCRIPTION>
<P>Minor update</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-06-18 16:04:54 +0100" MODIFIED_BY="Laura E Prescott">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Spanish Society of Dermato-Epidemiology and Evidence-based Dermatology (SEDE-DBE) and Clínica Plató, Barcelona</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2015-06-18 16:04:54 +0100" MODIFIED_BY="Laura E Prescott">
<SOURCE>
<NAME>Cochrane Child Health Field. Alberta Research Centre for Child Health Evidence, University of Alberta</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2015-06-18 16:04:54 +0100" MODIFIED_BY="Laura E Prescott">
<NAME>The National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The NIHR, UK, is the largest single funder of the Cochrane Skin Group.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-05-11 10:30:00 +0100" MODIFIED_BY="Laura Prescott ">
<SUMMARY MODIFIED="2016-05-04 17:01:01 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2015-11-04 11:58:48 +0000" MODIFIED_BY="Finola  M Delamere">Antifungal medicines for treating children with ringworm</TITLE>
<SUMMARY_BODY MODIFIED="2016-05-04 17:01:01 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>
</P>
<P>Tinea capitis, or ringworm, is a fungal infection of the scalp caused mainly by two species of fungi called <I>Trichophyton</I> and <I>Microsporum</I>. It is common in children. Most fungal infections can be treated with antifungal creams applied directly to the skin (topical treatments). However, because the fungal infection is found at the root of the hair follicles, where topical treatments cannot reach, tinea capitis always requires medication administered by mouth so that the treatment spreads throughout the entire body (systemic treatments). There are several different types of antifungal medicines available.</P>
<P>
<B>Review question</B>
</P>
<P>Which antifungal medicine is best for treating ringworm on the scalp in children?</P>
<P>
<B>Study characteristics</B>
</P>
<P>In November 2015, we searched for studies that used the gold standard design for clinical trials (randomised controlled trials) of antifungal treatments taken by mouth. We found 25 studies in which 4449 children under 18 years (4 studies with 2637 children were new to this update) had taken part.</P>
<P>
<B>Key results</B>
</P>
<P>With respect to complete cure (both cure of the infection and visible cure (i.e. fungal and clinical cure) low to moderate quality evidence suggests that newer treatments such as terbinafine, itraconazole and fluconazole are at least as good as griseofulvin, the usual treatment in children with tinea capitis caused by <I>Trichophyton</I> infections. However, new evidence in this update suggests that terbinafine may have better effects than griseofulvin for completely curing children with <I>T. tonsurans</I> infection. By contrast, in children with <I>Microsporum</I> infections, new evidence seems to indicate that griseofulvin is more effective than terbinafine.</P>
<P>Terbinafine, itraconazole and fluconazole appear to have similar effects in terms of the proportion of participants achieving complete cure, whereas ketoconazole appears to be less effective than griseofulvin for children with tinea capitis caused by <I>Trichophyton</I> species. However, the quality of this evidence is low. With some interventions, the proportion with complete clinical cure was in excess of 90% (e.g. one study of terbinafine versus griseofulvin for <I>Trichophyton</I> infections), but in many of the comparisons tested, the proportion cured was much lower.</P>
<P>The included studies reported on negative side effects, which were similarly mild and reversible for terbinafine, griseofulvin, itraconazole, ketoconazole and fluconazole. They included skin-specific effects such as itching as well as abdominal discomfort, headache and nausea.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>The quality of the evidence in this review was generally low to moderate, so further research is likely to have an important effect on our confidence in these results. Some evidence was even of very low quality. We still need more and better evidence to help us understand the effectiveness and adverse events of systemic antifungal drugs for tinea capitis in children.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-05-04 16:54:25 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-11-04 12:05:58 +0000" MODIFIED_BY="Finola  M Delamere">
<P>Tinea capitis is a common contagious fungal infection of the scalp in children. Systemic therapy is required for treatment and to prevent spread. This is an update of the original Cochrane review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-11-04 11:53:45 +0000" MODIFIED_BY="Finola  M Delamere">
<P>To assess the effects of systemic antifungal drugs for tinea capitis in children.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-05-03 13:17:05 +0100" MODIFIED_BY="[Empty name]">
<P>We updated our searches of the following databases to November 2015: the Cochrane Skin Group Specialised Register, CENTRAL (2015, Issue 10), MEDLINE (from 1946), EMBASE (from 1974), LILACS (from 1982), and CINAHL (from 1981). We searched five trial registers and checked the reference lists of studies for references to relevant randomised controlled trials (RCTs). We obtained unpublished, ongoing trials and grey literature via correspondence with experts in the field and from pharmaceutical companies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-04-26 08:37:14 +0100" MODIFIED_BY="[Empty name]">
<P>RCTs of systemic antifungal therapy in children with normal immunity under the age of 18 with tinea capitis confirmed by microscopy, growth of fungi (dermatophytes) in culture or both.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-11-04 11:54:12 +0000" MODIFIED_BY="Finola  M Delamere">
<P>We used standard methodological procedures expected by Cochrane.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-04-29 12:47:39 +0100" MODIFIED_BY="[Empty name]">
<P>We included 25 studies (N = 4449); 4 studies (N = 2637) were new to this update.</P>
<P>Terbinafine for four weeks and griseofulvin for eight weeks showed similar efficacy for the primary outcome of complete (i.e. clinical and mycological) cure in three studies involving 328 participants with <I>Trichophyton </I>species infections (84.2% versus 79.0%; risk ratio (RR) 1.06, 95% confidence interval (CI) 0.98 to 1.15; low quality evidence).</P>
<P>Complete cure with itraconazole (two to six weeks) and griseofulvin (six weeks) was similar in two studies (83.6% versus 91.0%; RR 0.92, 95% CI 0.81 to 1.05; N = 134; very low quality evidence). In two studies, there was no difference between itraconazole and terbinafine for two to three weeks treatment (73.8% versus 78.8%; RR 0.93, 95% CI 0.72 to 1.19; N = 160; low quality evidence). In three studies, there was a similar proportion achieving complete cured with two to four weeks of fluconazole or six weeks of griseofulvin (41.4% versus 52.7%; RR 0.92, 95% CI 0.81 to 1.05; N = 615; moderate quality evidence). Current evidence for ketoconazole versus griseofulvin was limited. One study favoured griseofulvin (12 weeks) because ketoconazole (12 weeks) appeared less effective for complete cure (RR 0.76, 95% CI 0.62 to 0.94; low quality evidence). However, their effects appeared to be similar when the treatment lasted 26 weeks (RR 0.95, 95% CI 0.83 to 1.07; low quality evidence). Another study indicated that complete cure was similar for ketoconazole (12 weeks) and griseofulvin (12 weeks) (RR 0.89, 95% CI 0.57 to 1.39; low quality evidence). For one trial, there was no significant difference for complete cure between fluconazole (for two to three weeks) and terbinafine (for two to three weeks) (82.0% versus 94.0%; RR 0.87, 95% CI 0.75 to 1.01; N = 100; low quality evidence). For complete cure, we did not find a significant difference between fluconazole (for two to three weeks) and itraconazole (for two to three weeks) (82.0% versus 82.0%; RR 1.00, 95% CI 0.83 to 1.20; low quality evidence).</P>
<P>This update provides new data: in children with <I>Microsporum</I> infections, a meta-analysis of two studies found that the complete cure was lower for terbinafine (6 weeks) than for griseofulvin (6-12 weeks) (34.7% versus 50.9%; RR 0.68, 95% CI 0.53 to 0.86; N = 334; moderate quality evidence). In the original review, there was no significant difference in complete cure between terbinafine (four weeks) and griseofulvin (eight weeks) in children with <I>Microsporum</I> infections in one small study (27.2% versus 60.0%; RR 0.45, 95% CI 0.15 to 1.35; N = 21; low quality evidence).</P>
<P>One study provides new evidence that terbinafine and griseofulvin for six weeks show similar efficacy (49.5% versus 37.8%; RR 1.18, 95% CI 0.74 to 1.88; N = 1006; low quality evidence). However, in children infected with <I>T. tonsurans</I>, terbinafine was better than griseofulvin (52.1% versus 35.4%; RR 1.47, 95% CI 1.22 to 1.77; moderate quality evidence). For children infected with <I>T. violaceum, </I>these two regimens have similar effects (41.3% versus 45.1%; RR 0.91, 95% CI 0.68 to 1.24; low quality evidence). Additionally, three weeks of fluconazole was similar to six weeks of fluconazole in one study in 491 participants infected with <I>T. tonsurans</I> and <I>M. canis</I> (30.2% versus 34.1%; RR 0.88, 95% CI 0.68 to 1.14; low quality evidence).</P>
<P>The frequency of adverse events attributed to the study drugs was similar for terbinafine and griseofulvin (9.2% versus 8.3%; RR 1.11, 95% CI 0.79 to 1.57; moderate quality evidence), and severe adverse events were rare (0.6% versus 0.6%; RR 0.97, 95% CI 0.24 to 3.88; moderate quality evidence). Adverse events for terbinafine, griseofulvin, itraconazole, ketoconazole, and fluconazole were all mild and reversible.</P>
<P>All of the included studies were at either high or unclear risk of bias in at least one domain. Using GRADE to rate the overall quality of the evidence, lower quality evidence resulted in lower confidence in the estimate of effect.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-05-04 16:54:25 +0100" MODIFIED_BY="[Empty name]">
<P>Newer treatments including terbinafine, itraconazole and fluconazole are at least similar to griseofulvin in children with tinea capitis caused by <I>Trichophyton </I>species. Limited evidence suggests that terbinafine, itraconazole and fluconazole have similar effects, whereas ketoconazole may be less effective than griseofulvin in children infected with <I>Trichophyton</I>. With some interventions the proportion achieving complete clinical cure was in excess of 90% (e.g. one study of terbinafine or griseofulvin for <I>Trichophyton</I> infections), but in many of the comparisons tested, the proportion cured was much lower.</P>
<P>New evidence from this update suggests that terbinafine is more effective than griseofulvin in children with <I>T. tonsurans</I> infection.</P>
<P>However, in children with <I>Microsporum</I> infections, new evidence suggests that the effect of griseofulvin is better than terbinafine. We did not find any evidence to support a difference in terms of adherence between four weeks of terbinafine versus eight weeks of griseofulvin. Not all treatments for tinea capitis are available in paediatric formulations but all have reasonable safety profiles.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-05-10 09:35:35 +0100" MODIFIED_BY="Laura Prescott ">
<BACKGROUND MODIFIED="2016-05-03 11:28:03 +0100" MODIFIED_BY="[Empty name]">
<P>This is an updated version of an original Cochrane review (<LINK REF="REF-Gonzalez-2007" TYPE="REFERENCE">Gonzalez 2007</LINK>).</P>
<CONDITION MODIFIED="2016-05-03 11:28:03 +0100" MODIFIED_BY="[Empty name]">
<P>Tinea capitis is the medical term for an infection of the scalp (also known as scalp ringworm) involving the skin and the hair (<LINK REF="REF-Higgins-2000" TYPE="REFERENCE">Higgins 2000</LINK>). It is caused by fungi (dermatophytes), mainly by <I>Trichophyton</I> or <I>Microsporum</I> species that invade the hair shaft (<LINK REF="REF-Higgins-2000" TYPE="REFERENCE">Higgins 2000</LINK>). The clinical hallmark is one or more patches of hair loss, sometimes with a black dot pattern (studded with broken-off hairs), which may be accompanied by inflammation, scaling, pustules and itching (<LINK REF="REF-Chan-2004" TYPE="REFERENCE">Chan 2004</LINK>; <LINK REF="REF-Higgins-2000" TYPE="REFERENCE">Higgins 2000</LINK>).</P>
<P>Tinea capitis is uncommon in adults and is mostly seen in preteen children from disadvantaged communities in countries of all income levels (<LINK REF="REF-Chan-2004" TYPE="REFERENCE">Chan 2004</LINK>; <LINK REF="REF-Ginter_x002d_Hanselmayer-2007" TYPE="REFERENCE">Ginter-Hanselmayer 2007</LINK>). Over the past 30 years, the reported incidence of tinea capitis has increased significantly, as travel and migration have been associated with changes in epidemiology and in distribution of the species of fungi that are likely to cause tinea capitis (<LINK REF="REF-Aly-1999" TYPE="REFERENCE">Aly 1999</LINK>).</P>
<P>There are several species of dermatophytes characteristically associated with tinea capitis. <I>Trichophyton </I>infections are most common in Central America, the United States and in parts of Western Europe. Cases of <I>Microsporum </I>infections are mainly seen in South America, Southern and Central Europe, Africa and the Middle East (<LINK REF="REF-Havlickova-2008" TYPE="REFERENCE">Havlickova 2008</LINK>).</P>
<P>Tinea capitis is contagious and can be transmitted by humans, animals or objects carrying the fungus (<LINK REF="REF-Yu-2005" TYPE="REFERENCE">Yu 2005</LINK>). Carrier states also exist where the fungus is present on the scalp but there is no clinical infection (<LINK REF="REF-Pomeranz-1999" TYPE="REFERENCE">Pomeranz 1999</LINK>). Although it is not life-threatening in people with normal immunity, if left untreated there may be persistent symptoms (<LINK REF="REF-Elewski-2000" TYPE="REFERENCE">Elewski 2000</LINK>). The inflammatory form, kerion, can result in scarring alopaecia (hair loss), or permanent baldness (<LINK REF="REF-Elewski-2000" TYPE="REFERENCE">Elewski 2000</LINK>).</P>
<P>Physicians should confirm the clinical diagnosis by identifying the presence of fungi within the hair shaft in hair samples viewed under the microscope, by growing the fungus from such samples in laboratory conditions (mycological diagnosis) or both (<LINK REF="REF-Higgins-2000" TYPE="REFERENCE">Higgins 2000</LINK>). The main methods of collecting samples for microbiological diagnosis involve either scraping or brushing the scalp and plucking the affected hairs (<LINK REF="REF-Fuller-2003" TYPE="REFERENCE">Fuller 2003</LINK>). Looking at the sample under a microscope is the fastest way to diagnose the infection, and if the result is positive, treatment can commence immediately (<LINK REF="REF-Fuller-2003" TYPE="REFERENCE">Fuller 2003</LINK>). However, sometimes this method indicates someone does not have the condition even if they actually do. Culturing the scrapings is more sensitive and allows accurate identification of the organism involved; however, this method may take up to four weeks to provide a result (<LINK REF="REF-Fuller-2003" TYPE="REFERENCE">Fuller 2003</LINK>; <LINK REF="REF-Gupta-1999" TYPE="REFERENCE">Gupta 1999</LINK>). A Wood's light (filtered ultraviolet light) can be used to detect infections that fluoresce under this type of light such as <I>M. canis </I>and <I>M. audouinii,</I> but it is not helpful in diagnosing <I>T. tonsurans</I> tinea capitis (<LINK REF="REF-Elewski-2000" TYPE="REFERENCE">Elewski 2000</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-04-29 10:39:04 +0100" MODIFIED_BY="[Empty name]">
<P>The primary aim of treatment for tinea capitis is to achieve complete clinical (signs and symptoms) and mycological cure (culture negative) as quickly as possible with minimal adverse events. Most superficial fungal infections can be treated topically (treatment applied directly to the skin), but tinea capitis always requires systemic medication (which spreads throughout the entire body) because the fungal infection is found at the root of the hair follicles, where topical agents cannot reach (<LINK REF="REF-Higgins-2000" TYPE="REFERENCE">Higgins 2000</LINK>). Topical medications are only used as adjuvant therapy alongside systemic treatments (<LINK REF="REF-Higgins-2000" TYPE="REFERENCE">Higgins 2000</LINK>).</P>
<P>Tinea capitis mainly occurs in children, and there are potential problems with persuading them to take their medicine (<LINK REF="REF-Hay-2006" TYPE="REFERENCE">Hay 2006</LINK>). Factors enhancing adherence include an acceptable taste and a short course of therapy. The latter factor may be important in reducing the risk of adverse events.</P>
<P>Griseofulvin has traditionally been the most widely prescribed and commonly used antifungal treatment for tinea capitis in clinical practice (<LINK REF="REF-Bennett-2000" TYPE="REFERENCE">Bennett 2000</LINK>; <LINK REF="REF-Friedlander-2000" TYPE="REFERENCE">Friedlander 2000</LINK>). The paediatric dosage of griseofulvin is 10 to 25 mg/kg/d for six to eight weeks (<LINK REF="REF-Blumer-1999" TYPE="REFERENCE">Blumer 1999</LINK>). It is still a relatively inexpensive drug and has been used as the standard to evaluate many newer agents (<LINK REF="REF-Blumer-1999" TYPE="REFERENCE">Blumer 1999</LINK>). However, it has a bitter, unpleasant taste and should be taken with meals for one to two months, which may affect adherence in children (<LINK REF="REF-Bennett-2000" TYPE="REFERENCE">Bennett 2000</LINK>). The liquid form is not always available.</P>
<P>Physicians increasingly consider treating tinea capitis with newer antifungal agents, such as ketoconazole, itraconazole, terbinafine or fluconazole (<LINK REF="REF-Friedlander-2000" TYPE="REFERENCE">Friedlander 2000</LINK>; <LINK REF="REF-Gonzalez-2007" TYPE="REFERENCE">Gonzalez 2007</LINK>), but there is concern regarding the use of these drugs in children because of the possibility of rare but potentially serious side effects, such as liver toxicity or drug interaction (<LINK REF="REF-Blumer-1999" TYPE="REFERENCE">Blumer 1999</LINK>). These newer agents are also expensive, which is an important consideration given that tinea capitis is endemic in some of the poorest communities in the world.</P>
</INTERVENTION>
<THEORY MODIFIED="2016-04-26 09:29:44 +0100" MODIFIED_BY="[Empty name]">
<P>The main mechanism of action of griseofulvin is binding and inactivating the microtubular proteins that are essential for mitosis (cell division), thus arresting cell division of the fungal cell. Griseofulvin also inhibits nucleic acid synthesis and impairs synthesis of the fungal cell wall (<LINK REF="REF-Fuller-2014" TYPE="REFERENCE">Fuller 2014</LINK>).</P>
<P>The mechanism of action of terbinafine involves inhibition of squalene epoxidase, which is a key enzyme in sterol biosynthesis in the fungal cell. This causes a deficiency in ergosterol within the fungal cell membrane, which results in damage to the fungi cell membrane (<LINK REF="REF-Abdel_x002d_Rahman-2005" TYPE="REFERENCE">Abdel-Rahman 2005</LINK>).</P>
<P>The mechanism of action of the azole antifungals (e.g. itraconazole and fluconazole) is inhibition of the cytochrome P450-dependent enzyme lanosterol 14-alpha-demethylase, which is essential for the conversion of lanosterol to ergosterol. Disruptions in the synthesis of ergosterol lead to damage in the cell membrane of fungi and damage to the fungal cell (<LINK REF="REF-Zonios-2008" TYPE="REFERENCE">Zonios 2008</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-04-29 10:08:37 +0100" MODIFIED_BY="[Empty name]">
<P>There is a choice between several systemic antifungal drugs for treating children with tinea capitis.</P>
<P>We wish to determine the comparative efficacy and safety profiles for these drugs. Furthermore, because of the worldwide distribution of this infection and the responsiveness of fungal species to different drugs, the cost implications may also be very important. We are also interested in comparing different lengths of treatment, because shorter courses of treatment, if effective, would be preferable to prolonged therapy, which may increase the risk of adverse events and the likelihood of non-adherence.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of systemic antifungal drugs for tinea capitis in children.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-05-03 16:56:33 +0100" MODIFIED_BY="Laura Prescott ">
<SELECTION_CRITERIA MODIFIED="2016-04-29 10:08:38 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-05-20 13:54:47 +0100" MODIFIED_BY="Finola M  Delamere">
<P>Randomised controlled trials (RCTs).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-04-26 09:32:27 +0100" MODIFIED_BY="[Empty name]">
<P>Children with normal immunity under the age of 18 years with tinea capitis confirmed by microscopy, growth of dermatophytes in culture or both.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-04-26 09:34:39 +0100" MODIFIED_BY="[Empty name]">
<P>We considered studies of all regimens of any systemic antifungal drug interventions for tinea capitis using the following comparisons.</P>
<UL>
<LI>Any systemic treatment versus no treatment or placebo.</LI>
<LI>Comparison of two or more systemic therapies.</LI>
<LI>Comparison of different doses and regimens of the same systemic therapy.</LI>
<LI>Comparison of systemic versus topical therapies.</LI>
</UL>
<P>We anticipated that studies would not focus on some systemic antifungal agents, such as amphotericin B, flucytosine, caspofungin or miconazole, because of either a lack of antifungal spectrum of activity or a lack of acceptable toxicity in this population.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-04-29 10:08:38 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-04-29 10:08:38 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>The proportion of participants with complete cure, i.e., clinical and mycological cure. We defined complete clinical cure as resolution of itching and clinical signs, such as redness, scaling, and oedema. We defined complete mycological cure as negative results on microscopy, no growth in culture or both.</LI>
<LI>The frequency and type of adverse events.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-04-26 12:44:16 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>The proportion of participants with clinical cure only.</LI>
<LI>Measurement of recurrence of the condition after the end of the intervention period.</LI>
<LI>Percentage of drop-outs as a surrogate for participant adherence.</LI>
<LI>The time taken to cure.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-05-03 16:56:33 +0100" MODIFIED_BY="Laura Prescott ">
<P>We aimed to identify all relevant RCTs regardless of language or publication status (published, unpublished, in press, or in progress).</P>
<ELECTRONIC_SEARCHES MODIFIED="2016-05-03 16:56:33 +0100" MODIFIED_BY="Laura Prescott ">
<P>For this update, we revised all our search strategies in line with current Skin Group practices. We searched the following databases up to 23rd November 2015:</P>
<UL>
<LI>The Cochrane Skin Group Specialised Register using the search strategy in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) 2015, Issue 10, in <I>The Cochrane Library </I>using the strategy in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</LI>
<LI>MEDLINE via Ovid (from 1946) using the strategy in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</LI>
<LI>EMBASE via Ovid (from 1974) using the strategy in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</LI>
<LI>LILACS (Latin American and Caribbean Health Science Information database, from 1982) using the strategy in <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5.</LINK>
</LI>
<LI>CINAHL via EBSCO (Cumulative Index to Nursing and Allied Health Literature, from 1981) using the strategy in <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Trial registers</HEADING>
<P>We searched the following trial registers up to 30th November 2015 using the strategy in <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>.</P>
<UL>
<LI>The ISRCTN registry (<A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A>).</LI>
<LI>The US National Institutes of Health Ongoing Trials Register (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>).</LI>
<LI>The Australian New Zealand Clinical Trials Registry (<A HREF="http://www.anzctr.org.au">www.anzctr.org.au</A>).</LI>
<LI>The World Health Organization International Clinical Trials Registry platform (<A HREF="http://www.who.int/trialsearch">www.who.int/trialsearch</A>).</LI>
<LI>The EU Clinical Trials Register (<A HREF="https://www.clinicaltrialsregister.eu/">https://www.clinicaltrialsregister.eu/</A>).</LI>
</UL>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-05-03 13:25:35 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">References from included studies</HEADING>
<P>We handsearched the bibliographies of included and excluded studies for further references to relevant trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Unpublished literature</HEADING>
<P>We sought information on unpublished and ongoing trials as well as grey literature via correspondence with authors of published studies and pharmaceutical companies. We consulted the Ringworm Committee of the European Confederation of Medical Mycology with regard to unpublished data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Conference proceedings</HEADING>
<P>We stated in the protocol that we would search the conference proceedings from major dermatology and mycology meetings. We were unable to search proceedings from mycology meetings, and we understand that the Cochrane Skin Group is searching some of the major dermatology meetings. We will search mycology meeting abstracts for an update of this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>We asked pharmaceutical companies for surveillance data on adverse events.<BR/>
</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-05-03 11:34:04 +0100" MODIFIED_BY="[Empty name]">
<P>Some parts of the 'Methods' section of this review use text that was originally published in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We included 'Summary of findings' tables in our review to summarise the primary outcomes and assessed the quality of the body of evidence using the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias).</P>
<STUDY_SELECTION MODIFIED="2016-05-03 11:33:30 +0100" MODIFIED_BY="[Empty name]">
<P>For the original review, two authors (GB and UG) checked titles and abstracts identified from the searches. If study design was not clear from the abstract, then two authors (GB and UG) independently reviewed the full text of the study. The authors also decided which trials met the inclusion criteria and resolved any disagreement by discussion between the authors or referred to a third author (JT) when necessary. We listed the excluded studies and reasons for exclusion in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' tables.</P>
<P>In this update, two authors (XC and MY) independently selected the studies using the same methods as before. We resolved discrepancies between XC and MY through discussion with XH.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-05-03 11:34:04 +0100" MODIFIED_BY="[Empty name]">
<P>For the previously published version of the review, at least two authors (TS and UG) extracted data independently using a pre-designed data extraction form. We extracted reported data for cure rates for all evaluated drugs, paying particular attention to the doses and frequencies of treatment administration (including 'pulsed' regimens: administering the drug in waves with drug-free intervals). We used the extracted data to populate the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. We resolved disagreements by discussion, and we attempted to obtain missing information from authors whenever possible.</P>
<P>In this update, two authors (XC and MY) independently extracted the information from the newly included studies, and another author (MZ) checked and compared the data extraction forms.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-04-26 10:01:16 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (MY and XC) independently assessed the quality of included studies according to the methods recommended in Sections 8.9 to 8.15 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We resolved discrepancies between MY and XC by consulting another author (MZ).</P>
<P>In addition, we considered the following factors in order to address other potential biases: reporting of sample size calculation, definition of inclusion and exclusion criteria, reporting of type of fungi involved, baseline comparability and statement of funding resources.</P>
<UL>
<LI>Low risk of bias: study appears to be free of other sources of bias.</LI>
<LI>High risk of bias: had extreme baseline imbalance; has been claimed to have been fraudulent.</LI>
<LI>Unclear risk of bias: insufficient information to permit judgement of 'high' or 'low'; had some drawbacks in either of the items listed above except for extreme baseline imbalance.</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-04-26 10:02:32 +0100" MODIFIED_BY="[Empty name]">
<P>We expressed dichotomous data, such as proportion of participants achieving complete cure, as risk ratios (RR). We analysed these in Review Manager (RevMan) using the Mantel-Haenszel test, unless stated otherwise (<LINK REF="REF-Revman-2014" TYPE="REFERENCE">Revman 2014</LINK>). We reported all outcomes with 95% confidence intervals (CIs) if possible.</P>
<P>We reported data that could not be combined by meta-analyses narratively. We expressed the time taken to cure as a mean.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-04-26 10:04:09 +0100" MODIFIED_BY="[Empty name]">
<P>We did not consider internally controlled trials, such as those with cross-over and within-participant designs, because even with a washout period, they are inappropriate designs for systemic treatment (because effects of antifungal therapy may endure over the washout period, as most participants would experience a cure or at least some improvement in the first period of a cross-over study).</P>
<P>For RCTs with multiple intervention groups, we combined groups to a single pair-wise comparison or split the shared group into two or more groups and included two or more independent comparisons, as recommended by Cochrane (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-04-26 10:04:47 +0100" MODIFIED_BY="[Empty name]">
<P>We contacted the trial authors of <LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK> and <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK> by email on 9 January 2015 to ask for for missing data; however, we did not receive any response. For the previous version of the review, we sent an email (when an email address was available) to authors of published studies asking for unpublished, ongoing trials and grey literature. We also consulted the Ringworm Committee of the European Confederation of Medical Mycology about unpublished data. We did not receive any positive response.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-04-26 10:05:29 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed statistical heterogeneity in the analyses results by inspecting the forest plots to detect non-overlapping CIs, and by implementing the I<SUP>2</SUP> statistic (with a value of at least 50% being interpreted as moderate to high levels of heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-04-26 10:06:43 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to perform funnel plots for publication bias if 10 or more studies contributed data. However, we could not carry this out because of the small number of included studies for each outcome.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-04-29 10:52:47 +0100" MODIFIED_BY="[Empty name]">
<P>We used <LINK REF="REF-Revman-2014" TYPE="REFERENCE">Revman 2014</LINK> to combine some outcomes. To estimate differences between treatments, we pooled trials that evaluated similar interventions using meta-analysis based on a random-effects model (Mantel-Haenszel method), if possible, to calculate a weighted treatment effect across trials.</P>
<P>For each trial, we calculated complete cure at follow-up based on the reported mycological and clinical results. Although we failed to specify the acceptable window for the timing in the primary outcome assessment in the original protocol, we decided during the course of the review to combine studies that recorded primary outcomes at 12 to 20 weeks on the basis that these are the range of time periods that best reflect clinical decision-making in practice.</P>
<P>When necessary, we categorised the duration of treatment into three groups.</P>
<UL>
<LI>Short term (closest to 2 weeks, but between 1 and 4 weeks).</LI>
<LI>Medium term (closest to 6 weeks, but between 5 and 8 weeks).</LI>
<LI>Long term (closest to 12 weeks, but between 9 and 14 weeks).</LI>
</UL>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-04-26 10:12:02 +0100" MODIFIED_BY="[Empty name]">
<P>In the original protocol we planned to perform subgroup analyses where adequate information was given for severity of infection, geographical setting of the trial, and dermatophyte species, whose variation may play an important role in the response to treatment. To explore reasons for heterogeneity in the review, we performed subgroup analyses where the trial report gave adequate information, based on dermatophyte species variation and duration of treatment.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-11-04 14:24:00 +0000" MODIFIED_BY="Finola  M Delamere">
<P>In the original protocol we planned to exclude some studies or subgroups in sensitivity analyses, but we did not perform any sensitivity analyses in this review.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-05-10 09:35:35 +0100" MODIFIED_BY="Laura Prescott ">
<STUDY_DESCRIPTION MODIFIED="2016-05-03 14:14:32 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2016-04-29 10:35:02 +0100" MODIFIED_BY="[Empty name]">
<P>The electronic database searches for this update yielded 85 studies after duplicates were removed. We discarded 79 studies after screening titles and abstract and examined the full text of the remaining 6 records. We excluded two further studies (<LINK REF="STD-Koumantaki_x002d_Mathioudaki-2005" TYPE="STUDY">Koumantaki-Mathioudaki 2005</LINK>; <LINK REF="STD-Shemer-2013" TYPE="STUDY">Shemer 2013</LINK>; see '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'), and we identified four new studies for inclusion in this update (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>; <LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK>; see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'). We did not identify any other studies in our searches of ongoing trial registers or from other resources.</P>
<P>The original review identified 21 trials of systemic treatments for tinea capitis (<LINK REF="REF-Gonzalez-2007" TYPE="REFERENCE">Gonzalez 2007</LINK>).</P>
<P>Please see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for the study flow diagram.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-05-03 14:14:32 +0100" MODIFIED_BY="[Empty name]">
<P>In total, we included 25 studies that randomised 4449 participants (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). We found no other trials that compared an active treatment to placebo. The trials compared different active treatments: either different drugs or different regimens of the same drug.</P>
<SUBSECTION>
<HEADING LEVEL="4">Design</HEADING>
<P>All included studies were parallel group RCTs. Ten of them had a multi-arm design (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>; <LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Haroon-1996" TYPE="STUDY">Haroon 1996</LINK>; <LINK REF="STD-Kullavanijaya-1997" TYPE="STUDY">Kullavanijaya 1997</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>; <LINK REF="STD-Solomon-1997" TYPE="STUDY">Solomon 1997</LINK>; <LINK REF="STD-Talarico-Filho-1998" TYPE="STUDY">Talarico Filho 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sample size</HEADING>
<P>Only six studies reported a sample size calculation (<LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>; <LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>, <LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>; <LINK REF="STD-Ungpakorn-2004" TYPE="STUDY">Ungpakorn 2004</LINK>).</P>
<P>Regarding the sample size, we organised the studies into three distinct groups.</P>
<UL>
<LI>Nine studies were small (N &lt; 50) (<LINK REF="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" TYPE="STUDY">Cáceres-Ríos 2000</LINK>; <LINK REF="STD-Dastghaib-2005" TYPE="STUDY">Dastghaib 2005</LINK>; <LINK REF="STD-Hamm-1999" TYPE="STUDY">Hamm 1999</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TYPE="STUDY">López-Gómez 1994</LINK>; <LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>; <LINK REF="STD-Rademaker-1998" TYPE="STUDY">Rademaker 1998</LINK>; <LINK REF="STD-Solomon-1997" TYPE="STUDY">Solomon 1997</LINK>; <LINK REF="STD-Tanz-1985" TYPE="STUDY">Tanz 1985</LINK>; <LINK REF="STD-Ungpakorn-2004" TYPE="STUDY">Ungpakorn 2004</LINK>).</LI>
<LI>Eight studies were medium (N = 51 to 150) (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>; <LINK REF="STD-Jahangir-1998" TYPE="STUDY">Jahangir 1998</LINK>; <LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK>; <LINK REF="STD-Kullavanijaya-1997" TYPE="STUDY">Kullavanijaya 1997</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>; <LINK REF="STD-Talarico-Filho-1998" TYPE="STUDY">Talarico Filho 1998</LINK>; <LINK REF="STD-Tanz-1988" TYPE="STUDY">Tanz 1988</LINK>).</LI>
<LI>Eight studies were large (N &gt; 150) (<LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>; <LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>; <LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK>; <LINK REF="STD-Haroon-1996" TYPE="STUDY">Haroon 1996</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Settings</HEADING>
<P>The studies included in this review took place in many parts of the world.</P>
<P>Eight took place in Asia: four in Pakistan (<LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK>; <LINK REF="STD-Haroon-1996" TYPE="STUDY">Haroon 1996</LINK>; <LINK REF="STD-Jahangir-1998" TYPE="STUDY">Jahangir 1998</LINK>; <LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK>); two in Thailand (<LINK REF="STD-Kullavanijaya-1997" TYPE="STUDY">Kullavanijaya 1997</LINK>; <LINK REF="STD-Ungpakorn-2004" TYPE="STUDY">Ungpakorn 2004</LINK>); one in China (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>); and one in Iran (<LINK REF="STD-Dastghaib-2005" TYPE="STUDY">Dastghaib 2005</LINK>).</P>
<P>Five studies were carried out in Europe: one in Germany (<LINK REF="STD-Hamm-1999" TYPE="STUDY">Hamm 1999</LINK>); one in Turkey (<LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>); two in Spain (<LINK REF="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TYPE="STUDY">López-Gómez 1994</LINK>; <LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>); and one in the UK (<LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>).</P>
<P>Two studies were from South America (<LINK REF="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" TYPE="STUDY">Cáceres-Ríos 2000</LINK>; <LINK REF="STD-Talarico-Filho-1998" TYPE="STUDY">Talarico Filho 1998</LINK>), five were completed in North America (<LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>; <LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>; <LINK REF="STD-Solomon-1997" TYPE="STUDY">Solomon 1997</LINK>; <LINK REF="STD-Tanz-1985" TYPE="STUDY">Tanz 1985</LINK>; <LINK REF="STD-Tanz-1988" TYPE="STUDY">Tanz 1988</LINK>), and one study took place in New Zealand (<LINK REF="STD-Rademaker-1998" TYPE="STUDY">Rademaker 1998</LINK>).</P>
<P>Four of the studies were conducted in several locations: <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK> took place in the United States and South Africa; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>, in Europe and South America; <LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK> in the United States, Peru, the United Kingdom, Egypt, Russia and South Africa; and <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>, in the United States, Guatemala, Chile, Costa Rica and India.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>With regard to age, most of the participants of included studies were older than two years. <LINK REF="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" TYPE="STUDY">Cáceres-Ríos 2000</LINK> and <LINK REF="STD-Talarico-Filho-1998" TYPE="STUDY">Talarico Filho 1998</LINK> included participants as young as one year. Another study involved participants as young as six months of age (<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>). The upper age limit in the majority of the trials was 16 years, although <LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK> included participants ranging in age from 2 to 65 years. In that trial, 94 of the 105 participants were under 12 years of age, so we assumed all the participants were under 16 years of age and therefore analysed the whole population. Three other studies reported a total of four adults in their samples (<LINK REF="STD-Kullavanijaya-1997" TYPE="STUDY">Kullavanijaya 1997</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TYPE="STUDY">López-Gómez 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fungal type</HEADING>
<P>Each of the 25 studies reported the types of fungi cultured; some provided general percentages and reported exact proportions of the types of fungi within each arm. The <I>Trichophyton</I> species predominated over <I>Microsporum </I>species. <I>T. tonsurans</I> and <I>M. canis</I> were responsible for causing infection in the highest proportion of participants. <I>T. tonsurans</I> was the most commonly identified fungus in 11 studies (<LINK REF="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" TYPE="STUDY">Cáceres-Ríos 2000</LINK>; <LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>; <LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>; <LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>; <LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>; <LINK REF="STD-Ginsburg-1987" TYPE="STUDY">Ginsburg 1987</LINK>; <LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK>; <LINK REF="STD-Solomon-1997" TYPE="STUDY">Solomon 1997</LINK>; <LINK REF="STD-Tanz-1985" TYPE="STUDY">Tanz 1985</LINK>; <LINK REF="STD-Tanz-1988" TYPE="STUDY">Tanz 1988</LINK>); <I>T. violaceum</I> was the predominant fungus in four studies (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK>; <LINK REF="STD-Haroon-1996" TYPE="STUDY">Haroon 1996</LINK>; <LINK REF="STD-Jahangir-1998" TYPE="STUDY">Jahangir 1998</LINK>); in one study, the proportions of <I>M. canis</I> and <I>T. tonsurans</I> were the same (<LINK REF="STD-Hamm-1999" TYPE="STUDY">Hamm 1999</LINK>); and <I>M. canis</I> was the main fungus in five trials (<LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TYPE="STUDY">López-Gómez 1994</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>; <LINK REF="STD-Rademaker-1998" TYPE="STUDY">Rademaker 1998</LINK>; <LINK REF="STD-Talarico-Filho-1998" TYPE="STUDY">Talarico Filho 1998</LINK>). Three trials identified the causative fungi, but their relative frequencies were not provided so it was impossible to determine the frequencies: <I>T. tonsurans</I> and <I>M. ferrugineum</I> were identified in one study (<LINK REF="STD-Kullavanijaya-1997" TYPE="STUDY">Kullavanijaya 1997</LINK>), <I>T. tonsurans</I> and <I>T. violaceum</I> in another (<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>), and <I>T. mentagrophytes</I> and <I>M. canis</I> in a third study (<LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>). In addition, one study failed to classify the causative species of fungi (<LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>The standard dose for griseofulvin used in trials is generally 10 to 20 mg/kg/d or 125 mg/d in participants weighing 10 to 20 kg; 250 mg/d in those weighing from 20 to 40 kg and 500 mg/d for those over 40 kg. Unless otherwise stated, the standard dosing for terbinafine studies was 62.5 mg/d in participants weighing from 10 to 20 kg; 125 mg/d from 20 to 40 kg, and 250 mg/d over 40 kg.</P>
<P>In total, we studied five different antifungal agents: griseofulvin, terbinafine, itraconazole, fluconazole and ketoconazole.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparisons</HEADING>
<P>We evaluated a variety of regimens, including between-drug and within-drug comparisons. We considered griseofulvin to be the standard because it is the oldest agent, and 17 studies used it as a control. Of the 25 included studies, 17 compared griseofulvin as standard therapy with terbinafine (<LINK REF="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" TYPE="STUDY">Cáceres-Ríos 2000</LINK>; <LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK>; <LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>; <LINK REF="STD-Rademaker-1998" TYPE="STUDY">Rademaker 1998</LINK>), itraconazole (<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TYPE="STUDY">López-Gómez 1994</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>), ketoconazole (<LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>; <LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>; <LINK REF="STD-Tanz-1985" TYPE="STUDY">Tanz 1985</LINK>; <LINK REF="STD-Tanz-1988" TYPE="STUDY">Tanz 1988</LINK>), or fluconazole (<LINK REF="STD-Dastghaib-2005" TYPE="STUDY">Dastghaib 2005</LINK>; <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>). <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK> and <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK> compared griseofulvin, itraconazole and fluconazole.</P>
<P>Ten studies compared terbinafine versus griseofulvin (<LINK REF="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" TYPE="STUDY">Cáceres-Ríos 2000</LINK>; <LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>;<LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK>; <LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>; <LINK REF="STD-Rademaker-1998" TYPE="STUDY">Rademaker 1998</LINK>), two versus itraconazole (<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>) and two versus fluconazole (<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>). Seven studies compared different treatment duration regimens for terbinafine (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>; <LINK REF="STD-Hamm-1999" TYPE="STUDY">Hamm 1999</LINK>; <LINK REF="STD-Haroon-1996" TYPE="STUDY">Haroon 1996</LINK>; <LINK REF="STD-Kullavanijaya-1997" TYPE="STUDY">Kullavanijaya 1997</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>; <LINK REF="STD-Talarico-Filho-1998" TYPE="STUDY">Talarico Filho 1998</LINK>), and one compared different doses (<LINK REF="STD-Ungpakorn-2004" TYPE="STUDY">Ungpakorn 2004</LINK>).</P>
<P>Three studies (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Gupta-2001">Gupta 2001</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-L_x00f3_pez_x002d_G_x00f3_mez-1994">López-Gómez 1994</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Memisoglu-1999">Memisoglu 1999</A>) compared itraconazole with other antifungals: three with griseofulvin (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Gupta-2001">Gupta 2001</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-L_x00f3_pez_x002d_G_x00f3_mez-1994">López-Gómez 1994</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Memisoglu-1999">Memisoglu 1999</A>), two with terbinafine (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Gupta-2001">Gupta 2001</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Memisoglu-1999">Memisoglu 1999</A>) and two with fluconazole (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Gupta-2001">Gupta 2001</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Memisoglu-1999">Memisoglu 1999</A>). Ketoconazole was compared with griseofulvin in four trials (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Gan-1987">Gan 1987</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Mart_x00ed_nez_x002d_Roig-1988">Martínez-Roig 1988</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Tanz-1985">Tanz 1985</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Tanz-1988">Tanz 1988</A>). </P>
<P>Five trials studied fluconazole (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Dastghaib-2005">Dastghaib 2005</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Foster-2005">Foster 2005</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Gupta-2001">Gupta 2001</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Memisoglu-1999">Memisoglu 1999</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Solomon-1997">Solomon 1997</A>); four with griseofulvin (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Dastghaib-2005">Dastghaib 2005</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Foster-2005">Foster 2005</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Gupta-2001">Gupta 2001</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Memisoglu-1999">Memisoglu 1999</A>), two with terbinafine (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Gupta-2001">Gupta 2001</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Memisoglu-1999">Memisoglu 1999</A>), two with itraconazole (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Gupta-2001">Gupta 2001</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Memisoglu-1999">Memisoglu 1999</A>), one by itself with varying doses (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Solomon-1997">Solomon 1997</A>), and one by itself with different durations of treatment (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1604181207571288269737516612118&amp;format=REVMAN_GRAPHS#STD-Foster-2005">Foster 2005</A>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<P>All but three studies reported the proportion of participants with complete cure, which was our pre-specified primary outcome (<LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>; <LINK REF="STD-Rademaker-1998" TYPE="STUDY">Rademaker 1998</LINK>; <LINK REF="STD-Tanz-1985" TYPE="STUDY">Tanz 1985</LINK>). Most of the studies reported complete cure at 12 to 16 weeks but three reported at 8 weeks (<LINK REF="STD-Dastghaib-2005" TYPE="STUDY">Dastghaib 2005</LINK>; <LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>), one at 10 weeks (<LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>), one at 2 weeks, 4 weeks, 8 weeks and one year (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>), one at 3, 6 and 10 weeks (<LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>), one at 2, 4 and 6 weeks (<LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK>), and two at 20 to 24 weeks (<LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>; <LINK REF="STD-Ungpakorn-2004" TYPE="STUDY">Ungpakorn 2004</LINK>).</P>
<P>Three studies failed to report our other primary outcome: adverse events (<LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>; <LINK REF="STD-Kullavanijaya-1997" TYPE="STUDY">Kullavanijaya 1997</LINK>; <LINK REF="STD-Solomon-1997" TYPE="STUDY">Solomon 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<P>Fourteen studies reported the proportion of participants with clinical cure only, which was our first pre-specified secondary outcome (<LINK REF="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" TYPE="STUDY">Cáceres-Ríos 2000</LINK>; <LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Hamm-1999" TYPE="STUDY">Hamm 1999</LINK>; <LINK REF="STD-Haroon-1996" TYPE="STUDY">Haroon 1996</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TYPE="STUDY">López-Gómez 1994</LINK>; <LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>; <LINK REF="STD-Rademaker-1998" TYPE="STUDY">Rademaker 1998</LINK>; <LINK REF="STD-Solomon-1997" TYPE="STUDY">Solomon 1997</LINK>; <LINK REF="STD-Talarico-Filho-1998" TYPE="STUDY">Talarico Filho 1998</LINK>; <LINK REF="STD-Tanz-1988" TYPE="STUDY">Tanz 1988</LINK>).</P>
<P>Only three studies reported recurrence of the condition after the end of the intervention period, which was our second pre-specified secondary outcome (<LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>; <LINK REF="STD-Rademaker-1998" TYPE="STUDY">Rademaker 1998</LINK>; <LINK REF="STD-Solomon-1997" TYPE="STUDY">Solomon 1997</LINK>).</P>
<P>Twelve studies reported the percentage of drop-outs as a surrogate for participant adherence, our third pre-specified secondary outcome (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>; <LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>; <LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Hamm-1999" TYPE="STUDY">Hamm 1999</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TYPE="STUDY">López-Gómez 1994</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>; <LINK REF="STD-Talarico-Filho-1998" TYPE="STUDY">Talarico Filho 1998</LINK>; <LINK REF="STD-Tanz-1985" TYPE="STUDY">Tanz 1985</LINK>; <LINK REF="STD-Tanz-1988" TYPE="STUDY">Tanz 1988</LINK>).</P>
<P>Four studies reported the time taken to cure, our fourth pre-specified secondary outcome (<LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>; <LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>; <LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Follow-up</HEADING>
<P>The follow-up period ranged from six weeks in <LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>, <LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK> and <LINK REF="STD-Tanz-1985" TYPE="STUDY">Tanz 1985</LINK> to one year in <LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>. Although most studies had a 12-week follow-up period, five trials had longer follow-up periods ranging from 16 to 24 weeks (<LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>; <LINK REF="STD-Kullavanijaya-1997" TYPE="STUDY">Kullavanijaya 1997</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>; <LINK REF="STD-Solomon-1997" TYPE="STUDY">Solomon 1997</LINK>; <LINK REF="STD-Ungpakorn-2004" TYPE="STUDY">Ungpakorn 2004</LINK>). In addition, two trials had a 10-week follow-up period (<LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other</HEADING>
<P>Some of the studies did not provide detailed information on the clinical setting or baseline characteristics of sex, age and infection severity, or they did not report the comparability between arms or the duration of symptoms or signs. <LINK REF="STD-Rademaker-1998" TYPE="STUDY">Rademaker 1998</LINK> did not compare the baseline characteristics at all, and two trials did not report the information on comparability (<LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>; <LINK REF="STD-Solomon-1997" TYPE="STUDY">Solomon 1997</LINK>). Finally, only five trials reported information about the severity of the infection (<LINK REF="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" TYPE="STUDY">Cáceres-Ríos 2000</LINK>; <LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Tanz-1985" TYPE="STUDY">Tanz 1985</LINK>). For the 25 studies, the most common reason for excluding a participant from the trial was treatment with any antifungal agent within one month prior to entering the trial.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-04-29 11:13:33 +0100" MODIFIED_BY="[Empty name]">
<P>We provide details of the excluded studies in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table.</P>
<P>In this update, we excluded <LINK REF="STD-Koumantaki_x002d_Mathioudaki-2005" TYPE="STUDY">Koumantaki-Mathioudaki 2005</LINK> and <LINK REF="STD-Shemer-2013" TYPE="STUDY">Shemer 2013</LINK> because we found that neither of them were RCTs after reading the full texts.</P>
<P>The original review excluded 3 of the initial 24 trials of systemic treatments for tinea capitis because they evaluated the therapy for the inflammatory component (kerion) caused by tinea capitis infection (<LINK REF="STD-Ginsburg-1987" TYPE="STUDY">Ginsburg 1987</LINK>; <LINK REF="STD-Honig-1994" TYPE="STUDY">Honig 1994</LINK>; <LINK REF="STD-Hussain-1999" TYPE="STUDY">Hussain 1999</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Studies awaiting classification</HEADING>
<P>One trial reported in a conference paper appeared to meet the inclusion criteria, but as we could not obtain further information, we could neither include or exclude it (<LINK REF="STD-Pather-2006" TYPE="STUDY">Pather 2006</LINK>). See <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-04-29 11:16:49 +0100" MODIFIED_BY="[Empty name]">
<P>Please see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> for our judgements about each 'Risk of bias' item presented as percentages across all included studies and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for the judgements about each domain for all the included studies.</P>
<ALLOCATION MODIFIED="2016-04-29 11:13:59 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Randomisation</HEADING>
<P>All included studies stated or implied that treatment allocation was randomised; however, there were only four studies that reported an adequate generation method of randomisation: two used a computer-generated random number table (<LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>; <LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>), and two used a table of random numbers (<LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>Only two studies reported adequate allocation concealment (<LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>).</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2016-04-26 10:55:00 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Performance bias</HEADING>
<P>Five included studies reported that participants or personnel were not blinded; therefore, we judged these studies to be at high risk of performance bias (<LINK REF="STD-Dastghaib-2005" TYPE="STUDY">Dastghaib 2005</LINK>; <LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>; <LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>; <LINK REF="STD-Rademaker-1998" TYPE="STUDY">Rademaker 1998</LINK>; <LINK REF="STD-Talarico-Filho-1998" TYPE="STUDY">Talarico Filho 1998</LINK>).</P>
<P>We judged the other 20 studies as being at unclear risk of performance bias, either because they did not report blinding of participants or personnel (<LINK REF="STD-Hamm-1999" TYPE="STUDY">Hamm 1999</LINK>; <LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK>; <LINK REF="STD-Jahangir-1998" TYPE="STUDY">Jahangir 1998</LINK>; <LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK>), or because they did not describe the method of blinding (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>; <LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK>; <LINK REF="STD-Haroon-1996" TYPE="STUDY">Haroon 1996</LINK>; <LINK REF="STD-Kullavanijaya-1997" TYPE="STUDY">Kullavanijaya 1997</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TYPE="STUDY">López-Gómez 1994</LINK>; <LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>; <LINK REF="STD-Solomon-1997" TYPE="STUDY">Solomon 1997</LINK>; <LINK REF="STD-Tanz-1985" TYPE="STUDY">Tanz 1985</LINK>; <LINK REF="STD-Tanz-1988" TYPE="STUDY">Tanz 1988</LINK>; <LINK REF="STD-Ungpakorn-2004" TYPE="STUDY">Ungpakorn 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Detection bias</HEADING>
<P>Five included studies reported that outcome assessors were not blinded; therefore, we judged these studies to be at high risk of detection bias (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>; <LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>; <LINK REF="STD-Rademaker-1998" TYPE="STUDY">Rademaker 1998</LINK>; <LINK REF="STD-Talarico-Filho-1998" TYPE="STUDY">Talarico Filho 1998</LINK>).</P>
<P>We deemed the other 20 studies to be at unclear risk of detection bias, either because they did not report blinding of outcome assessors (<LINK REF="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" TYPE="STUDY">Cáceres-Ríos 2000</LINK>; <LINK REF="STD-Hamm-1999" TYPE="STUDY">Hamm 1999</LINK>; <LINK REF="STD-Jahangir-1998" TYPE="STUDY">Jahangir 1998</LINK>; <LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK>), or because they did not describe the method of blinding (<LINK REF="STD-Dastghaib-2005" TYPE="STUDY">Dastghaib 2005</LINK>; <LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>; <LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK>; <LINK REF="STD-Haroon-1996" TYPE="STUDY">Haroon 1996</LINK>; <LINK REF="STD-Kullavanijaya-1997" TYPE="STUDY">Kullavanijaya 1997</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TYPE="STUDY">López-Gómez 1994</LINK>; <LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>; <LINK REF="STD-Solomon-1997" TYPE="STUDY">Solomon 1997</LINK>; <LINK REF="STD-Tanz-1985" TYPE="STUDY">Tanz 1985</LINK>; <LINK REF="STD-Tanz-1988" TYPE="STUDY">Tanz 1988</LINK>; <LINK REF="STD-Ungpakorn-2004" TYPE="STUDY">Ungpakorn 2004</LINK>).</P>
</SUBSECTION>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-04-29 11:15:44 +0100" MODIFIED_BY="[Empty name]">
<P>Overall, after randomising 4449 people, 471 participants (10.6%) were lost. Only six studies performed intention-to-treat (ITT) analyses (<LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>; <LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>; <LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>; <LINK REF="STD-Talarico-Filho-1998" TYPE="STUDY">Talarico Filho 1998</LINK>).</P>
<P>We considered 14 studies to be at low risk of attrition bias because either less than 10% of participants dropped out, or because the drop-outs were between 10% and 20% but balanced in numbers across intervention groups (<LINK REF="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" TYPE="STUDY">Cáceres-Ríos 2000</LINK>; <LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Hamm-1999" TYPE="STUDY">Hamm 1999</LINK>; <LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK>; <LINK REF="STD-Haroon-1996" TYPE="STUDY">Haroon 1996</LINK>; <LINK REF="STD-Jahangir-1998" TYPE="STUDY">Jahangir 1998</LINK>; <LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK>; <LINK REF="STD-Kullavanijaya-1997" TYPE="STUDY">Kullavanijaya 1997</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TYPE="STUDY">López-Gómez 1994</LINK>; <LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>; <LINK REF="STD-Talarico-Filho-1998" TYPE="STUDY">Talarico Filho 1998</LINK>; <LINK REF="STD-Ungpakorn-2004" TYPE="STUDY">Ungpakorn 2004</LINK>).</P>
<P>We judged 10 studies to be at high risk of attrition bias because either more than 20% of participants dropped out, whether ITT analysis was performed or not (<LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>; <LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>; <LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>; <LINK REF="STD-Solomon-1997" TYPE="STUDY">Solomon 1997</LINK>; <LINK REF="STD-Tanz-1985" TYPE="STUDY">Tanz 1985</LINK>; <LINK REF="STD-Tanz-1988" TYPE="STUDY">Tanz 1988</LINK>), or the drop-outs were between 10% and 20% but ITT analysis was not performed (<LINK REF="STD-Dastghaib-2005" TYPE="STUDY">Dastghaib 2005</LINK>; <LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>).</P>
<P>
<LINK REF="STD-Rademaker-1998" TYPE="STUDY">Rademaker 1998</LINK> was at unclear risk of attrition bias, as it did not provide sufficient information on drop-outs to make a judgement.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-04-26 11:23:53 +0100" MODIFIED_BY="[Empty name]">
<P>All included studies reported findings on all outcomes listed in the 'Methods' section; therefore, we judged all included studies as being at low risk of reporting bias. However, we did not have access to the original study protocols in any of the included studies.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-04-29 11:16:49 +0100" MODIFIED_BY="[Empty name]">
<P>Ninteen of the 25 included studies did not report the method of sample size calculation (<LINK REF="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" TYPE="STUDY">Cáceres-Ríos 2000</LINK>; <LINK REF="STD-Dastghaib-2005" TYPE="STUDY">Dastghaib 2005</LINK>; <LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>; <LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Hamm-1999" TYPE="STUDY">Hamm 1999</LINK>; <LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK>; <LINK REF="STD-Haroon-1996" TYPE="STUDY">Haroon 1996</LINK>; <LINK REF="STD-Jahangir-1998" TYPE="STUDY">Jahangir 1998</LINK>; <LINK REF="STD-Kullavanijaya-1997" TYPE="STUDY">Kullavanijaya 1997</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TYPE="STUDY">López-Gómez 1994</LINK>; <LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>; <LINK REF="STD-Rademaker-1998" TYPE="STUDY">Rademaker 1998</LINK>; <LINK REF="STD-Solomon-1997" TYPE="STUDY">Solomon 1997</LINK>; <LINK REF="STD-Talarico-Filho-1998" TYPE="STUDY">Talarico Filho 1998</LINK>; <LINK REF="STD-Tanz-1985" TYPE="STUDY">Tanz 1985</LINK>; <LINK REF="STD-Tanz-1988" TYPE="STUDY">Tanz 1988</LINK>).</P>
<P>Nine studies did not report the funding sources (<LINK REF="STD-Dastghaib-2005" TYPE="STUDY">Dastghaib 2005</LINK>; <LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>; <LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Jahangir-1998" TYPE="STUDY">Jahangir 1998</LINK>; <LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>; <LINK REF="STD-Rademaker-1998" TYPE="STUDY">Rademaker 1998</LINK>; <LINK REF="STD-Solomon-1997" TYPE="STUDY">Solomon 1997</LINK>).</P>
<P>Three studies did not report their inclusion or exclusion criteria (<LINK REF="STD-Hamm-1999" TYPE="STUDY">Hamm 1999</LINK>; <LINK REF="STD-Kullavanijaya-1997" TYPE="STUDY">Kullavanijaya 1997</LINK>; <LINK REF="STD-Rademaker-1998" TYPE="STUDY">Rademaker 1998</LINK>); two other studies did not report baseline comparability (<LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK>; <LINK REF="STD-Tanz-1988" TYPE="STUDY">Tanz 1988</LINK>). However, whether these factors introduced bias to the results remained unclear. We therefore judged these studies as being at unclear risk of other bias.</P>
<P>In addition, all but two of the included studies reported the proportion of different types of fungi (<LINK REF="STD-Kullavanijaya-1997" TYPE="STUDY">Kullavanijaya 1997</LINK>; <LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>). Most included studies recruited children infected with both <I>Trichophyton and Microsporum. </I>
<LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK> and <LINK REF="STD-Ungpakorn-2004" TYPE="STUDY">Ungpakorn 2004</LINK> only recruited children infected with <I>Microsporum</I>, while <LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>, <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>, <LINK REF="STD-Jahangir-1998" TYPE="STUDY">Jahangir 1998</LINK> and <LINK REF="STD-Solomon-1997" TYPE="STUDY">Solomon 1997</LINK> only recruited children infected with <I>Trichophyton.</I> <LINK REF="STD-Tanz-1985" TYPE="STUDY">Tanz 1985</LINK> recruited children infected with <I>Trichophyton</I>,<I> Scopulariopsis</I>,<I> Penicillium </I>and unidentified fungus. We list the details of type of fungi in each study in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' tables.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-05-10 09:35:35 +0100" MODIFIED_BY="Laura Prescott ">
<P>Numbers given show the total numbers of participants included in the analysis. When it was possible to calculate an effect size, we reported this with the 95% confidence interval (CI). We used the P value of 0.05 as the cutoff value to determine statistical significance; when P values were below this threshold, we stated whether the result favoured the intervention group or the control condition. In the text below, we report an I² statistical value for heterogeneity as moderate or high if it exceeds 50%.</P>
<P>We have presented the results for our pre-specified outcomes below under the following 13 comparisons.</P>
<OL>
<LI>Terbinafine versus griseofulvin (short treatment duration).</LI>
<LI>Terbinafine versus griseofulvin in <I>Trichophyton</I> infections (medium treatment duration).</LI>
<LI>Terbinafine (medium- and long-term treatment) versus griseofulvin in <I>Microsporum</I> infections.</LI>
<LI>Terbinafine short- versus long-term.</LI>
<LI>Terbinafine standard dose compared to terbinafine double dose.</LI>
<LI>Itraconazole versus griseofulvin.</LI>
<LI>Itraconazole versus terbinafine.</LI>
<LI>Ketoconazole versus griseofulvin.</LI>
<LI>Fluconazole versus griseofulvin.</LI>
<LI>Fluconazole versus terbinafine.</LI>
<LI>Fluconazole versus itraconazole.</LI>
<LI>Fluconazole dosages (1.5, 3.0 and 6.0 mg/kg/d).</LI>
<LI>Treatment durations of fluconazole (short-term versus medium-term).</LI>
</OL>
<P>We have summarised the results of included studies that we could not combine in meta-analyses because of differences between studies in terms of design. We present the results of studies that could not be pooled in meta-analyses using data and information derived from the reports of individual studies.</P>
<P>We produced eight 'Summary of findings' tables for the first primary outcome of complete clinical cure (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>; <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>; <LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>; <LINK REF="SOF-06" TYPE="SOF">Summary of findings table 6</LINK>; <LINK REF="SOF-07" TYPE="SOF">Summary of findings table 7</LINK>; <LINK REF="SOF-08" TYPE="SOF">Summary of findings table 8</LINK>). In <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> we also reported our primary outcome of adverse events.</P>
<SUBSECTION>
<HEADING LEVEL="3">1. Terbinafine (2 to 4 weeks) versus griseofulvin (6 to 8 weeks); short treatment duration; 6 to 24 weeks follow-up</HEADING>
<P>Eight studies assessed the efficacy of terbinafine used in the short-term for 2 to 4 weeks as compared to griseofulvin (used for 8 weeks) (<LINK REF="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" TYPE="STUDY">Cáceres-Ríos 2000</LINK>; <LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK>; <LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>; <LINK REF="STD-Rademaker-1998" TYPE="STUDY">Rademaker 1998</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Complete cure, i.e. clinical and mycological cure, at 12 to 24 weeks follow-up</HEADING>
<P>Five studies reported on complete cure (<LINK REF="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" TYPE="STUDY">Cáceres-Ríos 2000</LINK>; <LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>). This update did not identify any new studies addressing this outcome.</P>
<P>A pooled analysis of the five studies found that the difference in the proportion of participants with complete cure between four weeks of terbinafine and eight weeks of griseofulvin was not statistically significant (73.6% versus 68.4%; RR 1.08, 95% CI 0.94 to 1.24; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="6">Trichophyton infections</HEADING>
<P>Three studies included participants with <I>Trichophyton</I> infections (<LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK>). <LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK> compared terbinafine for 4 weeks with 10 mg/kg/d of griseofulvin for 8 weeks in 105 participants, of whom 87.6% had <I>T. violaceum </I>tinea capitis. The proportion of participants with complete cure at week 12 was 93% (52/56) in the terbinafine group and 80% (39/49) in the griseofulvin group (RR 1.17, 95% CI 0.99 to 1.37; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>
<LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK> recruited 210 participants and included 147 in the ITT analyses. <I>Trichophyton</I> infection accounted for 84.4% of the terbinafine group (N = 65) and 82.9% of the griseofulvin group (N = 58). At 24 weeks, the proportion of participants with complete cure was 69.2% (45/65) in the terbinafine group and 67.2% (39/58) in the griseofulvin group (RR 1.03, 95% 0.81 to 1.31; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>)</P>
<P>
<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK> compared 50 participants in each treatment group with infections caused by <I>T. tonsurans</I> and <I>T. violaceum</I>. In this trial, administration of terbinafine for 2 to 3 weeks was compared with microsize griseofulvin 20 mg/kg for 6 weeks. The proportion of participants with complete cure at week 12 was 94% (47/50) for the terbinafine group and 92% (46/50) for the griseofulvin treated group (RR 1.02, 95% CI 0.92 to 1.14; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>In the pooled analysis of 328 participants with a confirmed <I>Trichophyton</I> infection, terbinafine for four weeks and griseofulvin for 8 weeks showed similar efficacy in three studies (84.2% versus 79.0%; RR 1.06 95% CI 0.98 to 1.15; low quality evidence; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK>; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Microsporum infections</HEADING>
<P>In <LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>, the proportion of the 21 children with <I>Microsporum</I> infections who achieved complete cure in the terbinafine (for four weeks) group and the griseofulvin (for eight weeks) group were 27.2% (3/11) and 60.0% (6/10), respectively (RR 0.45, 95% CI 0.15 to 1.35; N = 21; low quality evidence; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Mixed Trichophyton and Microsporum infections</HEADING>
<P>
<LINK REF="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" TYPE="STUDY">Cáceres-Ríos 2000</LINK> and <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK> included participants with <I>Trichophyton</I> and <I>Microsporum</I> infections but did not report results separately. In <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>, complete cure at the final follow-up visit (week 12) was 39% (15/39) for the group treated with four weeks of terbinafine compared with 44% (17/39) in the group treated with eight weeks of ultra microsized griseofulvin (RR 0.88, 95% CI 0.52 to 1.50; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). There was a similar proportion of participants with complete cure within the subgroups infected with <I>M. canis</I> (48% of participants) and <I>Trichophyton</I> species according to the principal investigators of that study. The other study, <LINK REF="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" TYPE="STUDY">Cáceres-Ríos 2000</LINK>, evaluated terbinafine for four weeks versus microsized griseofulvin for 8 weeks in 50 participants from Peru and found a significant increase in complete cure with terbinafine (76%; 19/25) compared to griseofulvin (44%; 11/25) measured at 12 weeks (RR 1.73, 95% CI 1.05 to 2.83; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The causative organisms were <I>T. tonsurans</I> and <I>M. canis, </I>at 74% and 26%, respectively.</P>
<P>A pooled analysis of the two studies showed no significant difference between the groups (53.1% versus 43.8%; RR 1.24, 95% CI 0.64 to 2.42; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Seven studies reported this outcome (<LINK REF="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" TYPE="STUDY">Cáceres-Ríos 2000</LINK>; <LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK>; <LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>), of which two were new studies added in this update (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK>).</P>
<P>
<LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK> reported that the incidence of adverse events was comparable between the two groups, with none of participants showing serious side effects, except for nausea and mild abdominal discomfort. <LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK> reported one case of vomiting in the griseofulvin group and no side effects in the terbinafine group.</P>
<SUBSECTION>
<HEADING LEVEL="6">Drug-related adverse events</HEADING>
<P>In the open study (<LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>), 36 participants in the terbinafine group reported 57 adverse events (pruritus, urticaria, skin scaling), and 4 participants withdrew from the study due to adverse events (vomiting, dizziness, urticaria and weight loss). A total of 52 adverse events, predominantly abdominal discomfort and vomiting, were detected in 27 participants in the griseofulvin group, and 1 participant withdrew from the study due to abdominal pain, headache and vomiting. There was no significant difference regarding adverse events that might be attributed to either of the study drugs in the terbinafine (26/77) or griseofulvin (17/70) group (33.8% versus 24.3%, RR 1.39, 95% CI 0.83 to 2.34; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>Some studies reported good tolerability for terbinafine because there were no or few adverse events, and these had either an uncertain or no relationship to the treatment (<LINK REF="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" TYPE="STUDY">Cáceres-Ríos 2000</LINK>; <LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK>). <LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK> reported tonsillitis, cutaneous infestations, raised hepatic enzymes, raised triglycerides and eosinophilia, and <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK> reported mild elevated triglycerides, with an uncertain relationship to the drug. The following adverse events were reported less commonly and may not have been caused by griseofulvin: skin infections, skin infestations, elevated hepatic enzymes, elevated serum triglycerides, elevated serum uric acid, anaemia, eosinophilia, leucocytosis and granulocytopenia (<LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>). <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK> reported three gastric problems and three cases of nausea in the griseofulvin group. Griseofulvin was associated with a small number of adverse events in other trials.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>None of the included studies reported measurement of recurrence of the condition after the end of the intervention period or the time taken to cure.</P>
<SUBSECTION>
<HEADING LEVEL="5">Proportion of participants with clinical cure only</HEADING>
<P>Three studies reported the proportion of patients achieving only a clinical cure (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK>); two were new studies added in this update (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK>). We did not pool the data from these studies because of significant clinical heterogeneity, especially due to the various fungal types in different studies.</P>
<P>
<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK> compared the effects of terbinafine for two weeks, terbinafine for four weeks, and griseofulvin for treating participants infected with <I>T. violaceum</I> (55.1%), <I>A. vanbreuseghemi</I> (30.6%) and <I>T. tonsurans</I> (14.3%). Investigators found that the clinical cure in week 8 was 85.2% (23/27) in the 2-week terbinafine group and 84.2% (16/19) in the griseofulvin group (RR 1.01, 95% CI 0.79 to 1.30; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). The corresponding rate was 78.3% (18/23) in the 4-week terbinafine group and 84.2% (16/19) in the griseofulvin group (RR 0.93, 95% CI 0.70 to 1.24; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). When the follow-up was extended to one year, all participants in the three groups achieved clinical cure.</P>
<P>
<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK> reported that the proportion of participants with clinical cure was determined at the end of treatment (week four for terbinafine and week six for griseofulvin) showing better results in the griseofulvin group (70%, 35/50) than in the terbinafine group (40%, 20/50) (RR 0.57, 95% CI 0.39 to 0.84; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>
<LINK REF="STD-Khan-2011" TYPE="STUDY">Khan 2011</LINK> compared the effects of terbinafine for four weeks and griseofulvin for treating patients infected with <I>T. tonsurans</I> (75%) and <I>M. canis</I> (22%). The proportion of participants with clinical cure only at week six seemed to be higher in the terbinafine group than in the griseofulvin group, but the difference was not statistically significant (70% versus 55%; RR 1.27, 95% CI 0.96 to 1.69; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Percentage of drop-outs as a surrogate for participant adherence</HEADING>
<P>Four studies reported on the percentage of drop-outs as a surrogate for participant adherence (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>), including one new study added to this update (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>). <LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK> reported no drop-outs in the terbinafine group and one in the griseofulvin group (5.3%, 1/19) (RR 0.13, 95% CI 0.01 to 3.08; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>The percentage of drop-outs was 35.9% (37/103) versus 24.2% (26/107) (RR 1.48, 95% CI 0.97 to 2.26 <LINK REF="STD-Fuller-2001" TYPE="STUDY">Fuller 2001</LINK>); 4.0% (2/50) versus 8.0% (4/50) (RR 0.50, 95% CI 0.10 to 2.61 <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>); 10.2% (4/39) versus 17.9% (7/39) (RR 0.57, 95% CI 0.18 to 1.80; <LINK REF="STD-Memisoglu-1999" TYPE="STUDY">Memisoglu 1999</LINK>) in the terbinafine and griseofulvin groups, respectively (see <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Only one study reported no drop-outs from either treatment arm (<LINK REF="STD-Haroon-1995" TYPE="STUDY">Haroon 1995</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Terbinafine (6 weeks) versus griseofulvin (6 weeks) in Trichophyton infections; medium treatment duration; 10 weeks follow-up</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Complete cure, i.e. clinical and mycological cure</HEADING>
<P>Two studies reported on complete cure (<LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>), including one new study added to this update (<LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>). This study included 1549 participants and compared terbinafine (5 to 8 mg/kg for 6 weeks) with griseofulvin (10 to 20 mg/kg for 6 weeks) in children with tinea capitis. In this study, 49.3% of the participants were infected with <I>T. tonsurans</I>, 15.6% were infected with <I>T. violaceum</I>, and 15.1% were infected with <I>M. canis</I>.</P>
<SUBSECTION>
<HEADING LEVEL="6">Trichopyton tonsurans infections</HEADING>
<P>In those infected with <I>T. tonsurans</I>, 52.1% (264/507) of participants in the terbinafine group versus 35.4% (91/257) in the griseofulvin group achieved a complete cure (RR 1.47, 95% CI 1.22 to 1.77; N = 764; moderate quality evidence; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Trichopyton violaceum infections</HEADING>
<P>In those infected with <I>T. violaceum</I>, 41.3% (66/160) of participants in the terbinafine group versus 45.1% (37/82) in the griseofulvin group achieved a complete cure (RR 0.91, 95% CI 0.68 to 1.24; N = 242; low quality evidence; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>The pooled data of participants infected with <I>Trichophyton</I> indicated that there was no significant difference between the terbinafine group and the griseofulvin group (49.5% versus 37.8%; RR 1.18, 95% CI 0.74 to 1.88; N = 1006; low quality evidence; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Drug-related adverse events</HEADING>
<P>Both <LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK> and <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK> reported this outcome. New evidence from <LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK> indicated that 51.9% (541/1042) of participants in the terbinafine group and 49.1% (249/507) in the griseofulvin group reported an adverse effect during the study (RR 1.06, 95% CI 0.95 to 1.18). A total of 9.2% (96/1042) of participants in the terbinafine group and 8.3% (42/507) in the griseofulvin group had adverse events attributed to the study drugs (RR 1.11, 95% CI 0.79 to 1.57; N = 1549; moderate quality evidence; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>)<I>.</I> The most frequent adverse events, accounting for more than 5% in any group, were nasopharyngitis, headache, pyrexia, cough, and vomiting. These individual adverse events were also similar between the two groups.</P>
<P>In addition, <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK> reported "adverse events from 18.4% to 42.4% for the terbinafine treatment groups and 16.7% for the griseofulvin group". The most common adverse events, accounting for approximately 5% in any group, were fever, pharyngitis, infections (parasitic, viral and upper respiratory tract) and influenza-like symptoms. Terbinafine was well tolerated in all treatment groups, although two participants prematurely discontinued treatment. One suffering from urticaria was in the terbinafine 6-week group; and the other, suffering from asymptomatic and reversible neutropaenia, was in the terbinafine 10-week group. Both events resolved without sequelae. Somnolence and gastrointestinal disorders were also reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Severe adverse events</HEADING>
<P>Severe adverse events were rare (0.6% in both groups; RR 0.97, 95% CI 0.24 to 3.88; N = 1549; moderate quality evidence; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>None of the studies comparing terbinafine (six weeks) to griseofulvin (six weeks) for <I>Trichophyton</I> infection reported recurrence of the condition after the end of the intervention period, percentage of drop-outs as a surrogate for participant adherence or the time taken to cure.</P>
<SUBSECTION>
<HEADING LEVEL="5">Proportion of participants with clinical cure only</HEADING>
<P>One new study reported the proportion of patients with a clinical cure only (<LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>). In participants infected with <I>T. tonsurans</I>, the proportion of participants with clinical cure only at week 10 was 70% (355/507) in the terbinafine group and 57.2% (147/257) in the griseofulvin group (RR 1.22, 95% CI 1.09 to 1.38; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). In participants infected with T. violaceum, the corresponding proportion was 65% (104/160) in the terbinafine group and 64.6% (53/82) in the griseofulvin group (RR 1.01, 95% CI 0.83 to 1.22; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Terbinafine (medium (6 to 8 weeks) and long term (10 to 12 weeks) treatment versus griseofulvin in Microsporum infections; 10-16 weeks follow-up</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Complete cure, i.e. clinical and mycological cure</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Microsporum infections</HEADING>
<P>We included two studies that reported data for participants infected with <I>Microsporum </I>(<LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>). In <LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>, a new study added in this update that included 1549 participants,15.1% were infected with <I>M. canis</I>. Of these, 27% (41/152) of participants in the medium-term terbinafine group versus 43.9% (36/82) in the griseofulvin group achieved complete cure (<LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>) (RR 0.61, 95% CI 0.43 to 0.88; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>Another open study, <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>, assessed medium- to long-term treatment regimens of terbinafine versus griseofulvin. In this study, 98.5% of the 165 included participants were infected with <I>M. canis</I>, and the remainder were infected with <I>M. audouini</I>. A lower proportion of participants treated with medium-term terbinafine achieved complete cure (51.4%, 36/70) compared to those treated with griseofulvin (70%, 21/30), but the difference was not statistically significant (RR 0.73, 95% CI 0.53 to 1.02; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). Long-term duration of treatment (10 or 12 weeks) resulted in the complete cure being higher in those in the griseofulvin group (70%, 21/30) compared to those in the terbinafine group (35%, 23/65) at 4 weeks after the end of treatment (RR 0.51, 95% CI 0.34 to 0.76; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>In participants infected with <I>Microsporum</I>, pooling the data from two studies for medium-term treatment (six or eight weeks) resulted in an increase in complete cure for those in the griseofulvin group compared to those in the terbinafine group at four weeks after the end of treatment (34.7% versus 50.9%; RR 0.68, 95% CI 0.53 to 0.86; N = 334; moderate quality evidence; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>None of the studies (<LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>) reported this outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>Neither of the included studies comparing short- or long-term treatment with terbinafine versus griseofulvin for <I>Microsporum</I> reported on recurrence of the condition after the end of the intervention period or the time taken to cure.</P>
<SUBSECTION>
<HEADING LEVEL="5">Proportion of participants with clinical cure only</HEADING>
<P>Two studies reported the proportion of participants with a clinical cure only (<LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>), including one new study added to this update (<LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>). According to <LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>, in participants infected with <I>M. canis</I>, the proportion of participants with clinical cure only at week 10 was 39.5% (60/152) in the terbinafine group and 57.3% (47/82) in the griseofulvin group (RR 0.69, 95% CI 0.53 to 0.90; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). In <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>
 at 16 weeks, the proportion of participants infected with <I>Microsporum</I> with clinical cure only was 61.1% (22/36) and 70.5% (24/34) in the groups treated with terbinafine for 6 and 8 weeks, respectively, and 60.6% (20/33) and 50% (16/32) in the groups treated with terbinafine for 10 and 12 weeks, respectively, compared to 80% (24/30) in the griseofulvin group. The control treatment (griseofulvin for 12 weeks) resulted in more cures compared with medium-term terbinafine treatment duration (6 to 8 weeks) (RR 0.82, 95% CI 0.64 to 1.05; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>) and long-term terbinafine treatment duration (10 to 12 weeks) (RR 0.69, 95% CI 0.52 to 0.92; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>), which was statistically significant in favour of griseofulvin. We pooled data from two studies (<LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>) in a meta-analysis. In participants infected with <I>Microsporum</I>, the proportion of participants with clinical cure only was significantly lower in the medium-term terbinafine treatment group than in the griseofulvin group (RR 0.76, 95% CI 0.63 to 0.91; N = 334; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Percentage of drop-outs as a surrogate for participant adherence</HEADING>
<P>
<LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK> reported on drop-outs as a surrogate to measure adherence. The percentage of drop-outs was 22.2% (8/36), 14.7% (5/34), 18.18% (6/33), 34.2% (12/32), and 23.3% (7/30), in the groups treated with terbinafine for 6, 8, 10, or 12 weeks and griseofulvin, respectively.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Terbinafine short-term versus long-term for treating Trichophyton and Microsporum infections; 12 to 20 weeks follow-up</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Complete cure, i.e. clinical and mycological cure</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">One to two weeks versus four weeks</HEADING>
<P>Four studies reported on complete cure (<LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>; <LINK REF="STD-Haroon-1996" TYPE="STUDY">Haroon 1996</LINK>; <LINK REF="STD-Kullavanijaya-1997" TYPE="STUDY">Kullavanijaya 1997</LINK>; <LINK REF="STD-Talarico-Filho-1998" TYPE="STUDY">Talarico Filho 1998</LINK>). Meta-analysis showed that a four-week treatment duration of terbinafine was significantly better than one to two weeks (65.1% versus 48.6%; RR 0.73, 95% CI 0.62 to 0.86; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Medium term (6 to 8 weeks) versus long-term (10 to 12 weeks)</HEADING>
<P>Medium-term (six to eight weeks) treatment duration of terbinafine appeared to be better than long-term (10 to 12 weeks) treatment duration, but the difference was not statistically significant (51.4% versus 35.3%; RR 1.45, 95% CI 0.97 to 2.17; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Five studies reported on adverse events (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>; <LINK REF="STD-Hamm-1999" TYPE="STUDY">Hamm 1999</LINK>; <LINK REF="STD-Haroon-1996" TYPE="STUDY">Haroon 1996</LINK>; <LINK REF="STD-Talarico-Filho-1998" TYPE="STUDY">Talarico Filho 1998</LINK>), including one study added to this update (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>).</P>
<P>
<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK> reported that none of the terbinafine treated patients experienced adverse events.</P>
<P>
<LINK REF="STD-Talarico-Filho-1998" TYPE="STUDY">Talarico Filho 1998</LINK> reported the following adverse events: mild itching and mild constipation in the one-week arm; mild headache and nausea in the two-week arm; mild urticaria, swelling of the lips (labial oedema), mild constipation, moderate loss of appetite, mild diarrhoea, mild nausea and moderate or partial loss of taste (recovered within eight weeks) in the four-week arm.</P>
<P>
<LINK REF="STD-Hamm-1999" TYPE="STUDY">Hamm 1999</LINK> reported: abdominal pain (mild to moderate), epistaxis (nose bleed), lack of appetite, headache, severe facial swelling, coughing and fever (mild to moderate) in the one-week arm; abdominal pain, fatigue, nausea, dyspepsia, headache and fever in the two-week arm. One additional participant had lack of appetite and gastroenteritis only during the additional four-week treatment period.</P>
<P>In <LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>, around 44% of the participants experienced mild to moderate adverse events, which were probably not related to treatment. The most frequent adverse events were "upper respiratory tract infections, gastrointestinal upsets and other events common in this patient population". Authors did not report relevant data but stated that the frequency of adverse events was similar between groups.</P>
<P>
<LINK REF="STD-Haroon-1996" TYPE="STUDY">Haroon 1996</LINK> compared three different regimens (at one, two and four weeks), reporting a few adverse events: headache, raised hepatic enzymes, raised triglycerides, eosinophilia and leucocytosis in the one-week arm; raised hepatic enzymes and eosinophilia in the two-week arm and raised hepatic enzymes, raised triglycerides, eosinophilia and leucocytosis in the four-week arm.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>None of the studies reported recurrence of the condition after the end of the intervention period.</P>
<SUBSECTION>
<HEADING LEVEL="5">Proportion of participants with clinical cure only</HEADING>
<P>Four studies reported on the proportion of participants achieving a clinical cure only, all of which were also included in the original review (<LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>; <LINK REF="STD-Haroon-1996" TYPE="STUDY">Haroon 1996</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>; <LINK REF="STD-Talarico-Filho-1998" TYPE="STUDY">Talarico Filho 1998</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="6">One to two weeks versus four weeks</HEADING>
<P>Meta-analysis of three included studies showed that a four-week treatment duration of terbinafine seemed to be better than one- to two-week treatment duration, but the difference was not statistically significant (75.1% versus 63.9%; RR 0.84, 95% 0.67 to 1.06; <LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>; <LINK REF="STD-Haroon-1996" TYPE="STUDY">Haroon 1996</LINK>; <LINK REF="STD-Talarico-Filho-1998" TYPE="STUDY">Talarico Filho 1998</LINK>; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Medium term (6 to 8 weeks) versus long-term (10 to 12 weeks)</HEADING>
<P>Data from <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK> showed that medium-term (6 to 8 weeks) treatment duration of terbinafine appeared to be better than long-term (10 to 12 weeks), but the difference was also not statistically significant (65.7% versus 55.4%; RR 1.19, 95% CI 0.90 to 1.56; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Percentage of drop-outs as a surrogate for participant adherence</HEADING>
<P>Two studies reported drop-outs as a surrogate for adherence (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>; <LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>), including one new study added to this update (<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK>).</P>
<P>
<LINK REF="STD-Deng-2011" TYPE="STUDY">Deng 2011</LINK> reported there were no drop-outs in the two-week or four-week terbinafine groups.</P>
<P>In <LINK REF="STD-Friedlander-2002" TYPE="STUDY">Friedlander 2002</LINK>, the percentage of drop-outs in the one-, two- and four-week arms were reported as 25% (14/56), 25.4%(15/59) and 19.3% (12/62), respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Time taken to cure</HEADING>
<P>One study, also included in the original review, reported on time taken to cure (<LINK REF="STD-Hamm-1999" TYPE="STUDY">Hamm 1999</LINK>). The time taken to cure was about two weeks if the causative organism was a <I>Trichophyton</I>. Participants infected with <I>Microsporum</I> only responded to an additional four-week treatment course of terbinafine, i.e. two to three weeks after an initial course of one or two weeks.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Terbinafine standard dose versus double dose in Microsporum infections; 20 weeks follow-up</HEADING>
<P>This update did not identify any new studies addressing the outcomes for this comparison. Likewise, we did not find any studies reporting on our primary outcome of adverse events or the secondary outcomes of proportion of participants with clinical cure only; measurement of recurrence of the condition after the end of the intervention period; or percentage of drop-outs as a surrogate for participant adherence.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Complete cure, i.e. clinical and mycological cure</HEADING>
<P>
<LINK REF="STD-Ungpakorn-2004" TYPE="STUDY">Ungpakorn 2004</LINK> reported on complete cure and assessed the efficacy of the standard dose of terbinafine compared to double doses of terbinafine after 20 weeks of follow-up. Both treatments were given in a pulsed protocol (one week on, three weeks off) for the treatment of tinea capitis caused by <I>Microsporum</I> species. The proportion with complete cure for the standard dose group reached 60.8% (14/23) and was similar to 68.4% (13/19) in the double dose group (RR 1.12, 95% CI 0.72 to 1.76; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Time taken to cure</HEADING>
<P>
<LINK REF="STD-Ungpakorn-2004" TYPE="STUDY">Ungpakorn 2004</LINK> also reported time taken to cure: at week 20 all participants were cured with the exception of one who at the beginning had moderately severe tinea capitis.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Itraconazole (six and two weeks) versus griseofulvin (six weeks) in Trichophyton and Microsporum infections</HEADING>
<P>This update did not identify any new studies addressing the outcomes for this comparison.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Complete cure, i.e. clinical and mycological cure</HEADING>
<P>Two studies reported complete cure (<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TYPE="STUDY">López-Gómez 1994</LINK>).</P>
<P>
<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK> compared six weeks of griseofulvin versus two to three weeks of itraconazole in 100 people, with the dose given according to the participant's weight. This study showed complete cure at 82% (41/50) for the itraconazole group and 92% (46/50) for the griseofulvin group (RR 0.89, 95% CI 0.76 to 1.04; <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>). The main causative fungi were <I>T. tonsurans</I> and <I>T.</I> <I>violaceum</I>, although investigators did not report the exact percentages. According to this trial, when <I>Trichophyton</I> species are the infecting fungi, both griseofulvin and itraconazole reach high complete cure percentages, although griseofulvin tends to be more effective. However the disadvantage was that griseofulvin was administered for six weeks treatment, while itraconazole was administered only for two to three weeks.</P>
<P>In another study involving 34 participants, in whom <I>M. canis</I> was the most common fungi, complete cure was the same for both drugs at 88% (15/17 and 15/17) (<LINK REF="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TYPE="STUDY">López-Gómez 1994</LINK>). This study compared six weeks of treatment with ultra microsize griseofulvin 500 mg/d or itraconazole 100 mg/d with a follow-up of 14 weeks. According to this trial, in tinea capitis involving <I>Microsporum </I>species, both itraconazole and griseofulvin reached high complete cure percentages within a treatment period of six weeks (RR 1.00, 95% CI 0.78 to 1.28; <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>).</P>
<P>We did not see a significant statistical difference between the different doses of itraconazole employed in the two studies and griseofulvin in the pooled analysis (83.6% versus 91.0%; RR 0.92, 95% CI 0.81 to 1.05; N = 134; very low quality evidence; <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Two studies reported adverse events (<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TYPE="STUDY">López-Gómez 1994</LINK>).</P>
<P>Authors did not report adverse events in the itraconazole group of either of the trials. In those treated with griseofulvin, two participants experienced nausea and intense stomach ache with severe vomiting at weeks two and four of treatment, requiring discontinuation of therapy (<LINK REF="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TYPE="STUDY">López-Gómez 1994</LINK>). <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK> reported three gastric problems and three cases of nausea in the griseofulvin group. One of the participants who experienced nausea dropped out of the study.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>None of the studies under this comparison reported recurrence of the condition after the end of the intervention period or the time taken to cure.</P>
<SUBSECTION>
<HEADING LEVEL="5">Proportion of participants with clinical cure only</HEADING>
<P>Only one study reported this outcome (<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>). The proportion of participants with clinical cure only at the end of treatment reported in the study were 44% (22/50) and 70% (35/50) in the itraconazole and in the griseofulvin groups, respectively (RR 0.63, 95% CI 0.44 t0 0.90; <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Percentage of drop-outs as a surrogate for participant adherence</HEADING>
<P>Two studies reported on drop-outs (<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TYPE="STUDY">López-Gómez 1994</LINK>).</P>
<P>In <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>, the percentage of drop-outs was the same for both treatment groups (8% versus 8%; RR 1.00, 95% CI 0.26 to 3.78; <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>). In <LINK REF="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TYPE="STUDY">López-Gómez 1994</LINK> the percentage of drop-outs was 5.5% (1/18) in the itraconazole group and 11.7% (2/17) in the griseofulvin group (RR 0.47, 95% CI 0.05 to 4.74; <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">7. Itraconazole versus terbinafine (both two weeks) in Trichophyton infections</HEADING>
<P>This update did not identify any new studies addressing the outcomes for this comparison.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Complete cure, i.e. clinical and mycological cure</HEADING>
<P>
<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK> and <LINK REF="STD-Jahangir-1998" TYPE="STUDY">Jahangir 1998</LINK> reported on complete cure.</P>
<P>
<LINK REF="STD-Jahangir-1998" TYPE="STUDY">Jahangir 1998 </LINK>had 60 participants and compared a two-week course of itraconazole (50 to 200 mg/d based on weight) with two weeks of terbinafine. <I>T. violaceum</I> was the causative fungus in 82% to 89% of the participants. Twelve weeks after the start of treatment, 53% (16/30) and 60% (18/30) of participants were completely cured in the terbinafine and itraconazole groups, respectively (RR 1.13, 95% CI 0.72 to 1.75; <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>). <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>, where <I>Trichophyton</I> was the species of fungus, compared itraconazole and terbinafine with a two- to three-week course of therapy. At 12 weeks, 94% (47/50) in the terbinafine group had a complete cure, compared to 82% (41/50) in the itraconazole group (RR 0.87, 95% CI 0.75 to 1.01; <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>).</P>
<P>In the pooled analyses, there was very little difference in the proportion of participants achieving complete cure with itraconazole and terbinafine (as treatment of <I>Trichophyton </I>species) when used for periods of two to three weeks (73.8% versus 78.8%; RR 0.93, 95% CI 0.72 to 1.19; N = 160; low quality evidence; <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Only <LINK REF="STD-Jahangir-1998" TYPE="STUDY">Jahangir 1998</LINK> reported adverse events. Two participants reported urticaria in the itraconazole group. In the terbinafine group, one participant experienced fever, body aches and vertigo, but no participant showed any significant haematological or biochemical change.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>No studies for this comparison reported recurrence of the condition after the end of the intervention period or the time taken to cure.</P>
<SUBSECTION>
<HEADING LEVEL="5">Proportion of participants with clinical cure only</HEADING>
<P>Only <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK> reported on the proportion of participants achieving clinical cure at the end of the four-week treatment, with similar results in both terbinafine and itraconazole treatment groups: 40% (20/50) and 44% (22/50), respectively (RR 1.10, 95% CI 0.69 to 1.75; <LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Percentage of drop-outs as a surrogate for participant adherence</HEADING>
<P>
<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK> reported that the percentage of drop-outs was 8% (4/50) for the itraconazole group and 4% (2/50) for the terbinafine group (RR 2.00, 95% CI 0.38 to 10.43, <LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">8. Ketoconazole versus griseofulvin (12 to 26 weeks) in Trichophyton infections; 12 to 26
weeks follow-up</HEADING>
<P>This update did not identify any new studies addressing the outcomes for this comparison.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Complete cure, i.e. clinical and mycological cure</HEADING>
<P>Two studies reported complete cure, but because of the differences in treatment durations between them, we did not pool the results (<LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>; <LINK REF="STD-Tanz-1988" TYPE="STUDY">Tanz 1988</LINK>).</P>
<P>
<LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK> was an open study in 80 participants where <I>Trichophyton</I> species predominated; investigators compared once-daily ketoconazole 5 mg/kg/d with once-daily griseofulvin 15 mg/kg/d. The children were examined every two weeks while they were receiving therapy (and at least one follow-up after the end of therapy). Treatment was stopped when there was either complete cure or after six months had passed. At the end of 12 weeks of therapy, 73.5% (25/34) of participants treated with ketoconazole had complete cure of their infection, compared with 96.4% (27/28) of the participants given griseofulvin (RR 0.76, 95% CI 0.62 to 0.94; N = 62; low quality evidence; <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>; <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK> ).</P>
<P>Those who did not achieve a complete clinical cure within 12 weeks continued to take therapy and were assessed between 12 and 26 weeks of therapy, until they exhibited complete resolution of clinical disease and negative hair sample cultures. During this period, the one remaining griseofulvin participant and six of the ketoconazole participants with continuing disease had complete clearance of clinical and mycological disease.</P>
<P>Thus, by the end of 26 weeks, all of the participants in the griseofulvin group were completely cured, and only three ketoconazole-treated patients remained with persistent clinical disease and positive mycological cultures (i.e. 91.2% (31/34) participants receiving ketoconazole compared with 100% (28/28) in the griseofulvin group (RR 0.95, 95% CI 0.83 to 1.07; N = 62; low quality evidence; <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>; <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>).</P>
<P>In <LINK REF="STD-Tanz-1988" TYPE="STUDY">Tanz 1988</LINK>, participants randomly received ketoconazole or griseofulvin for 12 weeks. The proportion of participants with complete cure was similar at 48% (16/33) in the ketoconazole group and 54% (25/46) in the griseofulvin group (RR 0.89, 95% CI 0.57 to 1.39; N = 79; low quality evidence; <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>; <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Four studies reported adverse events (<LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>; <LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>; <LINK REF="STD-Tanz-1985" TYPE="STUDY">Tanz 1985</LINK>; <LINK REF="STD-Tanz-1988" TYPE="STUDY">Tanz 1988</LINK>). Despite reports of liver disease (<LINK REF="REF-Lewis-1984" TYPE="REFERENCE">Lewis 1984</LINK>), we did not find any studies reporting this adverse effect. Ketoconazole use was associated with two cases of abdominal pain and one case of urticaria (<LINK REF="STD-Tanz-1985" TYPE="STUDY">Tanz 1985</LINK>). Only one participant from the ketoconazole group withdrew from the study and reported to have nausea. Other than this, there were no serious adverse reactions in any of the two groups (<LINK REF="STD-Tanz-1988" TYPE="STUDY">Tanz 1988</LINK>). No adverse events were reported in the ketoconazole group (<LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>; <LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>). One griseofulvin-treated participant showed a two-fold increase in serum alanine aminotransferase and aspartate aminotransferase after three weeks of treatment, but values returned to normal at the following weekly clinic visits (<LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Proportion of participants with clinical cure only</HEADING>
<P>Only one study reported this outcome (<LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>). The proportion of participants with clinical cure evaluated at the end of treatment were 100% (8/8) and 80% (4/5) in the ketoconazole and griseofulvin groups, respectively (RR 1.26, 95% CI 0.77 to 2.05; <LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Proportion of participants with recurrence of the condition after the end of the intervention period</HEADING>
<P>
<LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK> reported (page 48) that "three patients (two treated with ketoconazole and one treated with griseofulvin) had a recurrence of tinea capitis at four weeks (two patients) and at four months (one patient) following discontinuation of therapy".</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Percentage of drop-outs as a surrogate for participant adherence</HEADING>
<P>Two studies reported this outcome (<LINK REF="STD-Tanz-1985" TYPE="STUDY">Tanz 1985</LINK>; <LINK REF="STD-Tanz-1988" TYPE="STUDY">Tanz 1988</LINK>).</P>
<P>In <LINK REF="STD-Tanz-1985" TYPE="STUDY">Tanz 1985</LINK>, the percentage of drop-outs was 30% (3/10) and 41.6% (5/12) in the ketoconazole and griseofulvin groups, respectively (RR 0.72, 95% CI 0.23 to 2.30, <LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK>).</P>
<P>In <LINK REF="STD-Tanz-1988" TYPE="STUDY">Tanz 1988</LINK>, the percentage of drop-outs was 66.6% (22/33) and 56.5% (26/46) in the ketoconazole and griseofulvin groups, respectively (RR 1.18, 95% CI 0.83 to 1.67; <LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Time taken to cure</HEADING>
<P>Two studies reported this outcome (<LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>; <LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK>).</P>
<P>In <LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>, the time needed to improve was 60 days and 108 days in the ketoconazole and griseofulvin groups, respectively. Hair sample cultures took significantly longer to become negative (sterile) in the ketoconazole group (median eight weeks) than in the griseofulvin group (four weeks).</P>
<P>
<LINK REF="STD-Mart_x00ed_nez_x002d_Roig-1988" TYPE="STUDY">Martínez-Roig 1988</LINK> reported the mean time to clinical cure in weeks: 4.2 weeks in the griseofulvin group and 5.0 weeks in the ketoconazole group. They also reported the mean time needed to achieve negative cultures in weeks: 3.6 and 4.7 weeks in the griseofulvin and ketoconazole groups, respectively.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">9. Fluconazole (2 to 6 weeks) versus griseofulvin (6 weeks); 8-12 weeks follow-up</HEADING>
<P>The study by <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK> was new to this update.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Complete cure, i.e. clinical and mycological cure</HEADING>
<P>Three studies reported this outcome (<LINK REF="STD-Dastghaib-2005" TYPE="STUDY">Dastghaib 2005</LINK>; <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>).</P>
<P>
<LINK REF="STD-Dastghaib-2005" TYPE="STUDY">Dastghaib 2005</LINK> assessed 40 participants: 16 were infected with <I>T. violaceum</I>, 16 with <I>T. verrucosum</I> and 8 with <I>M. canis</I>. The children were treated with 5 mg/kg/d of fluconazole or 15 mg/kg/d griseofulvin for four and six weeks, respectively. Complete cure was reported for 79% (15/19) of the fluconazole arm and 76% (16/21) of the griseofulvin arm (RR 1.04, 95% CI 0.74 to 1.45; <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>).</P>
<P>
<LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK> included 880 participants: 86% were infected with <I>T. tonsurans </I>and 11% with <I>M. canis</I>; 721 of them were included in the analyses: 245 participants on short-term fluconazole, 246 participants on the medium-term fluconazole and 230 participants in the griseofulvin group. As we stated in the 'Methods' section, for RCTs with multiple intervention groups, we split the shared griseofulvin group (N = 230) in two (N = 115 each) to avoid double-counting<I>.</I>
</P>
<P>The children were randomly assigned to three groups and treated with a short-term course of fluconazole (6 mg/kg/d for three weeks; N = 245); medium-term use of fluconazole (6 mg/kg/d for six weeks; N = 246); or griseofulvin (11 mg/kg/d for six weeks; 230), respectively. Complete cure was not significantly different between the short-term fluconazole group and the griseofulvin group (30.2% versus 31.3%; RR 0.96, 95% CI 0.69 to 1.34; <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>).</P>
<P>
<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK> assessed 100 participants who were infected with <I>T. tonsurans</I> and/or <I>T.</I> <I>violaceum </I>(the exact percentages were not reported). They were treated with either fluconazole 6 mg/kg/d for two to three weeks or with microsize griseofulvin 20 mg/kg/d for six weeks. The proportion of participants with complete cure were 82% (41/50) and 92% (46/50), respectively (RR 0.89, 95% CI 0.76 to 1.04; <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="6">Short-term (2-4 weeks) fluconazole</HEADING>
<P>Meta-analysis of the three studies failed to show any significant difference between short-term use of fluconazole and griseofulvin for proportions of participants with complete cure i.e. clinical and mycological cure (41.4% versus 52.7%; RR 0.92, 95% CI 0.81 to 1.05<I>;</I> N = 615; moderate quality evidence; <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>; <LINK REF="STD-Dastghaib-2005" TYPE="STUDY">Dastghaib 2005</LINK>; <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>; <LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Medium-term (6 weeks) fluconazole</HEADING>
<P>There is a single trial in this subgroup (N = 361; <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>). There was no clear difference between between the medium-term fluconazole group and the griseofulvin group (34.1% versus 32.1%; RR 1.06, 95% CI 0.77 to 1.46; N = 361; low quality evidence; <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>; <LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Three studies reported this outcome (<LINK REF="STD-Dastghaib-2005" TYPE="STUDY">Dastghaib 2005</LINK>; <LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>).</P>
<P>
<LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK> included 1063 patients for safety evaluation and reported that the most frequent treatment-related adverse events were abdominal pain (1.3%) and diarrhoea (0.7%) in the short-term fluconazole group; headache (0.9%) and rash (0.6%) in the medium-term fluconazole group; and headache (1.7%), abdominal pain (1.4%) and dyspepsia (1.0%) in the griseofulvin group. There were no significant differences between the three groups with regard to all causality and treatment-related adverse events.</P>
<P>Two studies reported nausea as an adverse effect in the griseofulvin group (<LINK REF="STD-Dastghaib-2005" TYPE="STUDY">Dastghaib 2005</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>None of the studies in this comparison reported on recurrence of the condition after the end of the intervention period or the time taken to cure.</P>
<SUBSECTION>
<HEADING LEVEL="5">Proportion of participants with clinical cure only</HEADING>
<P>Two studies reported this outcome (<LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>).</P>
<P>
<LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK> reported that the proportions of participants with clinical cure only at week 10 were 40% (98/245), 46% (112/246), and 40% (92/230) in the short-term fluconazole, medium-term fluconazole, and griseofulvin groups, respectively.</P>
<P>
<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK> reported the proportions of participants with clinical cure only at the end of treatment (week 4 for fluconazole and week 6 for griseofulvin) were 26% (13/50) and 70% (35/50) in the fluconazole and griseofulvin groups, respectively (RR 0.37, 95% CI 0.22 to 0.61; <LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Percentage of drop-outs as a surrogate for participant adherence</HEADING>
<P>Two studies reported this outcome (<LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>; <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>).</P>
<P>
<LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK> reported that the percentages of drop-outs were 12% (37/302), 7% (21/286), and 8% (24/292) in the short-term fluconazole, medium-term fluconazole and griseofulvin groups, respectively.</P>
<P>The same percentage of drop-outs was reported for both groups in <LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK> (8% versus 8%, RR 1.00, 95% CI 0.26 to 3.78; <LINK REF="CMP-009.03" TYPE="ANALYSIS">Analysis 9.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">10. Fluconazole (2 to 3 weeks) versus terbinafine (2 to 3 weeks) in Trichophyton infections; 12 weeks follow-up</HEADING>
<P>This update did not identify any new studies addressing the outcomes for this comparison. Moreover, none of the trials evaluating this comparison reported on adverse events, recurrence of the condition after the end of the intervention period or the time taken to cure.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Complete cure, i.e. clinical and mycological cure</HEADING>
<P>Only one study reported this outcome (<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>). The efficacy of fluconazole for two to three weeks was compared with terbinafine, dosed according to weight for two to three weeks in <I>Trichophyton</I> infections. The proportions of participants with complete cure were 82% (41/50) for the fluconazole arm and 94% (47/50) for the terbinafine arm (RR 0.87, 95% CI 0.75 to 1.01; N = 100; low quality evidence; <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>; <LINK REF="SOF-06" TYPE="SOF">Summary of findings table 6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Proportion of participants with clinical cure only</HEADING>
<P>Only one study reported this outcome (<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>). The proportion of participants with clinical cure only at the end of treatment (week 4 for terbinafine and fluconazole) was not significantly different in the terbinafine group compared with the fluconazole group ((40% versus 26%; RR 1.54, 95% CI 0.86 to 2.74).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Percentage of drop-outs as a surrogate for participant adherence</HEADING>
<P>Only one study reported this outcome (<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>). The percentage of drop-outs was 4% (2/50) and 8% (4/50) in the terbinafine and fluconazole groups, respectively (RR 0.50, 95% CI 0.10 to 2.61).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">11. Fluconazole (2 to 3 weeks) versus itraconazole (2 to 3 weeks) in Trichophyton infections; 12 weeks follow-up</HEADING>
<P>This update did not identify any new studies addressing the outcomes for this comparison. Moreover, none of the trials evaluating this comparison reported on adverse events, recurrence of the condition after the end of the intervention period or the time taken to cure.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Complete cure, i.e. clinical and mycological cure</HEADING>
<P>Only one study reported this outcome (<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>). When fluconazole treatment was compared with itraconazole in participants with <I>Trichophyton</I> tinea capitis, in doses of 5 mg/kg/d daily for two to three weeks, the proportion of participants with complete cure was 82% (41/50 and 41/50) for both groups (RR 1.00, 95% CI 0.83 to 1.20; N = 100; low quality evidence; <LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>; <LINK REF="SOF-07" TYPE="SOF">Summary of findings table 7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome:</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Proportion of participants with clinical cure only</HEADING>
<P>Only one study reported this outcome (<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>). The proportion of participants with clinical cure only at the end of treatment (week four in itraconazole and fluconazole groups) was nearly double in the itraconazole group: 44% (22/50) compared with 26% (13/50) in the fluconazole group, but the difference was not statistically significant (RR 1.69, 95% CI 0.96 to 2.97; <LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Percentage of drop-outs as a surrogate for participant adherence</HEADING>
<P>Only one study reported this outcome (<LINK REF="STD-Gupta-2001" TYPE="STUDY">Gupta 2001</LINK>). The same percentage of drop-outs as a surrogate for participant adherence was reported in both treatment groups (8%, 4/50; RR 1.00, 95% CI 0.26 to 3.78; <LINK REF="CMP-011.03" TYPE="ANALYSIS">Analysis 11.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">12. Fluconazole low dose versus higher dose (1.5, 3.0 and 6.0 mg/kg/d) in Trichophyton infections; 4 months follow-up</HEADING>
<P>This update did not identify any new studies addressing the outcomes for this comparison. In fact, we found a single study for this comparison, and it only reported on one primary outcome (complete cure) and not on any of our secondary outcomes (<LINK REF="STD-Solomon-1997" TYPE="STUDY">Solomon 1997</LINK>). We categorised data into three subgroups comprising 1.5 mg versus 3.0 mg; 1.5 mg versus 6.0 mg; and 3.0 mg versus 6.0 mg.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Complete cure, i.e. clinical and mycological cure</HEADING>
<P>
<LINK REF="STD-Solomon-1997" TYPE="STUDY">Solomon 1997</LINK> compared different doses of fluconazole: 1.5 mg/kg/d, 3.0 mg/kg/d, and 6.0 mg/kg/d, for 20 days in a group of 41 participants with tinea capitis caused by the <I>Trichophyton</I> species. Authors reported efficacy in only 27 participants and did not provide details on drop-outs by group. However, they reported the total missing participants (34%) in the study. Thus, we assumed that the same percentage was applied for the missing participants in each group, being originally 12, 15 and 14 participants randomly assigned in the 1.5 mg/kg/d, 3.0 mg/kg/d and 6.0 mg/kg/d groups, respectively. Intention-to-treat efficacy rates in the 1.5 mg/kg/d, 3.0 mg/kg/d and 6.0 mg/kg/d groups were 17% (2/12), 40% (6/15) and 57% (8/14), respectively.</P>
<P>Although higher doses resulted in more cures than lower doses, none of the comparisons reached statistical significance (3.0 mg versus 1.5 mg: RR 2.40, 95% CI 0.59 to 9.82; <LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>; 6.0 mg versus 1.5 mg: RR 3.43, 95% CI 0.89 to 13.15; <LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>; 6.0 mg versus 3.0 mg: RR 1.43, 95% CI 0.66 to 3.08; <LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">13. Treatment durations of fluconazole (3 weeks versus 6 weeks); 10 weeks follow-up</HEADING>
<P>One new study added to this update evaluated this comparison, but it did not report on adverse events, recurrence of the condition after the end of the intervention period or the time taken to cure (<LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Complete cure, i.e. clinical and mycological cure</HEADING>
<P>
<LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK> compared different treatment duration of fluconazole: short-term use of fluconazole (6 mg/kg/d for three weeks) and medium-term use of fluconazole (6 mg/kg/d for six weeks). At week 10, there was no significant difference with regard to the proportion of participants with complete cure for the short-term and medium-term use of fluconazole in children infected with <I>T. tonsurans</I> and <I>M. canis</I> (30.2%, 74/245 versus 34.1%, 84/246; RR 0.88, 95% CI 0.68 to 1.14; N = 491; low quality evidence; <LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>; <LINK REF="SOF-08" TYPE="SOF">Summary of findings table 8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Proportion of participants with clinical cure only</HEADING>
<P>
<LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK> reported that short-term use of fluconazole and medium-term use of fluconazole had similar effects on clinical cure (RR 0.88, 95% CI 0.72 to 1.08).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Percentage of drop-outs as a surrogate for participant adherence</HEADING>
<P>
<LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK> reported the percentage of drop-outs was 12% (37/302) and 7% (21/286) in the short-term and medium-term fluconazole groups, respectively (RR 1.67, 95% CI 1.00 to 2.78).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-05-03 16:19:57 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2016-04-29 12:17:26 +0100" MODIFIED_BY="[Empty name]">
<P>In this updated review, we included 25 studies (comprising of 4449 participants), including 4 new studies (2637 participants) added to this update. The data from the included studies produced 13 main comparisons of interventions.</P>
<SUBSECTION>
<HEADING LEVEL="3">Terbinafine versus griseofulvin</HEADING>
<P>In our meta-analyses of terbinafine for 4 weeks versus griseofulvin for 8 weeks assessed at 12 to 24 weeks of follow-up, the result favoured neither terbinafine nor griseofulvin for <I>Trichophyton</I> infections (RR 1.06, 95% CI 0.98 to 1.15; N = 328, 3 RCTs; low quality evidence; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>) for our primary outcome of complete cure.This was also the case for mixed<I> Trichophyton</I> and <I>Microsporum</I> infections in two studies and in a single study analysis of <I>Microsporum</I> infections.</P>
<P>New evidence from <LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK> indicated that terbinafine (at standard doses according to the participant's weight for six weeks) achieved a similar proportion with complete cure as griseofulvin (at standard doses according to the participant's weight for six weeks) in children infected with <I>Trichophyton</I>, when followed up for 10 weeks (RR 1.18, 95% CI 0.74 to 1.88; N = 1006; 1 RCT; low quality evidence, <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). Sub-group analysis assessing response to treatment in children infected with <I>T. tonsurans </I>revealed that terbinafine is better than griseofulvin. This new evidence resulted in a change in the conclusions of this review. However, both of the two regimens had similar effects in children with <I>T. violaceum.</I>
</P>
<P>There is moderate quality evidence that griseofulvin (6 to 12 weeks) is better than medium-term (6 to 8 weeks) use of terbinafine with respect to the proportion of participants achieving complete cure (RR 0.68, 95% CI 0.53 to 0.86; N = 334; 2 RCTs; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).This evidence in favour of the efficacy of griseofulvin in <I>Microsporum</I> infection was newly added to this update (<LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>).</P>
<P>Moderate quality evidence also confirmed that the adverse events and severe adverse events are comparable between terbinafine and griseofulvin, the adverse events being mild and reversible in most cases (RR 1.11, 95% CI 0.79 to 1.57; N = 1549; 1 RCT; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Different dose regimens of terbinafine</HEADING>
<P>We investigated a possible relationship between dose, duration and response for terbinafine. A meta-analysis of four studies indicated that a four-week treatment duration of terbinafine was significantly better than one or two weeks of treatment with respect to complete cure of <I>Trichophyton</I> and <I>Microsporum</I> infections (RR 0.73, 95% CI 0.62 to 0.86; N = 552; 4 RCTs)<I>.</I> There were no differences in the proportion of participants who were completely cured, or cured clinically, when comparing medium-term (6 to 8 weeks) versus long-term (10 to 12 weeks) terbinafine in a single-study analysis. Comparisons of adverse events between the different terms of treatment showed that the adverse events were mild and comparable between the groups. A single-study comparison of the standard dose of terbinafine compared to a double dose in one study of <I>Microsporum </I>infections showed that the effectiveness in completely curing the infection was comparable between regimens when assessed at 20 weeks follow-up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Itraconazole versus griseofulvin</HEADING>
<P>A meta-analysis of two studies found no significant difference between itraconazole and griseofulvin for achieving a complete cure in children with <I>Trichophyton</I> and <I>Microsporum </I>(RR 0.92, CI 0.81 to 1.05; N = 134; 2 RCTs; very low quality evidence; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Itraconazole versus terbinafine</HEADING>
<P>A meta-analysis of two studies indicated that there was no significant difference between itraconazole and griseofulvin for achieving a complete cure in children infected with <I>Trichophyton</I> (RR 0.93, CI 0.72 to 1.19; N = 160; 2 RCTs; low quality evidence; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ketoconazole versus griseofulvin</HEADING>
<P>Current evidence regarding ketoconazole versus griseofulvin was limited. One study favoured griseofulvin, because ketoconazole (for 12 weeks) appeared to be less effective in terms of complete cure than griseofulvin for the same period (RR 0.76; 95% CI 0.62 to 0.94; <LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>). However, by the end of the study, when the treatment duration was extended up to a maximum of 26 weeks in those who had not achieved a cure by 12 weeks, their effects appeared to be similar (RR 0.95, 95% CI 0.83 to 1.07). Another study indicated that the proportion with a complete cure was similar in the ketoconazole (for 12 weeks) and griseofulvin (for 12 weeks) groups (RR 0.89, 95% CI 0.57 to 1.39; <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Fluconazole versus other therapies (griseofulvin or terbinafine or fluconazole)</HEADING>
<P>A meta-analysis of three studies indicated that fluconazole and griseofulvin had similar effects for achieving complete cure either in the short term of two to four weeks (RR 0.92, 95% CI 0.81 to 1.05; N = 500; 3 RCTs moderate quality evidence) or in the medium term of six weeks (RR 1.06, 95% CI 0.77 to 1.46; N = 361; 1 RCT low quality evidence, <LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>).</P>
<P>A single study analysis of one small trial showed no differences between either of the two interventions for the outcome of complete cure when fluconazole was compared with terbinafine, both administered for two to three weeks (RR 0.87 CI 0.75 to 1.01; N = 100; 1 RCT; low quality evidence; <LINK REF="SOF-06" TYPE="SOF">Summary of findings table 6</LINK>), or when fluconazole was compared to itraconazole each administered for two to three weeks, for <I>Trichophyton </I>infections (RR 1.00 CI 0.83 to 1.20; N = 100, 1 RCT low quality evidence, <LINK REF="SOF-07" TYPE="SOF">Summary of findings table 7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Different dosages of fluconazole</HEADING>
<P>The dosage of fluconazole was compared in one small single study analysis, that is, 1.5, 3.0, and 6.0 mg/k/d in <I>Trichophyton</I> infections, with no significant differences between the groups, although higher doses resulted in more cures in each comparison when followed up at 4 months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Different treatment duration of fluconazole</HEADING>
<P>A further single study analysis of treatment duration of fluconazole treatment comparing short-term (3-week) versus medium-term (6-week) treatment at 10 weeks follow-up, showed no significant differences between the groups for children infected with <I>T. tonsurans</I> and <I>M. canis</I>.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-04-28 11:25:26 +0100" MODIFIED_BY="[Empty name]">
<P>This review may help physicians worldwide weigh the advantages and disadvantages of systemic antifungal agents and the options when treating children with tinea capitis. It draws on detailed information derived from clinical trials assessing the efficacy of treatments for tinea capitis. However, caution is warranted when interpreting the data, because the 25 included studies published between 1987 to 2013 were conducted in different countries and included people of different ethnicities. Furthermore, fungal types varied from one trial to another. This means that our results may not be directly clinically applicable to individual participants and their specific situations.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-04-29 12:19:48 +0100" MODIFIED_BY="[Empty name]">
<P>The quality of evidence in this review for each outcome, as presented in the 'Summary of findings' tables, was very low to moderate. The main reasons for downgrading the quality of the evidence for these outcomes were imprecision due to low sample sizes and risk of bias in the included studies.</P>
<SUBSECTION>
<HEADING LEVEL="3">Limitations in study design, execution, and reporting</HEADING>
<P>The studies included in this review had several methodological limitations: only four studies adequately described the method of randomisation, and only two described adequate allocation concealment. Blinding of participants and personnel and blinding of outcome assessors was not adequate in any of the studies. Ten studies were at high risk of bias from incomplete reporting of outcome data (attrition bias), and although we judged that none was at high risk of selective reporting bias, we did not actually have access to the study protocols for comparison.</P>
<P>We detected other sources of bias, including failure to report disease severity or baseline comparability, but the extent to which these factors may have introduced bias was unclear. It is therefore important to emphasise that any conclusions that we have drawn are reliant on primary studies with varying degrees of bias. Readers should consider risk of bias when interpreting these results (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>) and exercise caution with findings derived from studies with high or unclear risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Inconsistency of the results</HEADING>
<P>Inconsistency refers to an unexplained heterogeneity of the results across studies.</P>
<P>In this review, most of the comparisons were assessed in single studies, so assessment of consistency of the results across studies was not necessary. In outcomes for which the data were pooled, inconsistency of effects was only identified for one outcome (complete cure, terbinafine versus griseofulvin, <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). In this outcome, we downgraded one level because I<SUP>2</SUP> of the pooled outcome was 85%, which indicated substantial heterogeneity. One source of heterogeneity in this analysis of <I>Trichophyton</I> infections may be that the analysis included both<I> T. tonsurans and T. violaceum </I>infections; however, the extent to which this clinical heterogeneity contributed to the observed statistical heterogeneity is unclear.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Imprecision of the results</HEADING>
<P>Results are considered imprecise when studies include relatively few patients and few effects. In this review, imprecision was identified in some comparisons, and the reason for imprecision was that total number of effects was less than 300 as recommended by the GRADE handbook (<LINK REF="REF-Sch_x00fc_nemann-2013" TYPE="REFERENCE">Schünemann 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Indirectness of the evidence</HEADING>
<P>The majority of the 4449 participants with fungal infections in the 25 included studies were aged 2 to 16 years, so the evidence we found directly relates to the disease population of interest. In this review, patient-reported outcomes (PROs), such as quality of life, were rarely reported in the included studies. PROs are important for evidence-based clinical decision making and need to be addressed in future studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Publication bias</HEADING>
<P>It was impossible to perform a funnel plot analysis to assess potential publication bias for any of our outcomes because of the limited number of trials; there were only one to three studies for each comparison.</P>
</SUBSECTION>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-04-29 12:20:43 +0100" MODIFIED_BY="[Empty name]">
<P>Our assessment of the included studies was based on the published manuscripts; therefore, the results were inevitably influenced by the reporting quality of these studies. Undoubtedly, poor reporting quality influences the accuracy of the assessments, and we were unable to obtain further information from the trial investigators we contacted. <LINK REF="STD-Pather-2006" TYPE="STUDY">Pather 2006</LINK> was a conference paper that appeared to meet the inclusion criteria, but as we could not obtain further information, we could not include or exclude it. This may be a source of potential bias, as the conclusions of the review could change once that study has been assessed. We attempted to conduct a comprehensive search for studies, but theoretically, there might be some missing studies because we did not search all local medical databases around the world.</P>
<P>In addition, clinical heterogeneity between included studies is inevitable because each study had participants with different ethnicities, types of fungal infection, severity of disease, dosages of drugs, and durations of treatment and follow-up. Clinical heterogeneity could introduce bias when we combined the results of different studies by meta-analysis.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-05-03 16:19:57 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Griseofulvin</HEADING>
<P>In this review, griseofulvin was employed as a standard therapy for the evaluation of any newer treatments for tinea capitis.</P>
<P>An earlier meta-analysis found that griseofulvin was an effective therapy for tinea capitis (<LINK REF="REF-Gupta-2008" TYPE="REFERENCE">Gupta 2008</LINK>). This conclusion is supported by the findings of our review: in our meta-analyses of griseofulvin versus terbinafine (two to four weeks), griseofulvin (six to eight weeks) was at least as effective as terbinafine for <I>Trichophyton, Microsporum </I>and mixed<I> Trichophyton</I> and <I>Microsporum </I>infections for our primary outcome of complete cure.</P>
<P>
<LINK REF="REF-Tey-2011" TYPE="REFERENCE">Tey 2011</LINK>, another meta-analysis, concluded that "griseofulvin is more efficacious than terbinafine in treating tinea capitis caused by <I>Microsporum</I> species". Additionally, <LINK REF="REF-Gupta-2013" TYPE="REFERENCE">Gupta 2013</LINK> performed a further meta-analysis of randomised controlled trials and found no differences in the overall efficacy of the two drugs at the doses specified, but differences were observed based on the infectious species, i.e. griseofulvin was superior for <I>Microsporum </I>spp<I>.</I>, whereas terbinafine was superior for <I>Trichophyton </I>spp<I>. </I>The recent guideline from the British Association of Dermatologists (BAD) also recommended griseofulvin as the first-line treatment for tinea capitis in children, especially in those infected with <I>Microsporum</I> spp. (<LINK REF="REF-Fuller-2014" TYPE="REFERENCE">Fuller 2014</LINK>). This update of the review also provides new, moderate quality evidence that for <I>Microsporum</I> infections, griseofulvin is better than terbinafine with respect to the proportion of participants achieving complete cure (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>), which is in agreement with previous reviews and guidelines.</P>
<P>In our other comparisons of griseofulvin with triazole antifungal agents (itraconazole, fluconazole and ketoconazole) we found no evidence that griseofulvin was superior in efficacy for the outcome of complete cure, but these were small trials, and the quality of the evidence was moderate at best.</P>
<P>We found only limited evidence about the most suitable doses, duration and formulations of griseofulvin. Dosage recommendations for griseofulvin vary due to different formulations (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1505261727570676812747138012144&amp;format=REVMAN#REF-Higgins-2000">Higgins 2000</A>), and taking griseofulvin with fatty food improves its absorption and bioavailability. Some trials recommended higher doses for microsized griseofulvin but not for ultra-microsized griseofulvin, although up to 25 mg/kg may be necessary (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1505261727570676812747138012144&amp;format=REVMAN#REF-Higgins-2000">Higgins 2000</A>). We found no evidence that directly compared different formulations of griseofulvin.</P>
<P>The main disadvantage of griseofulvin is perceived to be long duration of treatment required, which may lead to reduced adherence. The European Society for Pediatric Dermatology (ESPD) recommended, "The treatment decision between griseofulvin and newer antifungal agents for children with <I>Trichophyton </I>spp<I>. </I>for tinea capitis can be based on an individual patient on the balance between duration of treatment &#8260; adherence and economic considerations" (<LINK REF="REF-Kakourou-2010" TYPE="REFERENCE">Kakourou 2010</LINK>). It is still unclear if there is a difference in terms of adherence between four weeks of terbinafine versus eight weeks of griseofulvin, as in this review we did not find any evidence to support the hypothesis that adherence improves with shorter courses of treatment. It could be argued, though, that long courses of griseofulvin versus shorter courses of terbinafine for example, already incorporate any reduced adherence simply because of the longer duration of the former.</P>
<P>We included two studies that reported data on duration of treatment for participants infected with <I>Microsporum (</I>
<LINK REF="STD-Elewski-2008" TYPE="STUDY">Elewski 2008</LINK>; <LINK REF="STD-Lipozencic-2002" TYPE="STUDY">Lipozencic 2002</LINK>). A lower proportion of participants treated with six to eight weeks of terbinafine in <I>M. canis and M. audouini </I>infections achieved complete cure compared to those treated with griseofulvin (not statistically significant). Long-term duration of treatment (10 or 12 weeks) resulted in a higher proportion of participants achieving complete cure in the griseofulvin group than in the terbinafine group (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). However, in the absence of further direct comparisons of duration or formulations, we cannot comment further on the optimal regimens for treating tinea capitis in children with griseofulvin.</P>
<P>Griseofulvin is reported to be a safe drug, although it commonly causes side effects such as headaches and gastrointestinal upsets (<LINK REF="REF-Bennassar-2010" TYPE="REFERENCE">Bennassar 2010</LINK>). Despite the assumption that gastrointestinal disturbance is a major drawback of the older drugs like griseofulvin, we did not find reports of gastrointestinal disturbance associated with use of griseofulvin in our included studies. We acknowledge that while RCTs may not always provide a platform for reporting rare side effects, they are a reasonable method of detecting common ones. We included common adverse events as an outcome in our review; however, the included studies registered some infrequent adverse events that may or may not be related to griseofulvin treatment. We did find evidence that when they occur, severe adverse events are comparable between terbinafine and griseofulvin. In most cases, though, adverse events were mild and reversible. These included elevated serum liver enzymes, triglycerides and uric acid; anaemia, eosinophilia; leucocytosis and granulocytopenia. Although few observed adverse events were labelled as severe, periodic monitoring every month of organ system functions, including hepatic, renal and haematopoietic (blood) systems is advisable in those taking griseofulvin for more than eight weeks (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1505261727570676812747138012144&amp;format=REVMAN#REF-M_x00f6_hrenschlager-2005">Möhrenschlager 2005</A>).</P>
<P>Griseofulvin has traditionally been the most widely used systemic treatment for tinea capitis, and its advantages are that it is inexpensive, there is extensive experience of its use, the suspension dosage form allows for accurate dosing in children, and it is licensed in most countries. However, griseofulvin is no longer available in New Zealand and other countries including Canada (<LINK REF="REF-Bortolussi-2016" TYPE="REFERENCE">Bortolussi 2016</LINK>), as it has been superseded by newer antifungal drugs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Terbinafine</HEADING>
<P>The original version of this review found that terbinafine was at least as effective as griseofulvin for the treatment of <I>Trichophyton</I> infections of the scalp. In this update, we added some new evidence to support this finding. We found that for <I>T. tonsurans,</I> terbinafine is better than griseofulvin, while the two regimens had similar effects in children with <I>T. violaceum. </I>This finding also agrees with that of a previous meta-analysis comparing terbinafine against griseofulvin (<LINK REF="REF-Fleece-2004" TYPE="REFERENCE">Fleece 2004</LINK>).</P>
<P>The efficacy of terbinafine treatment may vary according to the fungal species isolated. New evidence in this update shows that terbinafine has a poorer effect on complete cure in participants with <I>Microsporum</I> infections. This finding correlates with the 2014 BAD guideline (<LINK REF="REF-Fuller-2014" TYPE="REFERENCE">Fuller 2014</LINK>), which concluded that terbinafine was more effective against <I>Trichophyton</I> species<I>; </I>whereas griseofulvin was more effective against <I>Microsporum </I>species<I>. </I>
</P>
<P>We found no evidence about formulations of terbinafine. While tablets may be preferred by some children (age five years and older perhaps), they may not allow for dosage individualisation (generally calculated by body weight, therefore smaller doses may be required than that provided by tablet formations). Drops or syrups are preferable to tablets for dosage individualisation in children, and there is a granule formation of terbinafine to be sprinkled on food (<LINK REF="REF-Fuller-2014" TYPE="REFERENCE">Fuller 2014</LINK>).</P>
<P>The duration of terbinafine therapy may be important. Limited evidence from observational studies suggests that longer therapeutic regimens of terbinafine may improve complete cure for those infected with <I>Microsporum</I> species (<LINK REF="REF-Aste-2004" TYPE="REFERENCE">Aste 2004</LINK>; <LINK REF="REF-Commens-2003" TYPE="REFERENCE">Commens 2003</LINK>; <LINK REF="REF-Devliotou-2004" TYPE="REFERENCE">Devliotou 2004</LINK>). In our meta-analysis of four studies that directly compared two weeks versus four weeks duration of terbinafine, a longer treatment duration was significantly better than a short duration for a complete cure.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Itraconazole</HEADING>
<P>Itraconazole is currently the preferred agent in most European countries, although it is not licensed in some countries (e.g. the United Kingdom) for treating tinea capitis in children aged 12 years or younger (<LINK REF="REF-Fuller-2014" TYPE="REFERENCE">Fuller 2014</LINK>). However, in this review, we only identified limited evidence based on small trials suggesting that oral itraconazole at weight-adjusted doses was effective and safe for tinea capitis caused by <I>T. violaceum</I> (two weeks of treatment) and <I>M. canis</I> (six weeks of treatment). More well-designed RCTs with large sample sizes are needed to confirm the safety, efficacy and optimal treatment regimens of itraconazole for paediatric tinea capitis patients.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Fluconazole</HEADING>
<P>In this update, we included a large RCT that compared short-term use of fluconazole (6 mg/kg/d for three weeks) with medium-term use of fluconazole (6 mg/kg/d for six weeks) (<LINK REF="STD-Foster-2005" TYPE="STUDY">Foster 2005</LINK>). According to this study, short-term and medium-term use of fluconazole had a similar effect on complete cure. In the 2014 BAD guideline (<LINK REF="REF-Fuller-2014" TYPE="REFERENCE">Fuller 2014</LINK>), fluconazole was recommended as an alternative to terbinafine for tinea capitis in children. However, the optimal regimen of fluconazole for treating paediatric tinea capitis remains unclear. Based on <LINK REF="REF-Fuller-2014" TYPE="REFERENCE">Fuller 2014</LINK> and the findings of this review, short-term duration of fluconazole may be a useful treatment regimen.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ketoconazole</HEADING>
<P>This review identified low quality evidence that indicated that ketoconazole appeared to have similar efficacy with griseofulvin for tinea capitis in children, although it appears to be less effective than griseofulvin for children with tinea capitis caused by <I>Trichophyton</I> species (<LINK REF="STD-Gan-1987" TYPE="STUDY">Gan 1987</LINK>). However, ketoconazole is not recommended for use in children because of potential adverse events, especially hepatotoxicity (<LINK REF="REF-Elewski-2000" TYPE="REFERENCE">Elewski 2000</LINK>), and oral ketoconazole was withdrawn from use in the United Kingdom and Europe in 2013 (<LINK REF="REF-Fuller-2014" TYPE="REFERENCE">Fuller 2014</LINK>).</P>
</SUBSECTION>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-05-03 11:51:57 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-04-29 12:29:06 +0100" MODIFIED_BY="[Empty name]">
<P>There is very low to moderate quality evidence to support the use of griseofulvin to treat tinea capitis in children, caused by <I>T. tonsurans</I>, <I>M. canis</I>, <I>T. mentagrophytes</I> and <I>T. violaceum</I>. Overall griseofulvin is considered to be safe in children. On the basis of the studies described, the recommended dosage regimen for children is continuous therapy for six to eight weeks with tablets or suspension including microsized and ultra-microsized preparations, adjusted according to the child's weight.</P>
<P>This review supports the idea that although griseofulvin will continue to remain the first-line choice in tinea capitis, terbinafine may constitute another first-line drug that is well tolerated and has few side effects. Long-term (more than six weeks) terbinafine therapy cannot be recommended on the basis of this review. However, new evidence of moderate quality in this update indicates that terbinafine (at standard doses for six weeks) may be a better choice than griseofulvin (at standard doses for six weeks) in children infected with <I>T. tonsurans</I>. However, the two regimens have similar effects in children with <I>T. violaceum</I>. In addition, in the case of <I>M. canis,</I> griseofulvin may be a better choice.</P>
<P>We included trials on various other drugs. Limited evidence indicates that terbinafine, itraconazole and fluconazole may have similar effects for children with tinea capitis caused by <I>Trichophyton </I>species. Ketoconazole appears to be less effective for children infected with <I>Trichophyton </I>species, but limited data prevents us from making any firm conclusions about their relative efficacy.</P>
<P>Some evidence based on a few studies shows that oral itraconazole at doses according to the child's weight for two to six weeks is effective and safe for tinea capitis caused by <I>T. violaceum</I> (two weeks of treatment) and <I>M. canis</I> (six weeks of treatment). In addition, evidence of moderate quality shows that two to four weeks of fluconazole are comparable to six weeks of griseofulvin, especially with tinea capitis caused by <I>Trichophyton</I> species.</P>
<P>The adverse events of terbinafine, griseofulvin, itraconazole, ketoconazole, and fluconazole were all mild and reversible, and the adverse events and severe adverse events are comparable between terbinafine and griseofulvin.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-05-03 11:51:57 +0100" MODIFIED_BY="[Empty name]">
<P>The majority of the literature about systemic antifungal treatment for tinea capitis is on griseofulvin. There need to be more studies on any advantages of the newer and relatively expensive antifungals such as ketoconazole,terbinafine, itraconazole and fluconazole, both in comparison to each other and to griseofulvin.</P>
<P>Any studies would need to be of adequate sample size, involving different treatment doses and duration of treatment to determine the clinical effectiveness and any adverse events. Importantly, further research is also required regarding the impact on mode of administration and adherence to treatment (which may be needed over several weeks) in children. Patient-reported outcomes such as quality of life are important for evidence-based clinical decisions and need to be addressed in future studies.</P>
<P>In order to ensure the reporting quality of any clinical trials undertaken, they must conform to the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement (<LINK REF="REF-Schulz-2010" TYPE="REFERENCE">Schulz 2010</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-05-04 15:48:06 +0100" MODIFIED_BY="Laura Prescott ">
<P>We acknowledge the authors of the original review: Terry Seaton; George Bergus; Jim Jacobson; and Cecilia Martínez-Monzón.</P>
<P>The original version of this review was funded by the Cochrane Child Health Field, Alberta Research Centre for Child Health Evidence, University of Alberta, Canada; The Spanish Society of Dermato-Epidemiology and Evidence-based dermatology (SEDE-DBE) and the Clínica Plató, Fundació Privada of Barcelona.</P>
<P>The Cochrane Skin Group editorial base wishes to thank Hywel Williams, who was the Dermatology Editor for this review; Ben Carter who was the Statistical Editor; Esther van Zuuren, who was Methods Editor; the clinical referee, Rachael Morris-Jones; another clinical referee who wishes to remain anonymous; and the consumer referee, Audrey Pellicano.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-05-11 10:30:00 +0100" MODIFIED_BY="Laura Prescott ">
<P>XC: none known.<BR/>XJ: none known.<BR/>MY: none known.<BR/>UG: none known.<BR/>XL: none known.<BR/>XH: none known.<BR/>SX: none known.<BR/>MZ: none known.<BR/>CB: "I am the proprietor of Systematic Research Ltd and derive an income from my work as a freelance researcher. I was paid for my contributions to this review.<BR/>I hold an honorary Chair at Coventry University; this does not constitute a competing interest in my view, but I make this declaration in the interested of transparency."</P>
<P>A clinical referee, who wishes to remain anonymous: "I received honoraries for study participation, as invited speaker, as well as travel grants for congress participation by Janssen."</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-05-11 10:14:18 +0100" MODIFIED_BY="Laura Prescott ">
<P>XC and XJ are joint first authors as they contributed equally to this review.<BR/>MZ was the contact person with the editorial base.<BR/>XC, MY, XJ, XH, SX and MZ co-ordinated contributions from the co-authors and wrote the final draft of the review.<BR/>XC, MY and XH screened papers against eligibility criteria.<BR/>XC, MZ and MY appraised the quality of papers.<BR/>XC and MY extracted data for the review and sought additional information about papers.<BR/>MY and XC entered data into RevMan.<BR/>MY and XC analysed and interpreted data.<BR/>UG worked on the 'Methods' sections.<BR/>UG, XC, and MY drafted the clinical sections of the background and responded to the clinical comments of the referees.<BR/>MY, XC, and MZ responded to the methodology and statistics comments of the referees.<BR/>XL was the consumer co-author and checked the review for readability and clarity, as well as ensuring outcomes are relevant to consumers.<BR/>MZ is the guarantor of the update.<BR/>CB worked with the authors after the first draft was produced and peer reviewed, to produce the final version of the review that was submitted for publication.</P>
<SUBSECTION>
<HEADING LEVEL="2">Disclaimer</HEADING>
<P>This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Skin Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.</P>
</SUBSECTION>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-04-29 10:17:31 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>: We updated and revised the text in the '<LINK TAG="INTERVENTION" TYPE="SECTION">Description of the intervention</LINK> and '<LINK TAG="THEORY" TYPE="SECTION">How the intervention might work</LINK>' sections of the Background.</P>
<P>
<B>Types of interventions</B>: In the protocol we planned to look at doses of drugs. We omitted this from the review and update because the doses and formulations of drugs varied significantly across studies, and it was impossible and not clinically important to merge the relevant results from different studies.</P>
<P>
<B>Types of outcome measures</B>: In the protocol, resolution of hair loss was one of the primary outcome measures of clinical cure. We omitted this from the original review and update, as hair loss is a clinical sign of tinea capitis, and the improvement of hair loss is usually considered a sign of our primary outcome of clinical cure.</P>
<P>We removed the secondary outcome from the protocol, "proportion of participants with partial clinical improvement" in this update because it is hard to define "partial clinical improvement".</P>
<P>
<B>Search methods</B>: We changed the databases that we planned to search in the protocol, because of lack of access to some of the databases we originally planned to search and changes to standard search routines. We did not update the adverse events search undertaken in 2005.</P>
<P>
<B>Data collection and analysis</B>: We updated the format of the review and used the pre-set subheadings available in <LINK REF="REF-Revman-2014" TYPE="REFERENCE">Revman 2014</LINK>. We organised our information about methods into the headings of: <LINK TAG="EFFECT_MEASURES" TYPE="SECTION">Measures of treatment effect</LINK>; <LINK TAG="UNIT_OF_ANALYSIS" TYPE="SECTION">Unit of analysis issues</LINK>; <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>; <LINK TAG="HETEROGENEITY_ASSESSMENT" TYPE="SECTION">Assessment of heterogeneity</LINK>; <LINK TAG="BIAS_ASSESSMENT" TYPE="SECTION">Assessment of reporting biases</LINK>; <LINK TAG="DATA_SYNTHESIS" TYPE="SECTION">Data synthesis</LINK>; <LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>; and <LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>.</P>
<P>
<B>Data synthesis</B>: In the original protocol, we failed to specify the acceptable window for the timing of the primary outcome assessment. We decided during the course of the review to combine studies that recorded primary outcomes at between 12 to 20 weeks on the basis that these are the range of time periods that best reflect clinical decision-making in practice.</P>
<P>
<B>Subgroup analysis and investigation of heterogeneity</B>: there were too few studies in each comparison or outcome to perform subgroup analysis as planned in the protocol.</P>
<P>
<B>Sensitivity analysis</B>: In the protocol we planned to conduct sensitivity analyses but there too few studies in each comparison or outcome to perform sensitivity analyses.</P>
<P>In this update we have produced 'Summary of findings' tables for the primary outcomes/comparisons, which were not a requirement when the protocol and review were published.</P>
<P>In this update, we modified the 'Risk of bias' tables for all included studies based on the new Cochrane 'Risk of bias' assessment tool and included details of how we assessed risk of bias in the 'Methods' section.</P>
<P>We modified our methods for analysing cross-over trials and trials with more than one treatment arm. We did not consider internally controlled trials, such as those with cross-over and within-participant designs, because even with a washout period, they are inappropriate designs for systemic treatment (because effects of antifungal therapy may endure over the washout period as most patients would experience a cure or at least some improvement in the first period of a cross-over study). For RCTs with multiple intervention groups, we combined groups to a single pair-wise comparison as recommended by Cochrane (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-05-03 15:23:08 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2016-05-03 13:29:12 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-05-03 13:27:48 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" MODIFIED="2016-05-03 13:26:23 +0100" MODIFIED_BY="[Empty name]" NAME="Cáceres-Ríos 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-04-29 09:12:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cáceres-Ríos H, Rueda M, Ballona R, Bustamante B</AU>
<TI>Comparison of terbinafine and griseofulvin in the treatment of tinea capitis</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2000</YR>
<VL>42</VL>
<NO>1 Pt 1</NO>
<PG>80-4</PG>
<IDENTIFIERS MODIFIED="2015-06-24 11:59:44 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-24 11:59:44 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="10607324"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-05-03 13:26:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cáceres-Ríos H, Rueda M, Ballona R, Mostajo F, Kumakawa H, Bustamante B</AU>
<TI>Comparison of terbinafine and griseofulvin in the treatment of tinea capitis. [Abstract 015]</TI>
<SO>Annales de Dermatologie et de Venereologie</SO>
<YR>1998</YR>
<VL>125</VL>
<NO>Suppl 1</NO>
<PG>1s21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dastghaib-2005" MODIFIED="2015-06-24 11:59:00 +0100" MODIFIED_BY="Helen Scott" NAME="Dastghaib 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-06-24 11:59:00 +0100" MODIFIED_BY="Helen Scott" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dastghaib L, Azizzadeh M, Jafari P</AU>
<TI>Therapeutic options for the treatment of tinea capitis: griseofulvin versus fluconazole</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>1</NO>
<PG>43-6</PG>
<IDENTIFIERS MODIFIED="2015-06-24 11:59:00 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-24 11:59:00 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="15897167"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deng-2011" MODIFIED="2015-06-24 11:57:15 +0100" MODIFIED_BY="Helen Scott" NAME="Deng 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-06-24 11:57:15 +0100" MODIFIED_BY="Helen Scott" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deng S, Hu H, Abliz P, Wan Z, Wang A, Cheng W, et al</AU>
<TI>A random comparative study of terbinafine versus griseofulvin in patients with tinea capitis in Western China</TI>
<SO>Mycopathologia</SO>
<YR>2011</YR>
<VL>172</VL>
<NO>5</NO>
<PG>365-72</PG>
<IDENTIFIERS MODIFIED="2015-06-24 11:57:15 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-24 11:57:15 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="21701791"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elewski-2008" MODIFIED="2015-06-24 11:56:37 +0100" MODIFIED_BY="Helen Scott" NAME="Elewski 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-06-24 11:56:37 +0100" MODIFIED_BY="Helen Scott" NOTES="&lt;p&gt;Department of Dermatology, University of Alabama, Birmingham, Alabama 35294-0009, USA. beelewski@aol.com&lt;/p&gt;" NOTES_MODIFIED="2015-06-24 11:56:37 +0100" NOTES_MODIFIED_BY="Helen Scott" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elewski BE, Caceres HW, DeLeon L, El Shimy S, Hunter JA, Korotkiy N, et al</AU>
<TI>Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2008</YR>
<VL>59</VL>
<NO>1</NO>
<PG>41-54</PG>
<IDENTIFIERS MODIFIED="2015-06-24 11:56:37 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-24 11:56:37 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="18378354"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foster-2005" MODIFIED="2015-06-24 11:55:47 +0100" MODIFIED_BY="Helen Scott" NAME="Foster 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-06-24 11:55:47 +0100" MODIFIED_BY="Helen Scott" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foster KW, Friedlander SF, Panzer H, Ghannoum MA, Elewski BE</AU>
<TI>A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2005</YR>
<VL>53</VL>
<NO>5</NO>
<PG>798-809</PG>
<IDENTIFIERS MODIFIED="2015-06-24 11:55:47 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-24 11:55:47 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="16243128"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friedlander-2002" MODIFIED="2016-04-29 09:14:03 +0100" MODIFIED_BY="[Empty name]" NAME="Friedlander 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-04-29 09:14:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Friedlander SF, Aly R, Krafchik B, Blumer J, Honig P, Stewart D, et al</AU>
<TI>Terbinafine in the treatment of <I>Trichophyton</I> tinea capitis: a randomized, double-blind, parallel-group, duration-finding study</TI>
<SO>Pediatrics</SO>
<YR>2002</YR>
<VL>109</VL>
<NO>4</NO>
<PG>602-7</PG>
<IDENTIFIERS MODIFIED="2015-06-24 11:54:50 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-24 11:54:50 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="11927703"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fuller-2001" MODIFIED="2015-06-24 11:53:57 +0100" MODIFIED_BY="Helen Scott" NAME="Fuller 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-06-24 11:53:57 +0100" MODIFIED_BY="Helen Scott" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fuller LC, Smith CH, Cerio R, Marsden RA, Midgley G, Beard AL, et al</AU>
<TI>A randomized comparison of 4 weeks of terbinafine vs. 8 weeks of griseofulvin for the treatment of tinea capitis</TI>
<SO>British Journal of Dermatology</SO>
<YR>2001</YR>
<VL>144</VL>
<NO>2</NO>
<PG>321-7</PG>
<IDENTIFIERS MODIFIED="2015-06-24 11:53:57 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-24 11:53:57 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="11251566"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gan-1987" MODIFIED="2015-06-24 11:52:53 +0100" MODIFIED_BY="Helen Scott" NAME="Gan 1987" YEAR="1987">
<REFERENCE MODIFIED="2015-06-24 11:52:53 +0100" MODIFIED_BY="Helen Scott" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gan VN, Petruska M, Ginsburg CM</AU>
<TI>Epidemiology and treatment of tinea capitis: ketoconazole vs. griseofulvin</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>1</NO>
<PG>46-9</PG>
<IDENTIFIERS MODIFIED="2015-06-24 11:52:53 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-24 11:52:53 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="3822616"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gupta-2001" MODIFIED="2015-08-21 02:29:02 +0100" MODIFIED_BY="[Empty name]" NAME="Gupta 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-08-21 02:29:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gupta AK, Adam P, Dlova N, Lynde CW, Hofstader S, Morar N, et al</AU>
<TI>Therapeutic options for the treatment of tinea capitis caused by trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole</TI>
<SO>Pediatric Dermatology</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>5</NO>
<PG>433-8</PG>
<IDENTIFIERS MODIFIED="2015-06-24 11:51:24 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-24 11:51:24 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="11737692"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamm-1999" MODIFIED="2016-05-03 13:27:48 +0100" MODIFIED_BY="[Empty name]" NAME="Hamm 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-04-29 09:14:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hamm H, Schwinn A, Bräutigam M, Weidinger G</AU>
<TI>Short duration treatment with terbinafine for tinea capitis caused by <I>Trichophyton</I> or <I>Microsporum</I> species. The Study Group</TI>
<SO>British Journal of Dermatology</SO>
<YR>1999</YR>
<VL>140</VL>
<NO>3</NO>
<PG>480-2</PG>
<IDENTIFIERS MODIFIED="2015-06-24 11:45:32 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-24 11:45:32 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="10233270"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-05-03 13:27:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwinn A, Hamm H, Bräutigam M, Weidinger G, Williams T</AU>
<TI>What is the best approach to tinea capitis with terbinafine? [Abstract P147]</TI>
<SO>Annales de Dermatologie et de Venereologie</SO>
<YR>1998</YR>
<VL>125</VL>
<NO>Suppl 1</NO>
<PG>1s133-1s134</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-29 09:18:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwinn A, Hamm H, Bräutigam M, Weidinger G, Williams T</AU>
<TI>What is the best approach to tinea capitis with terbinafine? [Abstract P199]. The 7th Congress of the European Academy of Dermatology and Venereology; 7-11 Oct 1998; Nice</TI>
<SO>Journal of the European Academy of Dermatology &amp; Venereology</SO>
<YR>1998</YR>
<VL>11</VL>
<NO>Suppl 2</NO>
<PG>s232</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haroon-1995" MODIFIED="2015-09-25 03:54:24 +0100" MODIFIED_BY="[Empty name]" NAME="Haroon 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-09-25 03:54:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Alvi KH, Iqbal N, Khan KA, Haroon TS, Hussain I, Aman S, et al</AU>
<TI>A randomized, double blind trial of the efficacy and tolerability of terbinafine once daily compared to griseofulvin once daily in the treatment of tinea capitis</TI>
<SO>Royal Society of Medicine Services International Congress Series</SO>
<YR>1992</YR>
<VL>205</VL>
<NO>pp</NO>
<PG>35-40</PG>
<ED>Shuster S, Jafary MH</ED>
<PB>Royal Society of Medicine Press Ltd</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-06-24 16:25:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haroon TS, Hussain I, Aman S, Jahangir M, Kazmi AH, Sami AR, et al</AU>
<TI>Randomized double-blind multicentre study of efficacy and tolerability of terbinafine for 1, 2, and 4 weeks in the treatment of tinea capitis</TI>
<SO>Journal of the European Academy of Dermatology &amp; Venereology</SO>
<YR>1995</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>s79-s80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-06-24 16:26:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Haroon TS, Hussain I, Aman S, Nagi AH, Ahmad I, Zahid M, et al</AU>
<TI>A randomized double-blind comparative study of terbinafine and griseofulvin in tinea capitis</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>1995</YR>
<VL>6</VL>
<NO>3</NO>
<PG>167-9</PG>
<IDENTIFIERS MODIFIED="2015-06-24 16:26:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-22 13:49:41 +0100" MODIFIED_BY="Helen Scott" TYPE="DOI" VALUE="10.3109/09546639509097176"/>
<IDENTIFIER MODIFIED="2015-06-24 16:26:43 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1995319728"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haroon-1996" MODIFIED="2015-06-22 13:48:38 +0100" MODIFIED_BY="Helen Scott" NAME="Haroon 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-06-22 13:48:38 +0100" MODIFIED_BY="Helen Scott" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Haroon TS, Hussain I, Aman S, Jahangir M, Kazmi AH, Sami AR, et al</AU>
<TI>A randomized double-blind comparative study of terbinafine for 1, 2, and 4 weeks in tinea capitis</TI>
<SO>British Journal of Dermatology</SO>
<YR>1996</YR>
<VL>135</VL>
<NO>1</NO>
<PG>86-8</PG>
<IDENTIFIERS MODIFIED="2015-06-22 13:48:38 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 13:48:38 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="8776365"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jahangir-1998" MODIFIED="2015-06-24 12:03:44 +0100" MODIFIED_BY="Helen Scott" NAME="Jahangir 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-06-24 12:03:44 +0100" MODIFIED_BY="Helen Scott" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jahangir M, Hussain I, Ul Hassan M, Haroon TS</AU>
<TI>A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis</TI>
<SO>British Journal of Dermatology</SO>
<YR>1998</YR>
<VL>139</VL>
<NO>4</NO>
<PG>672-4</PG>
<IDENTIFIERS MODIFIED="2015-06-24 12:03:44 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-24 12:03:44 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="9892912"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khan-2011" MODIFIED="2016-04-29 09:19:42 +0100" MODIFIED_BY="[Empty name]" NAME="Khan 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-04-29 09:19:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khan SU, Khan AR, Wazir SM</AU>
<TI>Efficacy of terbinafine vs. griseofulvin in tinea capitis in the northern areas of Pakistan</TI>
<SO>Journal of Pakistan Association of Dermatologists</SO>
<YR>2011</YR>
<VL>21</VL>
<NO>4</NO>
<PG>281-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kullavanijaya-1997" MODIFIED="2016-04-29 09:21:47 +0100" MODIFIED_BY="[Empty name]" NAME="Kullavanijaya 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-04-29 09:21:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kullavanijaya P, Reangchainam S, Ungpakorn R</AU>
<TI>Randomized single-blind study of efficacy and tolerability of terbinafine in the treatment of tinea capitis</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1997</YR>
<VL>37</VL>
<NO>2 Pt 1</NO>
<PG>272-3. Comment in Journal of the American Academy of Dermatology 1998; 39(1):136</PG>
<IDENTIFIERS MODIFIED="2015-06-22 13:40:24 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 13:40:24 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="9270519"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lipozencic-2002" MODIFIED="2016-04-29 09:22:59 +0100" MODIFIED_BY="[Empty name]" NAME="Lipozencic 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-04-29 09:22:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lipozencic J, Skerlev M, Orofino-Costa R, Zaitz VC, Horvath A, Chouela E, et al</AU>
<TI>A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to <I>Microsporum</I> species</TI>
<SO>British Journal of Dermatology</SO>
<YR>2002</YR>
<VL>146</VL>
<NO>5</NO>
<PG>816-23</PG>
<IDENTIFIERS MODIFIED="2015-06-22 13:39:35 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 13:39:35 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="12000378"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" MODIFIED="2016-04-29 09:23:29 +0100" MODIFIED_BY="[Empty name]" NAME="López-Gómez 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-04-29 09:23:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>López-Gómez S, Del Palacio A, Van Cutsem J, Soledad Cuétara M, Iglesias L, Ródriguez-Noriega A</AU>
<TI>Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children</TI>
<SO>International Journal of Dermatology</SO>
<YR>1994</YR>
<VL>33</VL>
<NO>10</NO>
<PG>743-7. Comment in the International Journal of Dermatology 1994;33(10):701</PG>
<IDENTIFIERS MODIFIED="2015-06-22 13:39:05 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 13:39:05 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="8002149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mart_x00ed_nez_x002d_Roig-1988" MODIFIED="2015-06-22 13:37:37 +0100" MODIFIED_BY="Helen Scott" NAME="Martínez-Roig 1988" YEAR="1988">
<REFERENCE MODIFIED="2015-06-22 13:37:37 +0100" MODIFIED_BY="Helen Scott" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Martínez-Roig A, Torres-Rodríguez JM, Bartlett-Coma A</AU>
<TI>Double blind study of ketoconazole and griseofulvin in dermatophytoses</TI>
<SO>The Pediatric Infectious Disease Journal</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>1</NO>
<PG>37-40</PG>
<IDENTIFIERS MODIFIED="2015-06-22 13:37:37 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 13:37:37 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="3277154"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Memisoglu-1999" MODIFIED="2015-06-22 13:36:36 +0100" MODIFIED_BY="Helen Scott" NAME="Memisoglu 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-06-22 13:36:36 +0100" MODIFIED_BY="Helen Scott" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Memisoglu HR, Erboz S, Akkaya S, Akan T, Aksungur VL, Ünal I, et al</AU>
<TI>Comparative study of the efficacy and tolerability of 4 weeks of terbinafine therapy with 8 weeks of griseofulvin therapy in children with tinea capitis</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>3</NO>
<PG>189-93</PG>
<IDENTIFIERS MODIFIED="2015-06-22 13:36:36 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 13:36:36 +0100" MODIFIED_BY="Helen Scott" TYPE="DOI" VALUE="10.3109/09546639909056027"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rademaker-1998" MODIFIED="2015-06-22 13:32:33 +0100" MODIFIED_BY="Helen Scott" NAME="Rademaker 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-06-22 13:32:33 +0100" MODIFIED_BY="Helen Scott" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rademaker M, Havill S</AU>
<TI>Griseofulvin and terbinafine in the treatment of tinea capitis in children</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1998</YR>
<VL>111</VL>
<NO>1060</NO>
<PG>55-7</PG>
<IDENTIFIERS MODIFIED="2015-06-22 13:32:33 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 13:32:33 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="9539918"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Solomon-1997" MODIFIED="2015-06-22 13:31:43 +0100" MODIFIED_BY="Helen Scott" NAME="Solomon 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-06-22 13:31:43 +0100" MODIFIED_BY="Helen Scott" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Solomon BA, Collins R, Sharma R, Silverberg N, Jain AR, Sedgh J, et al</AU>
<TI>Fluconazole for the treatment of tinea capitis in children</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1997</YR>
<VL>37</VL>
<NO>2 Pt 1</NO>
<PG>274-5</PG>
<IDENTIFIERS MODIFIED="2015-06-22 13:31:43 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 13:31:43 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="9270520"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Talarico-Filho-1998" MODIFIED="2015-06-22 13:30:55 +0100" MODIFIED_BY="Helen Scott" NAME="Talarico Filho 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-06-22 13:30:55 +0100" MODIFIED_BY="Helen Scott" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Filho ST, Cucé LC, Foss NT, Marques SA, Santamaria JR</AU>
<TI>Efficacy, safety and tolerability of terbinafine for tinea capitis in children: Brazilian multicentric study with daily oral tablets for 1, 2 and 4 weeks</TI>
<SO>Journal of the European Academy of Dermatology &amp; Venereology</SO>
<YR>1998</YR>
<VL>11</VL>
<NO>2</NO>
<PG>141-6</PG>
<IDENTIFIERS MODIFIED="2015-06-22 13:30:55 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 13:30:55 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="9784040"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanz-1985" MODIFIED="2015-06-22 13:29:23 +0100" MODIFIED_BY="Helen Scott" NAME="Tanz 1985" YEAR="1985">
<REFERENCE MODIFIED="2015-06-22 13:29:23 +0100" MODIFIED_BY="Helen Scott" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tanz RR, Stagl S, Esterly NB</AU>
<TI>Comparison of ketoconazole and griseofulvin for treatment of tinea capitis in childhood: a preliminary study</TI>
<SO>Pediatric Emergency Care</SO>
<YR>1985</YR>
<VL>1</VL>
<NO>1</NO>
<PG>16-8</PG>
<IDENTIFIERS MODIFIED="2015-06-22 13:29:23 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 13:29:23 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="3916457"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanz-1988" MODIFIED="2015-06-22 13:28:20 +0100" MODIFIED_BY="Helen Scott" NAME="Tanz 1988" YEAR="1988">
<REFERENCE MODIFIED="2015-06-22 13:28:20 +0100" MODIFIED_BY="Helen Scott" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tanz RR, Hebert AA, Esterly NB</AU>
<TI>Treating tinea capitis: Should ketoconazole replace griseofulvin?</TI>
<SO>Journal of Pedriatics</SO>
<YR>1988</YR>
<VL>112</VL>
<NO>6</NO>
<PG>987-91</PG>
<IDENTIFIERS MODIFIED="2015-06-22 13:28:20 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 13:28:20 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="3373408"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ungpakorn-2004" MODIFIED="2015-06-22 13:27:32 +0100" MODIFIED_BY="Helen Scott" NAME="Ungpakorn 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-06-22 13:27:32 +0100" MODIFIED_BY="Helen Scott" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ungpakorn R, Ayutyanont T, Reangchainam S, Supanya S</AU>
<TI>Treatment of Microsporum spp. tinea capitis with pulsed oral terbinafine</TI>
<SO>Clinical and Experimental Dermatology</SO>
<YR>2004</YR>
<VL>29</VL>
<NO>3</NO>
<PG>300-3</PG>
<IDENTIFIERS MODIFIED="2015-06-22 13:27:28 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 13:27:28 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="15115516"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-05-03 13:29:12 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ginsburg-1987" MODIFIED="2015-06-22 13:25:22 +0100" MODIFIED_BY="Helen Scott" NAME="Ginsburg 1987" YEAR="1987">
<REFERENCE MODIFIED="2015-06-22 13:25:22 +0100" MODIFIED_BY="Helen Scott" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ginsburg C, Ghan NV, Petruska M</AU>
<TI>Randomized controlled trial of intralesional corticosteroid and griseofulvin vs. griseofulvin alone for treatment of kerion</TI>
<SO>The Pediatric Infectious Disease Journal</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>12</NO>
<PG>1084-7</PG>
<IDENTIFIERS MODIFIED="2015-06-22 13:25:22 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 13:25:22 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="3324039"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Honig-1994" MODIFIED="2015-06-22 13:24:42 +0100" MODIFIED_BY="Helen Scott" NAME="Honig 1994" YEAR="1994">
<REFERENCE MODIFIED="2015-06-22 13:24:42 +0100" MODIFIED_BY="Helen Scott" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Honig PJ, Caputo GL, Leyden JJ, McGinley K, Selbst SM, McGravey AR</AU>
<TI>Treatment of kerions</TI>
<SO>Pediatric Dermatology</SO>
<YR>1994</YR>
<VL>11</VL>
<NO>1</NO>
<PG>69-71</PG>
<IDENTIFIERS MODIFIED="2015-06-22 13:24:42 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 13:24:42 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="8170855"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hussain-1999" MODIFIED="2015-06-22 13:23:56 +0100" MODIFIED_BY="Helen Scott" NAME="Hussain 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-06-22 13:23:56 +0100" MODIFIED_BY="Helen Scott" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hussain I, Muzaffar F, Rashid T, Ahmad TJ, Jahangir M, Haroon TS</AU>
<TI>A randomized, comparative trial of treatment of kerion celsi with griseofulvin plus oral prednisolone vs. griseofulvin alone</TI>
<SO>Medical Mycology</SO>
<YR>1999</YR>
<VL>37</VL>
<NO>2</NO>
<PG>97-9</PG>
<IDENTIFIERS MODIFIED="2015-06-22 13:23:56 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 13:23:56 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="10361264"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koumantaki_x002d_Mathioudaki-2005" MODIFIED="2015-06-22 13:23:13 +0100" MODIFIED_BY="Helen Scott" NAME="Koumantaki-Mathioudaki 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-06-22 13:23:13 +0100" MODIFIED_BY="Helen Scott" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koumantaki-Mathioudaki E, Devliotou-Panagiotidou D, Rallis E, Athanassopoulou V, Koussidou-Eremondi T, Katsambas A, et al</AU>
<TI>Is itraconazole the treatment of choice in Microsporum canis tinea capitis?</TI>
<SO>Drugs Under Experimental &amp; Clinical Research</SO>
<YR>2005</YR>
<VL>31</VL>
<NO>Suppl</NO>
<PG>11-5</PG>
<IDENTIFIERS MODIFIED="2015-06-22 13:23:13 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 13:23:13 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="16444907"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shemer-2013" MODIFIED="2016-05-03 13:29:12 +0100" MODIFIED_BY="[Empty name]" NAME="Shemer 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-05-03 13:29:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shemer A, Plotnik IB, Davidovici B, Grunwald MH, Magun R, Amichai B</AU>
<TI>Treatment of tinea capitis - griseofulvin versus fluconazole - a comparative study</TI>
<SO>Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]</SO>
<YR>2013</YR>
<VL>11</VL>
<NO>8</NO>
<PG>737-41</PG>
<IDENTIFIERS MODIFIED="2015-06-22 13:21:14 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 13:21:14 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="23575220"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-06-22 13:18:36 +0100" MODIFIED_BY="Helen Scott">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Pather-2006" MODIFIED="2015-06-22 13:18:36 +0100" MODIFIED_BY="Helen Scott" NAME="Pather 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-06-22 13:18:36 +0100" MODIFIED_BY="Helen Scott" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pather S</AU>
<TI>A prospective, randomized, single-blinded trial to determine the efficacy of single and weekly dose regimens of oral griseofulvin versus 6 weeks of daily dosing in the treatment of tinea capitis in children. British Society for Paediatric Dermatology: Summaries of Papers [PA-6]</TI>
<SO>British Journal of Dermatology</SO>
<YR>2006</YR>
<VL>155</VL>
<NO>Suppl 1</NO>
<PG>108-109</PG>
<IDENTIFIERS MODIFIED="2015-06-22 13:18:36 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 13:18:36 +0100" MODIFIED_BY="Helen Scott" TYPE="DOI" VALUE="10.1111/j.1365-2133.2006.07258_1.x"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-05-03 15:23:08 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-05-03 15:23:08 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abdel_x002d_Rahman-2005" MODIFIED="2016-04-13 14:42:43 +0100" MODIFIED_BY="Cathy Bennett" NAME="Abdel-Rahman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Abdel-Rahman SM, Herron J, Fallon-Friedlander S, Hauffe S, Horowitz A, Riviere GJ</AU>
<TI>Pharmacokinetics of terbinafine in young children treated for tinea capitis</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2005</YR>
<VL>24</VL>
<PG>886-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aly-1999" MODIFIED="2015-06-22 11:51:58 +0100" MODIFIED_BY="Helen Scott" NAME="Aly 1999" TYPE="JOURNAL_ARTICLE">
<AU>Aly R</AU>
<TI>Ecology, epidemiology and diagnosis of tinea capitis</TI>
<SO>The Pediatric Infectious Diseases Journal</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>2</NO>
<PG>180-5</PG>
<IDENTIFIERS MODIFIED="2015-06-22 11:51:58 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 11:51:58 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="10048699"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Aste-2004" MODIFIED="2016-04-29 09:26:27 +0100" MODIFIED_BY="[Empty name]" NAME="Aste 2004" TYPE="JOURNAL_ARTICLE">
<AU>Aste N, Pau M</AU>
<TI>Tinea capitis caused by <I>Microsporum canis </I>treated with terbinafine</TI>
<SO>Mycoses</SO>
<YR>2004</YR>
<VL>47</VL>
<NO>9-10</NO>
<PG>428-30</PG>
<IDENTIFIERS MODIFIED="2015-06-22 11:52:51 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 11:52:51 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="15504128"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bennassar-2010" MODIFIED="2016-04-13 14:43:03 +0100" MODIFIED_BY="Cathy Bennett" NAME="Bennassar 2010" TYPE="JOURNAL_ARTICLE">
<AU>Bennassar A, Grimalt R</AU>
<TI>Management of tinea capitis in childhood</TI>
<SO>Clinical, Cosmetic &amp; Investigational Dermatology: CCID</SO>
<YR>2010</YR>
<VL>3</VL>
<PG>89-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bennett-2000" MODIFIED="2015-09-17 17:49:41 +0100" MODIFIED_BY="Cathy Bennett" NAME="Bennett 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bennett ML, Fleischer AB, Loveless JW, Feldman SR</AU>
<TI>Oral griseofulvin remains the treatment of choice for tinea capitis in children</TI>
<SO>Pediatric Dermatology</SO>
<YR>2000</YR>
<VL>17</VL>
<NO>4</NO>
<PG>304-9</PG>
<IDENTIFIERS MODIFIED="2015-06-22 11:54:08 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 11:54:08 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="10990583"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Blumer-1999" MODIFIED="2015-06-22 11:55:28 +0100" MODIFIED_BY="Helen Scott" NAME="Blumer 1999" TYPE="JOURNAL_ARTICLE">
<AU>Blumer JL</AU>
<TI>Pharmacologic basis for the treatment of tinea capitis</TI>
<SO>The Pediatric Infectious Disease Journal</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>2</NO>
<PG>191-9</PG>
<IDENTIFIERS MODIFIED="2015-06-22 11:55:28 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 11:55:28 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="10048701"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bortolussi-2016" MODIFIED="2016-04-29 09:32:52 +0100" MODIFIED_BY="[Empty name]" NAME="Bortolussi 2016" TYPE="OTHER">
<AU>Bortolussi R, Martin S; Canadian Paediatric Society</AU>
<TI>Antifungal agents for common outpatient paediatric infections</TI>
<SO>http://www.cps.ca/documents/position/antifungal-agents-common-infections</SO>
<YR>(accessed 26 February 2016)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chan-2004" MODIFIED="2015-06-22 11:58:20 +0100" MODIFIED_BY="Helen Scott" NAME="Chan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chan YC, Friedlander SF</AU>
<TI>Therapeutic options in the treatment of tinea capitis</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>2</NO>
<PG>219-27</PG>
<IDENTIFIERS MODIFIED="2015-06-22 11:58:20 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 11:58:20 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="14996619"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Commens-2003" MODIFIED="2016-04-29 09:34:58 +0100" MODIFIED_BY="[Empty name]" NAME="Commens 2003" TYPE="JOURNAL_ARTICLE">
<AU>Commens C</AU>
<TI>Which drug is most effective in treating childhood tinea capitis caused by <I>Microsporum</I> species?</TI>
<SO>The Medical Journal of Australia</SO>
<YR>2003</YR>
<VL>178</VL>
<NO>11</NO>
<PG>577-8</PG>
<IDENTIFIERS MODIFIED="2015-06-22 11:58:58 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 11:58:58 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="12765508"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Devliotou-2004" MODIFIED="2016-04-29 09:35:13 +0100" MODIFIED_BY="[Empty name]" NAME="Devliotou 2004" TYPE="JOURNAL_ARTICLE">
<AU>Devliotou-Panagiotidou D, Koussidou-Eremondi TH</AU>
<TI>Efficacy and tolerability of 8 weeks' treatment with terbinafine in children with tinea capitis caused by <I>Microsporum canis</I>: a comparison of three doses</TI>
<SO>Journal of the European Academy of Dermatology &amp; Venereology</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>2</NO>
<PG>155-9</PG>
<IDENTIFIERS MODIFIED="2015-06-22 11:59:43 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 11:59:43 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="15009293"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elewski-2000" MODIFIED="2015-06-22 12:00:27 +0100" MODIFIED_BY="Helen Scott" NAME="Elewski 2000" TYPE="JOURNAL_ARTICLE">
<AU>Elewski BE</AU>
<TI>Tinea capitis: a current perspective</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2000</YR>
<VL>42</VL>
<NO>1 Pt 1</NO>
<PG>1-24</PG>
<IDENTIFIERS MODIFIED="2015-06-22 12:00:27 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 12:00:27 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="10607315"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fleece-2004" MODIFIED="2015-06-22 12:01:35 +0100" MODIFIED_BY="Helen Scott" NAME="Fleece 2004" TYPE="JOURNAL_ARTICLE">
<AU>Fleece D, Gaughan JP, Aronoff SC</AU>
<TI>Griseofulvin versus terbinafine in the treatment of tinea capitis: a meta-analysis of randomized, clinical trials</TI>
<SO>Pediatrics</SO>
<YR>2004</YR>
<VL>114</VL>
<NO>5</NO>
<PG>1312-5</PG>
<IDENTIFIERS MODIFIED="2015-06-22 12:01:35 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 12:01:35 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="15520113"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Friedlander-2000" MODIFIED="2015-06-22 12:02:14 +0100" MODIFIED_BY="Helen Scott" NAME="Friedlander 2000" TYPE="JOURNAL_ARTICLE">
<AU>Friedlander SF</AU>
<TI>The optimal therapy for tinea capitis</TI>
<SO>Pediatric Dermatology</SO>
<YR>2000</YR>
<VL>17</VL>
<NO>4</NO>
<PG>325-6</PG>
<IDENTIFIERS MODIFIED="2015-06-22 12:02:14 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 12:02:14 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="10990588"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fuller-2003" MODIFIED="2016-04-13 14:44:03 +0100" MODIFIED_BY="Cathy Bennett" NAME="Fuller 2003" TYPE="JOURNAL_ARTICLE">
<AU>Fuller LC, Child FJ, Midgley G, Higgins EM</AU>
<TI>Diagnosis and management of scalp ringworm</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<NO>7388</NO>
<PG>539-41</PG>
<IDENTIFIERS MODIFIED="2015-06-22 12:02:58 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 12:02:58 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="12623917"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fuller-2014" MODIFIED="2016-04-29 09:35:55 +0100" MODIFIED_BY="[Empty name]" NAME="Fuller 2014" TYPE="JOURNAL_ARTICLE">
<AU>Fuller LC, Barton RC, Mohd Mustapa MF, Proudfoot LE, Punjabi SP, Higgins EM</AU>
<TI>British Association of Dermatologists' guidelines for the management of tinea capitis 2014</TI>
<SO>Br J Dermatol</SO>
<YR>2014</YR>
<VL>171</VL>
<PG>454-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ginter_x002d_Hanselmayer-2007" MODIFIED="2016-04-29 09:36:12 +0100" MODIFIED_BY="[Empty name]" NAME="Ginter-Hanselmayer 2007" TYPE="JOURNAL_ARTICLE">
<AU>Ginter-Hanselmayer G, Weger W, Ilkit M, Smolle J</AU>
<TI>Epidemiology of tinea capitis in Europe: current state and changing patterns</TI>
<SO>Mycoses</SO>
<YR>2007</YR>
<VL>50</VL>
<NO>Suppl 2</NO>
<PG>6-13</PG>
<IDENTIFIERS MODIFIED="2015-06-22 12:05:12 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 12:05:12 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="17681048"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gupta-1999" MODIFIED="2016-04-29 09:36:36 +0100" MODIFIED_BY="[Empty name]" NAME="Gupta 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gupta AK, Hofstader SLR, Adam P</AU>
<TI>Tinea capitis: an overview with emphasis on management</TI>
<SO>Pediatric Dermatology</SO>
<YR>1999</YR>
<VL>16</VL>
<NO>3</NO>
<PG>171-89</PG>
<IDENTIFIERS MODIFIED="2015-06-22 12:13:40 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 12:13:40 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="10383772"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gupta-2008" MODIFIED="2016-04-13 14:44:47 +0100" MODIFIED_BY="Cathy Bennett" NAME="Gupta 2008" TYPE="JOURNAL_ARTICLE">
<AU>Gupta AK, Cooper EA, Bowen JE</AU>
<TI>Meta-analysis: griseofulvin efficacy in the treatment of tinea capitis</TI>
<SO>Journal of Drugs in Dermatology</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>4</NO>
<PG>369-72</PG>
<IDENTIFIERS MODIFIED="2016-02-26 09:47:01 +0000" MODIFIED_BY="Cathy Bennett">
<IDENTIFIER TYPE="PUBMED" VALUE="18459518"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gupta-2013" MODIFIED="2016-04-13 14:44:58 +0100" MODIFIED_BY="Cathy Bennett" NAME="Gupta 2013" TYPE="JOURNAL_ARTICLE">
<AU>Gupta AK, Drummond-Main C</AU>
<TI>Meta-analysis of randomized, controlled trials comparing particular doses of griseofulvin and terbinafine for the treatment of tinea capitis</TI>
<SO>Pediatric Dermatology</SO>
<YR>2013</YR>
<VL>30</VL>
<NO>1</NO>
<PG>1-6</PG>
<IDENTIFIERS MODIFIED="2016-02-26 15:53:14 +0000" MODIFIED_BY="Cathy Bennett">
<IDENTIFIER TYPE="PUBMED" VALUE="22994156"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Havlickova-2008" MODIFIED="2015-06-22 12:15:01 +0100" MODIFIED_BY="Helen Scott" NAME="Havlickova 2008" TYPE="JOURNAL_ARTICLE">
<AU>Havlickova B, Czaika VA, Friedrich M</AU>
<TI>Epidemiological trends in skin mycoses worldwide</TI>
<SO>Mycoses</SO>
<YR>2008</YR>
<VL>51</VL>
<NO>Suppl 4</NO>
<PG>2-15</PG>
<IDENTIFIERS MODIFIED="2015-06-22 12:15:01 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-04-10 10:54:46 +0100" MODIFIED_BY="Laura E Prescott" TYPE="DOI" VALUE="10.1111/j.1439-0507.2008.01606.x"/>
<IDENTIFIER MODIFIED="2015-06-22 12:15:01 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="18783559"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hay-2006" MODIFIED="2016-05-03 13:31:33 +0100" MODIFIED_BY="[Empty name]" NAME="Hay 2006" TYPE="BOOK_SECTION">
<AU>Hay R, Bendeck SE, Chen S, Estrada R, Haddix A, McLeod T, et al</AU>
<TI>Chapter 37 Skin Diseases</TI>
<SO>Disease Control Priorities in Developing Countries.</SO>
<YR>2006</YR>
<PG>online</PG>
<EN>2nd</EN>
<ED>Jamison DT, Breman JG, Measham AR, et al.</ED>
<PB>World Bank</PB>
<CY>Washington (DC)</CY>
<IDENTIFIERS MODIFIED="2015-06-22 12:23:18 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 12:23:18 +0100" MODIFIED_BY="Helen Scott" TYPE="OTHER" VALUE="www.ncbi.nlm.nih.gov/books/NBK11733/"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2000" MODIFIED="2015-06-22 12:24:53 +0100" MODIFIED_BY="Helen Scott" NAME="Higgins 2000" TYPE="JOURNAL_ARTICLE">
<AU>Higgins EM, Fuller LC, Smith CH</AU>
<TI>Guidelines for the management of tinea capitis</TI>
<SO>British Journal of Dermatology</SO>
<YR>2000</YR>
<VL>143</VL>
<NO>1</NO>
<PG>53-8</PG>
<IDENTIFIERS MODIFIED="2015-06-22 12:24:53 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 12:24:53 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="10886135"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-04-29 09:39:28 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS MODIFIED="2015-03-15 14:02:40 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kakourou-2010" MODIFIED="2016-04-29 09:39:43 +0100" MODIFIED_BY="[Empty name]" NAME="Kakourou 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kakourou T, Uksal U, European Society for Pediatric Dermatology</AU>
<TI>Guidelines for the management of tinea capitis in children</TI>
<SO>Pediatric Dermatology</SO>
<YR>2010</YR>
<VL>27</VL>
<NO>3</NO>
<PG>226-8</PG>
<IDENTIFIERS MODIFIED="2016-02-26 15:23:16 +0000" MODIFIED_BY="Cathy Bennett">
<IDENTIFIER TYPE="PUBMED" VALUE="20609140"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lewis-1984" MODIFIED="2016-05-03 15:23:08 +0100" MODIFIED_BY="[Empty name]" NAME="Lewis 1984" TYPE="JOURNAL_ARTICLE">
<AU>Lewis James H, Zimmerman HYMAN J, Benson Gordon D, Ishak Kamal G</AU>
<TI>Hepatic injury associated with ketoconazole therapy</TI>
<SO>Analysis of</SO>
<YR>1984</YR>
<VL>33</VL>
<PG>503-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pomeranz-1999" MODIFIED="2015-06-22 12:28:25 +0100" MODIFIED_BY="Helen Scott" NAME="Pomeranz 1999" TYPE="JOURNAL_ARTICLE">
<AU>Pomeranz AJ, Sabnis SS, McGrath GJ, Esterly NB</AU>
<TI>Asymptomatic dermatophyte carriers in the households of children with tinea capitis</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>1999</YR>
<VL>153</VL>
<NO>5</NO>
<PG>483-6</PG>
<IDENTIFIERS MODIFIED="2015-06-22 12:28:06 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 12:28:06 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="10323628"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Revman-2014" MODIFIED="2016-04-29 09:40:05 +0100" MODIFIED_BY="[Empty name]" NAME="Revman 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-2010" MODIFIED="2016-04-29 09:42:01 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 2010" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Altman DG, Moher D; CONSORT Group</AU>
<TI>CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c332</PG>
<IDENTIFIERS MODIFIED="2015-06-22 12:34:04 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 12:34:04 +0100" MODIFIED_BY="Helen Scott" TYPE="DOI" VALUE="10.1136/bmj.c332"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2013" MODIFIED="2016-04-29 09:44:07 +0100" MODIFIED_BY="[Empty name]" NAME="Schünemann 2013" TYPE="OTHER">
<AU>Schünemann H, Bro&#380;ek J, Guyatt G, Oxman A (editors)</AU>
<TI>GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations [updated October 2013]</TI>
<SO>gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html</SO>
<YR>(accessed 23 March 2016)</YR>
<IDENTIFIERS MODIFIED="2016-02-13 13:16:04 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2016-02-13 13:16:04 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Available from guidelinedevelopment.org/handbook."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tey-2011" MODIFIED="2016-02-26 10:53:19 +0000" MODIFIED_BY="Cathy Bennett" NAME="Tey 2011" TYPE="JOURNAL_ARTICLE">
<AU>Tey HL, Tan AS, Chan YC</AU>
<TI>Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>663-70</PG>
<IDENTIFIERS MODIFIED="2016-02-26 10:53:17 +0000" MODIFIED_BY="Cathy Bennett">
<IDENTIFIER TYPE="PUBMED" VALUE="21334096"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yu-2005" MODIFIED="2015-06-22 12:35:03 +0100" MODIFIED_BY="Helen Scott" NAME="Yu 2005" TYPE="JOURNAL_ARTICLE">
<AU>Yu J, Li R, Bulmer G</AU>
<TI>Current topics of tinea capitis in China</TI>
<SO>Japanese Journal of Medical Mycology</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>2</NO>
<PG>61-6</PG>
<IDENTIFIERS MODIFIED="2015-06-22 12:35:03 +0100" MODIFIED_BY="Helen Scott">
<IDENTIFIER MODIFIED="2015-06-22 12:35:03 +0100" MODIFIED_BY="Helen Scott" TYPE="MEDLINE" VALUE="15864248"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zonios-2008" MODIFIED="2016-04-13 14:47:55 +0100" MODIFIED_BY="Cathy Bennett" NAME="Zonios 2008" TYPE="JOURNAL_ARTICLE">
<AU>Zonios DI, Bennett JE</AU>
<TI>Update on azole antifungals</TI>
<SO>Seminars in Respiratory and Critical Care Medicine</SO>
<YR>2008</YR>
<VL>29</VL>
<PG>198-210</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-04-29 10:33:09 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Gonzalez-2007" MODIFIED="2016-04-29 10:33:09 +0100" MODIFIED_BY="[Empty name]" NAME="Gonzalez 2007" TYPE="COCHRANE_REVIEW">
<AU>Gonzalez U, Seaton T, Bergus G, Jacobson J, Martinez-Monzon C</AU>
<TI>Systemic antifungal therapy for tinea capitis in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>4</NO>
<PG>CD004685.pub2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD004685.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-05-03 16:21:08 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-05-03 16:21:08 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000">
<CHAR_METHODS MODIFIED="2016-04-28 12:28:47 +0100" MODIFIED_BY="[Empty name]">
<P>Triple-blind, parallel group RCT for 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 13:59:46 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lima (Perú)</LI>
<LI>N = 50 (23 males, 27 females) participants</LI>
<LI>Aged 1-14</LI>
<LI>Inclusion criteria: clinical and mycologic diagnosis of non-inflammatory tinea capitis; weight &gt; 10 kg; normal baseline laboratory evaluation (complete blood cell count, erythrocyte sedimentation rate, liver function tests and urinalysis)</LI>
<LI>Exclusion criteria: antimycotic therapy during the month before consultation; bacterial superinfection, systemic illness or unknown intolerance or allergy to terbinafine or griseofulvin</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>
<I>T. tonsurans</I>: 74%</LI>
<LI>
<I>M. canis</I>: 26%</LI>
</UL>
<LI>No mention of adherence assessment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 13:59:19 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: griseofulvin (microsize) tablet, 10-20 kg: 125 mg/d; 20-40 kg: 250 mg/d; &gt; 40 kg: 500 mg/d, for 8 weeks (N = 25)</LI>
<LI>Group 2: terbinafine tablet, 10-20 kg: 62.5 mg/d; 20-40 kg: 125 mg/d; &gt; 40 kg: 250 mg/d, once a day for 4 weeks plus 4 weeks of placebo (N = 25)</LI>
</UL>
<P>No co-treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:33 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The proportion of participants with complete cure at 12 weeks</LI>
<LI>The frequency and type of adverse events</LI>
<LI>The proportion of participants with clinical cure only at 12 weeks</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 12:28:25 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: not mentioned</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dastghaib-2005">
<CHAR_METHODS MODIFIED="2016-04-28 12:39:18 +0100" MODIFIED_BY="[Empty name]">
<P>Single-blind, parallel group RCT for 8 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 13:59:43 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Iran</LI>
<LI>N = 40</LI>
<LI>Aged between from 1 to 16; 80% were boys and 20% girls</LI>
<LI>Inclusion criteria: clinical and mycologic diagnosis of non-inflammatory tinea capitis</LI>
<LI>Exclusion criteria: a history of allergy to imidazoles; use of oral antifungals within 8 weeks or use of topical antifungals within 4 weeks before screening; a history of congenital or acquired immunodeficiency or disorders affecting kidney or liver function; concurrent therapy with other drugs; and systemic illness</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>
<I>T. verrucosum</I>: fluconazole: 26.3%; griseofulvin: 52.4%; total: 40%</LI>
<LI>
<I>T. violaceum</I>: fluconazole: 52.6%; griseofulvin: 28.6%; total: 40%</LI>
<LI>
<I>M. canis</I>: fluconazole: 21.1%; griseofulvin: 19%; total: 20%</LI>
</UL>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:00:26 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: griseofulvin 15 mg/kg/d for 6 weeks (N = 21)</LI>
<LI>Group 2: fluconazole 5 mg/kg/d for 4 weeks (N = 19)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:33 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The proportion of participants with complete cure after 8 weeks</LI>
<LI>The frequency and type of adverse events</LI>
<LI>Mycologic cure at the end of treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 12:40:36 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: not mentioned</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Deng-2011">
<CHAR_METHODS MODIFIED="2016-04-28 12:41:12 +0100" MODIFIED_BY="[Empty name]">
<P>3-arm, parallel group RCT for 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:00:39 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>China (Kashgar)</LI>
<LI>N = 88</LI>
<LI>Aged 2-14 years old. The mean ages were 8.42, 7.69, and 9.13 in the 3 groups, respectively.</LI>
<LI>78.3% males</LI>
<LI>Inclusion criteria: "Children with age older than two years old, weight more than 10 kg, no apparent other diseases, not using any steroids, not taking antifungal drugs for 4 weeks, and renal functions were normal."</LI>
<LI>Exlcusion criteria: "Children who did not return for observation on time, those who took other antifungal drugs locally and/or orally during treatment, and those who discontinued treatment due to side effects."</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>
<I>T. violaceum</I>: 55.1%</LI>
<LI>
<I>A. vanbreuseghemi</I>: 30.6%</LI>
<LI>
<I>T. tonsurans</I>: 14.3%</LI>
</UL>
<LI>Adherence assessment: not mentioned</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:01:03 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: griseofulvin, doses of 20mg/kg/d, for 4 consecutive weeks (N = 19)</LI>
<LI>Group 2: terbinafine, doses depend on weight:&lt; 20 kg, 62.5 mg/d; 20-40 kg, 125 mg/d; and &gt; 40 kg, 250 mg/d, for 2 consecutive weeks (N = 27)</LI>
<LI>Group 3: terbinafine, doses depend on weight:&lt; 20 kg, 62.5 mg/d; 20-40 kg, 125 mg/d; and &gt; 40 kg, 250 mg/d, for 4 consecutive weeks (N = 23)</LI>
</UL>
<P>No co-treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:34 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Clinical cure rates at 2, 4, 8 weeks, and 1 year after therapy</LI>
<LI>Clinical effectiveness rates at 2, 4, 8 weeks, and 1 year after therapy</LI>
<LI>Mycological cure rates at 2, 4, 8 weeks, and 1 year after therapy</LI>
<LI>The frequency and type of adverse events</LI>
<LI>Percentage of drop-outs as a surrogate for participant adherence</LI>
</UL>
<P>One of the primary outcomes of interest in this review (complete cure rate) was not reported in this study.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-29 10:17:36 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The enrolled: 88 participants were randomised, 70 participants were evaluated for adverse events, 69 participants were evaluated for clinical results</LI>
<LI>Funding: Novartis Pharmaceutica</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Elewski-2008">
<CHAR_METHODS MODIFIED="2016-04-28 12:46:13 +0100" MODIFIED_BY="[Empty name]">
<P>Multicentre, single-blind, parallel group RCT for 10 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:01:43 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>USA, Peru, UK, Egypt, Russia, and Sourth Africa</LI>
<LI>N = 1549</LI>
<LI>The mean age was 6.8 years (ranged from 4-12 years). 62.2% males.</LI>
<LI>Inclusion criteria: "Children were included if they were between 4 and 12 years of age and had a clinical diagnosis of tinea capitis confirmed by positive potassium hydroxide (KOH) microscopy at baseline."</LI>
<LI>Exclusion criteria: "Patients with protocol-defined clinically significant biochemistry and hematologic abnormalities were excluded from the study as were those with kerions requiring immediate treatment or treatment with systemic corticosteroids and/or systemic antibiotics, those with a condition or treatment that could interfere with evaluation of drug effect, or those with current or past liver disease. Other criteria for exclusion from study were presence of serious gastrointestinal disease, hypersensitivity to study agents, and history of systemic lupus erythematosus. Patients with systemic antifungal treatment or history of use of any other investigational agent within 2 months before screening; use of immunosuppressant, cytostatic, or radiation therapy within 1 month before screening; or topical treatment of the scalp within 1 week before baseline visit were also excluded from study participation."</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>
<I>T. tonsurans</I> 49.3%</LI>
<LI>
<I>T. violaceum</I> 15.6%</LI>
<LI>M. canis 15.1%</LI>
<LI>
<I>M. audouini</I> 1.5%</LI>
<LI>
<I>M. vanbreuseghemi</I> 0.3%</LI>
<LI>
<I>T. mentagrophytes</I> 0.2%</LI>
<LI>
<I>T. rubrum</I> 0.2%</LI>
<LI>
<I>M. gypseum</I> 0.1%</LI>
<LI>Other 6.5%</LI>
<LI>Negative 17.0%</LI>
</UL>
<LI>Adherence assessment: not mentioned</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:02:02 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: terbinafine, doses of 5-8 mg/kg for 6 weeks (N = 1040)</LI>
<LI>Group 2: griseofulvin, doses of 10-20 mg/kg for 6 weeks (N = 509)</LI>
</UL>
<P>No co-treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:37 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Complete cure rate at 10 weeks</LI>
<LI>Clinical cure rate at 10 weeks</LI>
<LI>Mycologic cure rate at 10 weeks</LI>
<LI>The frequency and severity of adverse events</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 12:34:51 +0100" MODIFIED_BY="[Empty name]">
<P>This article included 2 RCTs, but the results of the 2 RCTs were reported together.</P>
<P>Funding: Novartis Pharmaceuticals Corporation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-03 16:20:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Foster-2005">
<CHAR_METHODS MODIFIED="2016-04-28 12:51:04 +0100" MODIFIED_BY="[Empty name]">
<P>Multicentre, single-blind, parallel group RCT for 10 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-03 16:20:28 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>USA, Guatemala, Chile, Costa Rica and India</LI>
<LI>N = 880</LI>
<LI>Most participants (71%, 72%, and 73% in the 3 groups, respectively) were black</LI>
<LI>Aged 3-12 years old.</LI>
<LI>Inclusion criteria: "male or female between the ages of 3 and 12 years, a potassium hydroxide preparation positive for fungal elements on direct microscopy, a clinical diagnosis of tinea capitis, a guardian capable of providing informed consent who was able to be actively involved in the care and evaluation of the subject, a negative baseline urine pregnancy test if applicable, and otherwise healthy."</LI>
<LI>Exclusion criteria: participants with any of the following conditions were excluded: "a negative baseline potassium hydroxide preparation; a kerion requiring immediate treatment with systemic corticosteroids or antibiotics; previous treatment with topical or systemic antifungal therapy within the past 48 hours or 30 days, respectively; elevations in the blood levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase,g-glutamyl transferase, or total bilirubin higher than two times the upper limit of normal; history of active liver disease; previous treatment with any other investigational agent within eight weeks before enrolment in this study; a disease or condition that could impair absorption from the gastrointestinal tract; underlying liver, kidney, or other organ disease that could result in abnormalities in the absorption or metabolism of griseofulvin, fluconazole, or their metabolites; allergies to the aforementioned drugs, pregnant females or those at risk of becoming such; those currently taking any substance known to inhibit cytochrome P-450; those with concurrent skin disease that could obscure the diagnosis and treatment of tinea capitis; an immunocompromised state; or an enrolled family member."</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>
<I>T.tonsurans</I> 86%</LI>
<LI>
<I>M. canis</I> 11%</LI>
</UL>
<LI>Adherence assessment: not mentioned</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:02:31 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: fluconazole, dose of 6 mg/kg for 3 weeks followed by 3 weeks of placebo (N = 302)</LI>
<LI>Group 2: fluconazole, dose of 6 mg/kg for 6 weeks (N = 286)</LI>
<LI>Group 3: griseofulvin, dose of 11 mg/kg for 6 weeks (N = 292)</LI>
</UL>
<P>No co-treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:38 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Clinical outcomes</LI>
<UL>
<LI>Clinical cure rate at 3, 6, and 10 weeks</LI>
<LI>Clincial improvement rate at 3, 6, and 10 weeks</LI>
<LI>Clinical failure rate at 3, 6, and 10 weeks</LI>
</UL>
<LI>Combined outcomes</LI>
<UL>
<LI>Success rate at 3, 6, and 10 weeks</LI>
<LI>Partial success rate at 3, 6, and 10 weeks</LI>
<LI>Failure rate at 3, 6, and 10 weeks</LI>
</UL>
<LI>Mycological outcome</LI>
<UL>
<LI>The percentage of participants with negative cultures</LI>
</UL>
<LI>Safety outcomes</LI>
<UL>
<LI>The incidence of all causality and treatment-related adverse events</LI>
<LI>The frequency and type of adverse event</LI>
</UL>
</UL>
<P>One of the primary outcomes of interest in this review (complete cure rate) was not reported in this study.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 13:11:57 +0100" MODIFIED_BY="[Empty name]">
<P>Main data of this article were from 2 identical studies. The safety data from this article were from 3 studies. Overall, 90% of participants were from USA.</P>
<P>Funding: Prifzer, Inc.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Friedlander-2002">
<CHAR_METHODS MODIFIED="2016-04-28 12:55:09 +0100" MODIFIED_BY="[Empty name]">
<P>Triple-blind, parallel group RCT for 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:02:51 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>North America</LI>
<LI>N = 177 (78% were black; 57.2% males)</LI>
<LI>Age was 4 years or older (98% participants &lt; 18 years old; mean age, 7.4 years old), only 3 adults</LI>
<LI>Inclusion criteria: male and female participants aged 4 years or older, with clinically diagnosed tinea capitis caused by <I>Trichophyton</I> spp.</LI>
<LI>Exclusion criteria: any systemic treatment for tinea capitis in the month before enrolment. Kerions that required immediate treatment, concurrent seborrhoeic dermatitis, or other scalp conditions such as scabies, head lice, psoriasis, or atopic dermatitis. Immunocompromised participants or a history of malignancy within 5 years. Chronic or active liver disease. Serious gastrointestinal disease. Hypersensibility to terbinafine or placebo. Treatment with any other investigative agent within the previous 8 weeks. Pregnancy or lactation.</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>
<I>T. tonsurans</I>: 98.74%</LI>
<LI>
<I>T. soudanense</I>: 0.63%</LI>
<LI>
<I>T. verrucosum</I>: 0.63%</LI>
</UL>
<LI>Adherence assessed by asking participants to return unused medication at each visit</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:03:18 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: oral terbinafine 3-6 mg/kg/d for 1 week (N = 56)</LI>
<LI>Group 2: oral terbinafine 3-6 mg/kg/d for 2 weeks (N = 59)</LI>
<LI>Group 3: oral terbinafine 3-6 mg/kg/d for 4 weeks (N = 62)</LI>
</UL>
<P>Followed by placebo to complete 4 weeks when needed</P>
<P>Co-treatment: non-medicated shampoo twice weekly</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:39 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The proportion of participants with complete cure at 12 weeks</LI>
<LI>The frequency and type of adverse events</LI>
<LI>The proportion of participants with clinical cure only at 12 weeks</LI>
<LI>Percentage of drop-outs as a surrogate for participant adherence</LI>
<LI>The time taken to cure</LI>
<LI>Mycological cure at 12 weeks</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 12:57:00 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: not mentioned</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fuller-2001">
<CHAR_METHODS MODIFIED="2016-04-28 12:58:59 +0100" MODIFIED_BY="[Empty name]">
<P>Open-label, parallel group RCT for 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:03:28 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>UK</LI>
<LI>N = 210</LI>
<LI>Aged 2-16 years</LI>
<LI>Inclusion criteria: children aged 2-16 years old with clinical diagnosis of tinea capitis</LI>
<LI>Exclusion criteria: immunocompromised children and those receiving any topical antifungal agents within 7 days or systematic antifungal agents within 6 weeks prior to the start of the treatment</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>
<I>Microsporum audouini</I>: 13% (13/103) in the terbinafine group and 11.4% (12/107) in the griseofulvin group</LI>
<LI>
<I>M. canis</I>: 1.3% (1/103) in the terbinafine group and 1.4% (2/107) in the griseofulvin group</LI>
<LI>
<I>M.rivalieri</I>: 0% in the terbinafine group and 1.4% (2/107) in the griseofulvin group</LI>
<LI>
<I>Trichophyton tonsurans</I>: 64.9% (67/103) in the terbinafine group and 72.9% (78/107) in the griseofulvin group</LI>
<LI>
<I>T. soudanense</I>: 10.4% (11/103) in the terbinafine group and 4.3% (5/107) in the griseofulvin group</LI>
<LI>
<I>T. violaceum</I>: 2.6% (3/103) in the terbinafine group and 0% in the griseofulvin group</LI>
<LI>
<I>Trichophyton </I>species unknown: 2.6% (3/103) in the terbinafine group and 0% in the griseofulvin group</LI>
</UL>
<LI>Adherence assessed by direct questioning.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:03:48 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: griseofulvin suspension, 10 mg/kg/d, for 8 weeks (N = 107)</LI>
<LI>Group 2: terbinafine tablet, &lt; 20 kg: 62.5 mg/d; 20-40 kg: 125 mg/d ; &gt; 40 kg: 250 mg/d, for 4 weeks (N = 103)</LI>
</UL>
<P>Co-treatment: selenium sulphide shampoo, twice weekly for the first 2 weeks of treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:40 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Proportion of participants with complete cure at 24 weeks</LI>
<LI>Frequency and type of adverse events</LI>
<LI>Percentage of drop-outs as a surrogate for participant adherence: terbinafine group</LI>
<LI>Mycological cure at 24 weeks</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 13:04:14 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: Novartis Pharmaceuticals UK Ltd (Terbinafine).</P>
<P>The report of the study stated that "<I>T. tonsurans</I> accounted for 77% of the terbinafine group and 88% of the griseofulvin group. Microsporum species accounted for 14% of both groups" (i.e. 88% plus 14% = 102%). We used the data from this paper's tables (which seemed to be reliable).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gan-1987">
<CHAR_METHODS MODIFIED="2016-04-28 13:05:39 +0100" MODIFIED_BY="[Empty name]">
<P>Open-label, parallel group RCT for 26 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:03:55 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>USA (Dallas)</LI>
<LI>N = 80</LI>
<LI>Age 2.1-11.0 years (mean age 5.2 years).</LI>
<LI>The remaining children after the drop-outs were 63; 55% were female</LI>
<LI>Inclusion criteria: children with tinea capitis were eligible for the study</LI>
<LI>Exclusion criteria: presence of kerion; if their parents were unable to make a commitment for follow-up visits, or if there was a history of hepatocellular dysfunction or finally if they had received a systemic antifungal agent in the preceding 6 weeks</LI>
<LI>Fungi isolates (94% of the participants had positive fungal cultures)</LI>
</UL>
<UL>
<UL>
<LI>
<I>T. tonsurans</I>: 70%.</LI>
<LI>
<I>M. canis</I>: 11.6%.</LI>
<LI>
<I>T. mentagrophytes</I>: 1.6%.</LI>
<LI>
<I>T. violaceum</I>: 1.6%.</LI>
<LI>Uncertain classification: 15%.</LI>
</UL>
<LI>Adherence assessed by history and by quantifying the amount of residual medication brought in by the parents.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:04:12 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: griseofulvin tablet or suspension, 15 mg/kg/d, single daily dose; 2 to 12-26 weeks (depending on the participant's clinical response to therapy) (N = 40)</LI>
<LI>Group 2: ketoconazole tablet or crushed tablets suspended in sucrose syrup, 5 mg/kg/d, single daily dose 2-26 weeks depending on the participant's clinical response to the therapy (N = 40)</LI>
</UL>
<P>No co-treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:40 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The proportion of participants with complete cure at 12 and 26 weeks</LI>
<LI>Percentage of drop-outs as a surrogate for participant adherence</LI>
<LI>The time taken to cure (scalp clearing)</LI>
</UL>
<P>One of the primary outcomes of interest in the review (adverse events) was not reported in this study.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 13:08:21 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: not mentioned</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gupta-2001">
<CHAR_METHODS MODIFIED="2016-04-28 13:42:49 +0100" MODIFIED_BY="[Empty name]">
<P>Multicentre, double-blind, parallel group RCT for 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:04:21 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Canada and South Africa</LI>
<LI>N = 200</LI>
<LI>Inclusion criteria: children aged 6 months or older, with clinical signs and symptoms of tinea capitis with mycology that was positive for <I>Trichophyton</I> spp.</LI>
<LI>Exclusion criteria: those who had been or were on topical or oral antifungal agents for 2 or 4 weeks, respectively, prior to the starting therapy</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>griseofulvin group: <I>T. tonsurans</I>: 39/50 and <I>T. violaceum</I>: 11/50</LI>
<LI>terbinafine group: <I>T. tonsurans</I>: 37/50 and <I>T. violaceum</I>: 13/50</LI>
<LI>itraconazole group: <I>T. tonsurans</I>: 35/50 and <I>T. violaceum</I>: 15/50</LI>
<LI>fluconazole group: <I>T. tonsurans</I>: 44/50 and <I>T. violaceum</I>: 6/50</LI>
</UL>
<LI>No mention of adherence assessment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:04:57 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: microsize griseofulvin 20 mg/kg/d for 6 weeks (N = 50)</LI>
<LI>Group 2: terbinafine &lt; 20 kg: 62.5 mg; 20-40 kg: 125 mg; &gt; 40 kg: 250 mg for 2-3 weeks (N = 50)</LI>
<LI>Group 3: itraconazole 5 mg/kg/d for 2-3 weeks (N = 50)</LI>
<LI>Group 4: gluconazole 6 mg/kg/d for 2-3 weeks. (N = 50)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:41 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The proportion of participants with complete cure at 12 weeks</LI>
<LI>The frequency and type of adverse events</LI>
<LI>The proportion of participants with clinical cure only at the end of treatment</LI>
<LI>Percentage of drop-outs as a surrogate for participant adherence</LI>
<LI>Mycologic cure at 12 weeks</LI>
<LI>Effective therapy (mycologic cure with clinical cure or few residual symptoms) at 12 weeks</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 13:44:28 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: not mentioned</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hamm-1999">
<CHAR_METHODS MODIFIED="2016-04-28 13:47:40 +0100" MODIFIED_BY="[Empty name]">
<P>Triple-blind, parallel group RCT for 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:05:12 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Germany</LI>
<LI>N = 35 (16 males and 19 females)</LI>
<LI>The mean age was 9.3 years for males and 7.8 for females</LI>
<LI>Inclusion criteria: mycologically proven scalp infection</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>
<I>M. canis</I>: terbinafine for 1 week: 43.7%; terbinafine for 2 weeks: 26.3%</LI>
<LI>
<I>T. tonsurans</I>: terbinafine for 1 week: 37.5%; terbinafine for 2 weeks: 31.5%</LI>
<LI>
<I>T. violaceum</I>: terbinafine for 1 week: 6.25%; terbinafine for 2 weeks: 26.3%</LI>
<LI>
<I>T. mentagrophytes</I>: terbinafine for 1 week: 12.5%; terbinafine for 2 weeks: 5.3%</LI>
<LI>
<I>T. verrucosum</I>: terbinafine for 2 weeks: 5.3%</LI>
</UL>
<LI>No mention of adherence assessment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:05:31 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: terbinafine 10-20 kg: 62.5 mg/d; 20-40 kg: 125 mg/d; &gt; 40 kg: 250 mg/d once daily for 1 week (N = 16)</LI>
<LI>Group 2: terbinafine same dose for 2 weeks (N = 19)</LI>
</UL>
<P>No co-treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:42 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The proportion of participants with complete cure at 12 weeks</LI>
<LI>The frequency and type of adverse events</LI>
<LI>The time taken to cure</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 13:48:54 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were observed for 12 weeks. After 4 weeks, non-responders were offered an additional 4 weeks of treatment followed by a second observation period</P>
<P>Funding: Novartis (terbinafine)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haroon-1995">
<CHAR_METHODS MODIFIED="2016-04-28 13:52:15 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel group RCT for 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:05:39 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Pakistan</LI>
<LI>N = 105 (49 males, 56 females)</LI>
<LI>Aged 2-65; 94 were &lt; 12 years</LI>
<LI>Inclusion criteria: clinical evidence of dermatophytosis of the scalp; participant of any age that weighed more than 10 kg</LI>
<LI>Exclusion criteria: concomitant treatment with systemic or X-ray therapy; topical antifungal therapy within 2 weeks or oral antifungal within 4 weeks of entering the study</LI>
<LI>Fungi isolated included</LI>
<UL>
<LI>
<I>T. violaceum</I>: 87.6% (92/105)</LI>
<LI>
<I>T. tonsurans</I>: 38% (4/105)</LI>
<LI>
<I>T. rubrum</I>: 0.95% (1/105)</LI>
<LI>
<I>T. verrucosum</I>: 6.6% (7/105)</LI>
<LI>
<I>M. audouinii</I>: 0.95% (1/105)</LI>
</UL>
<LI>No mention of adherence assessment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:05:53 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: terbinafine 62.5-250 mg for 4 weeks, plus 4 weeks of placebo (N = 56)</LI>
<LI>Group 2; griseofulvin 125-500 mg for 8 weeks (N = 49)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:43 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Proportion of participants with complete cure at 12 weeks</LI>
<LI>Frequency and type of adverse events</LI>
<LI>Mycological cure at 12 weeks</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 13:54:01 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: Sandoz</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haroon-1996">
<CHAR_METHODS MODIFIED="2016-04-28 13:55:49 +0100" MODIFIED_BY="[Empty name]">
<P>Triple-blind, parallel group RCT for 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:06:03 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Pakistan</LI>
<LI>N = 161 (90 males, 71 females; 156 were children below 12)</LI>
<LI>Aged 3-13</LI>
<LI>Inclusion criteria: clinical and mycological evidence of dermatophytosis of the scalp; participants of any age that weighed more than 10 kg</LI>
<LI>Exclusion criteria: concomitant treatment with systemic or X-ray therapy; topical antifungal therapy within 2 weeks or oral antifungal within 4 weeks of entering the study</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>
<I>T. violaceum</I>: 71.5%</LI>
<LI>
<I>T. tonsurans</I>: 14.9%</LI>
<LI>
<I>T. verrucosum</I>: 4.3%</LI>
<LI>
<I>M. audouinii</I>: 4.3%</LI>
<LI>
<I>M. canis</I>: 2.5%</LI>
<LI>
<I>T. schoenleinii</I>: 1.9%</LI>
<LI>
<I>T. mentagrophytes</I>: 0.6%</LI>
</UL>
<LI>No mention of adherence assessment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 13:57:44 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: terbinafine, 10-20 kg: 62.5 mg/d; 20-40 kg: 125 mg/d ; &gt; 40 kg: 250 mg/d, once daily for 1 week plus 3 weeks of placebo (N = 53)</LI>
<LI>Group 2: terbinafine same dose for 2 weeks plus 2 weeks of placebo (N = 51)</LI>
<LI>Group 3: terbinafine same dose for 4 weeks (N = 57)</LI>
</UL>
<P>No co-treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:43 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The proportion of participants with complete cure at 12 weeks</LI>
<LI>The frequency and type of adverse events</LI>
<LI>The proportion of participants with clinical cure only at 12 weeks</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 13:58:02 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: Sandoz (terbinafine)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jahangir-1998">
<CHAR_METHODS MODIFIED="2016-04-28 14:06:21 +0100" MODIFIED_BY="[Empty name]">
<P>Triple-blind, parallel group RCT for 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:06:44 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Pakistan</LI>
<LI>N = 55</LI>
<LI>Inclusion criteria: subjects of either sex or any age, weighing 10 kg or more and suffering from mycologically confirmed tinea capitis</LI>
<LI>Exclusion criteria: history of allergy to imidazoles or allylamines, use of oral antifungals within 8 weeks or topical antifungals within 4 weeks before screening, concurrent therapy with rifampicin, phenytoin, digoxin, oral anticoagulants, cyclosporin, astemizole and terfenadine, psoriasis of the scalp, history of any systemic illness or abnormal liver and renal function tests</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>
<I>T. violaceum</I>: itraconazole group: 82.1%; terbinafine group: 88.9%</LI>
<LI>
<I>T. tonsurans</I>: itraconazole group: 7.1%; terbinafine group: 3.7%</LI>
<LI>
<I>T. mentagrophytes</I>: itraconazole group: 7.1%; terbinafine group:3.7%</LI>
<LI>
<I>T. verrucosum</I>: itraconazole group: 3.7%; terbinafine group: 3.7%</LI>
</UL>
<LI>No mention of adherence assessment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:07:25 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: itraconazole: &lt; 20 kg: 50 mg; 20-40 kg: 100 mg; &gt; 40 kg: 200 mg - supposed daily - for 2 weeks (N = 28)</LI>
<LI>Group 2: terbinafine: &lt; 20 kg: 62.5 mg; 20-40 kg: 125 mg; &gt; 40 kg: 200-250 mg - supposed daily - for 2 weeks (N = 27)</LI>
</UL>
<P>No co-treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:44 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The proportion of participants with complete cure at 12 weeks</LI>
<LI>The frequency and type of adverse events</LI>
<LI>Mycological cure at 12 weeks</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 14:07:40 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: not mentioned</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khan-2011">
<CHAR_METHODS MODIFIED="2016-04-28 14:10:23 +0100" MODIFIED_BY="[Empty name]">
<P>Triple-blind, parallel group RCT for 6 weeks (although the author stated this was a "third party blind" study in the abstract, it was unclear whether they applied blinding method or not).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:11:18 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Peshawar (Pakistan)</LI>
<LI>N = 120</LI>
<LI>Aged 3-12 years </LI>
<LI>75% participants were males</LI>
<LI>Inclusion criteria: "Males and females between the ages of 3 and 12 years with potassium hydroxide preparation positive for fungal elements on direct microscopy were included in the study."</LI>
<LI>Exclusion criteria: "Patients with negative baseline KOH preparation, patients having kerion and those having treatment with topical antifungal agents within past 2 weeks or systemic antifungal agents within past 30 days"; "patients with elevated liver enzymes and history of active liver disease"</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>
<I>T. tonsurans</I> 75%</LI>
<LI>
<I>M. canis</I> 22%</LI>
</UL>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:11:45 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: terbinafine, &lt;20 kg 62.5 mg; 20-40 kg 125 mg, for 4 weeks (N = 60)</LI>
<LI>Group 2: griseofulvin, 15 mg/kg, for 4 weeks (N = 60)</LI>
</UL>
<P>Co-treatment: not mentioned</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:45 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Clinical cure rate at 2, 4, and 6 weeks</LI>
<LI>Mycological cure rate at 2, 4, and 6 weeks</LI>
<LI>The type of adverse events</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 14:11:59 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: not mentioned</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kullavanijaya-1997">
<CHAR_METHODS MODIFIED="2016-04-28 14:12:42 +0100" MODIFIED_BY="[Empty name]">
<P>Single-blind, parallel group RCT for 20 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:15:03 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Bangkok (Thailand)</LI>
<LI>N = 82</LI>
<LI>All participants were children 7 years or older, except for 3 adults, all living in an orphanage</LI>
<LI>Fungi isolated: <I>T. tonsurans</I> and <I>M. ferrugineum;</I> proportions not stated</LI>
<LI>No mention of adherence assessment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:15:56 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: terbinafine 62.5-250 mg according to body weight - supposed once daily - for 1 week. N = 27 completed the study</LI>
<LI>Group 2: terbinafine same dose for 2 weeks. N = 28 completed the study</LI>
<LI>Group 3: terbinafine same dose for 4 weeks. N = 27 completed the study</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:46 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The proportion of participants with complete cure at 12 weeks</LI>
</UL>
<P>One of the primary outcomes of interest in this review (adverse events) was not reported in this study.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 14:16:32 +0100" MODIFIED_BY="[Empty name]">
<P>The proportions and percentages were done including the adults, because we are unaware which group they belonged to.</P>
<P>Funding: Sandoz (terbinafine)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lipozencic-2002">
<CHAR_METHODS MODIFIED="2016-04-28 14:18:04 +0100" MODIFIED_BY="[Empty name]">
<P>Multicentre, triple-blind, parallel group RCT for 16 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:19:52 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Europe and South America (22 centres)</LI>
<LI>N = 165</LI>
<LI>The majority of participants were white (77%); 63% were males and the mean age was 7.7 years, only 3 adults were enrolled in the study; 67% weighed between 20 and 40 kg.</LI>
<LI>Inclusion criteria: male or female aged &#8805; 4, with tinea capitis confirmed by positive culture of <I>Microsporum</I> spp., who were otherwise healthy outpatients and able to swallow the study drug tablets</LI>
<LI>Exclusion criteria: participants with conditions that could interfere with gastrointestinal absorption of terbinafine, with confirmed liver or renal impairment, with kerion or any severe concurrent disease of the scalp. Those using any antifungal therapy, radiotherapy, systemic therapy with cytostatic or immunosuppressive drugs within 1 month prior to the start of the study, and known intolerance or allergy to drugs used in the study</LI>
<LI>In addition, participants receiving griseofulvin treatment in this study were subject to exclusion according to the label instruction of that drug</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>
<I>M. canis</I>: 98.5%</LI>
<LI>Only 2 participants were infected with <I>M. audouinii</I>
</LI>
</UL>
<LI>No mention of adherence assessment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:20:50 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: terbinafine tablets &lt; 20 kg: 62.5 mg/d; 20-40 kg: 125 mg/d; &gt; 40 kg: 250 mg/d for 6 weeks, followed by placebo to complete the 12 week double-blind treatment phase (N = 36)</LI>
<LI>Group 2: terbinafine same dose for 8 weeks, followed by placebo to complete the 12 week double-blind treatment phase (N = 34)</LI>
<LI>Group 3: terbinafine same dose for 10 weeks, followed by placebo to complete the 12 week double-blind treatment phase (N = 33)</LI>
<LI>Group 4: terbinafine same dose for 12 weeks, followed by placebo to complete the 12 week double-blind treatment phase (N = 32)</LI>
<LI>Group 5: griseofulvin oral suspension 20 mg/kg/d for 12 weeks (open label) (N = 30)</LI>
</UL>
<P>Participants were provided with baby-shampoo to clean the scalp.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:48 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The proportion of participants with complete cure at 16 weeks</LI>
<LI>The frequency and type of adverse events</LI>
<LI>The proportion of participants with clinical cure only at 16 weeks</LI>
<LI>Percentage of drop-outs as a surrogate for participant adherence</LI>
<LI>The time taken to cure</LI>
<LI>Mycological cure at 16 weeks</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-25 01:49:55 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: Novartis Pharma AG</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994">
<CHAR_METHODS MODIFIED="2016-04-28 14:23:01 +0100" MODIFIED_BY="[Empty name]">
<P>Triple-blind, parallel group RCT for 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:23:18 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Madrid (Spain)</LI>
<LI>N = 35 (23 males and 12 females)</LI>
<LI>All participants were children younger than 12 years old, except for 1 adult who was 60 years old</LI>
<LI>Inclusion criteria: the presence of dermatophytes</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>
<I>T. tonsurans</I>: itraconazole group: 5.5%</LI>
<LI>
<I>M. canis</I>: itraconazole group: 88.8%; griseofulvin group: 94.1%</LI>
<LI>
<I>T. mentagrophytes</I>: itraconazole group: 5.5%</LI>
<LI>
<I>T. violaceum</I>: griseofulvin group: 5.9%</LI>
</UL>
<LI>No mention of adherence assessment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:24:15 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: itraconazole 100 mg/d for 6 weeks (N = 18, including 1 adult)</LI>
<LI>Group 2: griseofulvin (ultra microsize) 500 mg/d for 6 weeks (N = 17)</LI>
<LI>No co-treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:49 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The proportion of participants with complete cure at 14 weeks</LI>
<LI>The frequency and type of adverse events</LI>
<LI>The proportion of participants with clinical cure only at 14 weeks</LI>
<LI>Percentage of drop-outs as a surrogate for participant adherence</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 14:24:34 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: Janssen (itraconazole)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mart_x00ed_nez_x002d_Roig-1988">
<CHAR_METHODS MODIFIED="2016-04-28 14:25:33 +0100" MODIFIED_BY="[Empty name]">
<P>Triple-blind, parallel group RCT for 6 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:26:53 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Barcelona (Spain)</LI>
<LI>N = 13</LI>
<LI>Children aged 2-16</LI>
<LI>Sex distribution not reported</LI>
<LI>Inclusion criteria: children suffering from dermatophytic lesions</LI>
<LI>Exclusion criteria: not to have received previous antifungal therapy</LI>
<LI>Fungi isolated: <I>T. mentagrophytes</I>, <I>M. canis</I> and <I>Epidermophyton floccosum</I>
</LI>
<LI>Adherence assessed</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:27:23 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: ketoconazole tablet, 100 mg/d at 12-hourly intervals for 6 weeks (N = 8)</LI>
<LI>Group 2: griseofulvin tablet, 350 mg/d, at 12-hourly intervals for 6 weeks (N = 5)</LI>
</UL>
<P>Co-treatment: manual depilation in cases of inflammatory tinea capitis.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:50 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The frequency and type of adverse events</LI>
<LI>The proportion of participants with clinical cure only at the end of treatment</LI>
<LI>Measurement of recurrence of the condition after the end of the intervention period</LI>
<LI>The time taken to cure</LI>
</UL>
<P>One of the primary outcomes of interest in this review (complete cure rate) was not reported in this study.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 14:28:28 +0100" MODIFIED_BY="[Empty name]">
<P>Tinea corporis and tinea capitis study, information poorly stated<BR/>It needs to be taken into account that the study talks about 47 participants, which is the total, tinea capitis and tinea corporis participants, but for the purpose of our review we have only used the results of the 13 tinea capitis participants.</P>
<P>Funding: Laboratories Dr Esteve (ketoconazole)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Memisoglu-1999">
<CHAR_METHODS MODIFIED="2016-04-28 14:29:39 +0100" MODIFIED_BY="[Empty name]">
<P>Triple-blind, parallel group RCT for 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:30:26 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Turkey</LI>
<LI>N = 78</LI>
<LI>Children aged 2-13 years</LI>
<LI>Inclusion criteria: participants with clinically suspected tinea capitis, provisionally confirmed by detection of fungal hyphae in KOH.</LI>
<LI>Exclusion criteria: evidence of concomitant candida or bacterial infection</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>
<I>T. violaceum</I>: griseofulvin group: 11.4% (4/35); terbinafine group: 15.6% (5/32)</LI>
<LI>
<I>T. rubrum</I>: griseofulvin group: 22.8% (8/35); terbinafine group: 15.6%(5/32)</LI>
<LI>
<I>M. canis</I>: griseofulvin group: 48.5% (17/35); terbinafine group: 46.8%(15/32)</LI>
<LI>
<I>T. tonsurans</I>: griseofulvin group: 5.7% (2/35); terbinafine group: 6.25% (2/32)</LI>
<LI>
<I>T. mentagrophytes</I>: griseofulvin group: 5.7% (2/35); terbinafine group: 3.1% (1/32)</LI>
<LI>
<I>T. verrucosum</I>: griseofulvin group: 5.7% (2/35); terbinafine group: 3.1% (1/32)</LI>
<LI>
<I>M. audouinii</I>: terbinafine group: 3.1% (1/32)</LI>
<LI>Unidentified: terbinafine group: 6.25% (2/32)</LI>
</UL>
<LI>No mention of adherence assessment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:31:27 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: microsize griseofulvin 20 mg/kg/d for 6 weeks (N = 50)</LI>
<LI>Group 2: terbinafine &lt; 20 kg: 62.5 mg; 20 to 40 kg: 125 mg; &gt; 40 kg: 250 mg for 2-3 weeks (N = 50)</LI>
<LI>Group 3: itraconazole 5 mg/kg/d for 2-3 weeks (N = 50)</LI>
<LI>Group 4: gluconazole 6 mg/kg/d for 2-3 weeks (N = 50)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:50 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The proportion of participants with complete cure at 12 weeks</LI>
<LI>The frequency and type of adverse events</LI>
<LI>The proportion of participants with clinical cure only was scored at 12 weeks</LI>
<LI>Percentage of drop-outs as a surrogate for participant adherence</LI>
<LI>Mycological cure at 12 weeks</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 14:32:34 +0100" MODIFIED_BY="[Empty name]">
<P>At the beginning there were 39 participants in each group, after the drop-outs there were 32 and 35 left, and so the percentages do not match:</P>
<UL>
<LI>
<I>T. violaceum</I>: 13.4%</LI>
<LI>
<I>T. rubrum</I>: 19.4%</LI>
<LI>
<I>M. canis</I>: 47.7%</LI>
<LI>
<I>T. tonsurans</I>: 5.9%</LI>
<LI>
<I>T. mentagrophytes</I>:4.5%</LI>
<LI>
<I>T. verrucosum</I>: 4.5%</LI>
<LI>
<I>M. audouinii</I> : 1.5%</LI>
<LI>Unidentified: 3%</LI>
</UL>
<P>These fungi percentages are the total over 67, not over 78 participants.</P>
<P>Funding: not mentioned.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rademaker-1998">
<CHAR_METHODS MODIFIED="2016-04-28 14:33:25 +0100" MODIFIED_BY="[Empty name]">
<P>Open-label, parallel group RCT for 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:33:40 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>New Zealand</LI>
<LI>N = 24</LI>
<LI>16 male and 8 female</LI>
<LI>Age ranged between 2 and 15 years old</LI>
<LI>Inclusion criteria: paediatric participants under 16 years old with culture positive tinea capitis</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>
<I>M. canis</I> 71%</LI>
<LI>
<I>T. verrucosum</I> 29%</LI>
</UL>
<LI>No mention of adherence assessment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:34:22 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: griseofulvin 10 mg/kg/d for 8 weeks (N = 14)</LI>
<LI>Group 2: terbinafine &lt; 20 kg: 62.5 mg/d; 20 to 40 kg: 125 mg/d; &gt; 40 kg: 250 mg/d for 4 weeks (N = 10)</LI>
</UL>
<P>Co-treatment: ketoconazole shampoo twice a week and econazole cream nightly was recommended</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:51 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The frequency and type of adverse events</LI>
<LI>The proportion of participants with clinical cure only</LI>
<LI>Measurement of recurrence of the condition after the end of the intervention period</LI>
</UL>
<P>One of the primary outcomes of interest in this review (complete cure rate) was not reported in this study.</P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 14:35:14 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: not mentioned</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Solomon-1997">
<CHAR_METHODS MODIFIED="2016-04-28 14:36:09 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, parallel group RCT for 16 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:37:39 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>New York (USA)</LI>
<LI>N = 27</LI>
<LI>15 females and 13 males aged 2-15 years</LI>
<LI>Inclusion criteria: mycologic confirmation of infection before initiation of therapy; children from 2 to 15 years of age; normal complete blood cell count with differential, liver function test, and SMA-7; and parental consent</LI>
<LI>Exclusion criteria: participants who had received antimycotic therapy within 2 weeks of initial visit; a history of kidney or liver disease; participants with history of hypersensitivity reaction to any of the ingredients of fluconazole; participants receiving interactive medications within preceding 30 days; participants with coexisting immunosuppressive disease; and participants with inflammatory tinea capitis</LI>
<LI>Fungi isolated: <I>T. tonsurans</I> 100%</LI>
<LI>No mention of adherence assessment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:38:27 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: fluconazole tablets or suspension 1.5 mg/kg/d for 20 days, N = 8 completed the study</LI>
<LI>Group 2: fluconazole tablets or suspension 3 mg/kg/d for 20 days, N = 10 completed the study</LI>
<LI>Group 3: fluconazole tablets or suspension 6 mg/kg/d for 20 days, N = 9 completed the study</LI>
</UL>
<P>No co-treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:53 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Proportion of participants with complete cure at 6 to 16 weeks</LI>
<LI>Proportion of participants with clinical cure only</LI>
<LI>Measurement of recurrence of the condition after the end of the intervention period</LI>
</UL>
<P>One of the primary outcomes of interest in this review (adverse events) was not reported in this study</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 14:39:01 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: not mentioned</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-03 16:21:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Talarico-Filho-1998">
<CHAR_METHODS MODIFIED="2016-04-28 14:39:56 +0100" MODIFIED_BY="[Empty name]">
<P>Single-blind, parallel group RCT for 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-03 16:21:08 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Brazil</LI>
<LI>N = 132 (63 females and 69 males)</LI>
<LI>Aged 1-14 years</LI>
<LI>Inclusion criteria: children of both sexes with tinea capitis, aged 1-14 years, weighing &#8805; 20 kg</LI>
<LI>Exclusion criteria: use of any systemic antifungal therapy within 1 month or topical antifungal therapy within 2 weeks prior to the start of the study or both; conditions that could interfere with gastrointestinal absorption of terbinafine; confirmed liver/renal impairment, haematological disorders; radiotherapy, systemic therapy with cytostatic or immunosuppressive drugs, or therapy with antibacterial, antiviral or antihelmintic drugs, either currently or during the 2 weeks preceding the beginning of the study</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>
<I>T. tonsurans</I>: terbinafine for 1 week: 88.6% (3/35); terbinafine for 2 weeks: 18.5% (7/38); terbinafine for 4 weeks: 26.5% (9/34)</LI>
<LI>
<I>T. mentagrophytes</I>: terbinafine for 1 week: 2.8% (1/35); terbinafine for 4 weeks: 5.9% (2/34)</LI>
<LI>
<I>M. canis</I>: terbinafine for 1 week: 77.1% (27/35); terbinafine for 2 weeks: 73.3% (28/38); terbinafine for 4 weeks: 55.9% (19/34)</LI>
<LI>
<I>T. rubrum</I>: terbinafine for 1 week: 8.6% (3/35); terbinafine for 2 weeks: 7.9% (3/38); terbinafine for 4 weeks: 5.9% (2/34)</LI>
<LI>
<I>T. schoenleini</I>: terbinafine for 1 week: 2.8% (1/35); terbinafine for 4 weeks: 2.9% (1/34)</LI>
<LI>
<I>M. gypseum</I>: terbinafine for 4 weeks: 2.9% (1/34)</LI>
</UL>
<LI>No mention of adherence assessment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:43:38 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: terbinafine 10 to 20 kg: 62.5 mg/d; 20 to 40 kg: 125 mg/d; &gt; 40 kg: 250 mg/d once daily for 1 week plus 3 weeks of placebo (N = 42)</LI>
<LI>Group 2: terbinafine same dose for 2 weeks plus 2 weeks of placebo (N = 44)</LI>
<LI>Group 3: terbinafine same dose for 4 weeks same dose (N = 46)</LI>
</UL>
<P>No co-treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:54 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The proportion of participants with complete cure at 12 weeks</LI>
<LI>The frequency and type of adverse events</LI>
<LI>The proportion of participants with clinical cure only at 12 weeks</LI>
<LI>Percentage of drop-outs as a surrogate for participant adherence</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 14:44:29 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: Sandoz (terbinafine)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tanz-1985">
<CHAR_METHODS MODIFIED="2016-04-28 14:46:11 +0100" MODIFIED_BY="[Empty name]">
<P>Triple-blind, parallel group RCT for 6 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:47:05 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Chicago (USA)</LI>
<LI>N = 22</LI>
<LI>Inclusion criteria: children 2-16 years old were eligible if they had clinically diagnosed or mycologically proven tinea capitis</LI>
<LI>Exclusion criteria: those that had received systemic antimycotic therapy within 1 month of enrolment, if griseofulvin therapy was contraindicated; if they had a serious concurrent disease or a history of hepatitis; if they were taking warfarin-like anticoagulants or barbiturates, or if they were pregnant</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>
<I>T. tonsurans</I>: 50% (11/22)</LI>
<LI>
<I>Scopulariopsis </I>spp. : 4.5% (1/22)</LI>
<LI>
<I>Penicillium </I>spp. :4.5% (1/22)</LI>
<LI>Unidentified fungus: 4.5% (1/22)</LI>
</UL>
<LI>Adherence assessed</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:48:13 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: griseofulvin tablet, 500 mg/d, plus 'ketoconazole' placebo tablet (participants &lt; 40 kg: half tablet) for 6 weeks (N = 12)</LI>
<LI>Group 2: ketoconazole tablet, 200 mg/d, plus 'griseofulvin' placebo tablet (participants weighing &lt; 40 kg: half tablet) for 6 weeks (N = 10)</LI>
</UL>
<P>Co-treatment: antiseborrhoeic shampoo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:55 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The frequency and type of adverse events</LI>
<LI>Percentage of drop-outs as a surrogate for participant adherence</LI>
<LI>Mycological cure at 12 weeks</LI>
</UL>
<P>One of the primary outcomes of interest in this review (complete cure rate) was not reported in this study</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-25 01:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: Janssen (ketoconazole)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tanz-1988">
<CHAR_METHODS MODIFIED="2016-04-28 14:50:26 +0100" MODIFIED_BY="[Empty name]">
<P>Triple-blind, parallel group RCT for 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:51:05 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Chicago (USA)</LI>
<LI>N = 79 (65% female)</LI>
<LI>92% black</LI>
<LI>Inclusion criteria: children aged 2-16 years old, with tinea capitis or mycologic evidence of dermatophyte infection of the scalp</LI>
<LI>Exclusion criteria: participants receiving systemic antimycotic therapy within 30 days of the initial visit; if they had a history of porphyria, liver disease, or immunodeficiency; if they were pregnant or if they were receiving warfarin-like anticoagulants or barbiturates</LI>
<LI>Fungi isolated</LI>
<UL>
<LI>
<I>T. tonsurans</I>: 64% of the enrolled participants and 74% of the evaluable participants</LI>
<LI>
<I>M. canis</I>: 12% of the enrolled participants and 13% of evaluable participants</LI>
</UL>
<LI>Adherence not assessed</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:52:01 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: griseofulvin (microsize) 250 mg tablet ( 10 to 20 mg/kg/d) plus 'ketoconazole' placebo tablet, single daily dose, for 12 weeks (N = 46)</LI>
<LI>Group 2: ketoconazole 200 mg tablet (3.3 to 6.6 mg/kg/d) plus 'griseofulvin' placebo tablet in a single daily dose for 12 weeks (N = 33)</LI>
</UL>
<P>Co-treatment: antiseborrhoeic shampoos</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:56 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The proportion of participants with complete cure at 12 weeks</LI>
<LI>The frequency and type of adverse events</LI>
<LI>The proportion of participants with clinical cure at 12 weeks</LI>
<LI>Percentage of drop-outs as a surrogate for participant adherence</LI>
<LI>Mycological cure at 12 weeks</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 14:52:31 +0100" MODIFIED_BY="[Empty name]">
<P>Not much information given apart from the total cured results<BR/>The enrolled : 79 were randomised, 46 were evaluable</P>
<P>Funding: Janssen (ketoconazole)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 10:17:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ungpakorn-2004">
<CHAR_METHODS MODIFIED="2016-04-28 14:53:20 +0100" MODIFIED_BY="[Empty name]">
<P>Triple-blind, parallel group RCT for 20 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 14:53:45 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Thailand</LI>
<LI>N = 42</LI>
<LI>Inclusion criteria: not to have received any topical or systemic antifungal therapy in the preceding 2 or 4 weeks, respectively</LI>
<LI>Fungi isolated: <I>Microsporum</I> spp.:</LI>
<UL>
<LI>
<I>M. ferrugineum</I> 50% (21/42)</LI>
<LI>
<I>M. canis</I> 47.6% (20/42)</LI>
<LI>
<I>M. gypseum</I> 2.3% (81/42)</LI>
</UL>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 14:54:07 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Group 1: oral terbinafine 10 to 20 kg: 62.5 mg/d; 20 to 40 kg: 125 mg/d; over 40 kg: 250 mg/d, in a pulsed regimen (N = 23)</LI>
<LI>Group 2: oral terbinafine at double dose, in a similar pulsed regimen (N = 19)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:57 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Proportion of participants with complete cure at 20 weeks</LI>
<LI>Mycological cure at 20 weeks.</LI>
</UL>
<P>One of the primary outcomes of interest in this review (adverse events) was not reported in this study</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 14:54:28 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: Institute of Dermatology Research Funds and Novartis (Thailand)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>ITT</B>: intention-to-treat; <B>KOH</B>: potassium hydroxide; <B>RCT</B>: randomised controlled trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-04-28 15:00:26 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-11-04 14:56:25 +0000" MODIFIED_BY="Finola  M Delamere" STUDY_ID="STD-Ginsburg-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-04 14:56:25 +0000" MODIFIED_BY="Finola  M Delamere">
<P>Excluded because this study evaluated the therapy for inflammatory lesions caused by tinea capitis.The main aim of this study was to analyse the treatment of kerions in tinea capitis, combining the tinea capitis treatment of griseofulvin plus intralesional corticosteroid to try to reduce the inflammation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-28 14:58:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Honig-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-28 14:58:02 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded because this study evaluated the therapy for inflammatory lesions caused by tinea capitis. It combined griseofulvin for the tinea capitis with steroids to modulate the immune-mediated inflammation, hasten resolution of kerions and minimise scar formation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-11-04 14:56:52 +0000" MODIFIED_BY="Finola  M Delamere" STUDY_ID="STD-Hussain-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-04 14:56:52 +0000" MODIFIED_BY="Finola  M Delamere">
<P>Excluded because this study evaluated the therapy for inflammatory lesions caused by tinea capitis. It combined griseofulvin treatment and griseofulvin treatment plus prednisolone, a glucocorticoid.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-28 15:00:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koumantaki_x002d_Mathioudaki-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-28 15:00:14 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded because this study was not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-28 15:00:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shemer-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-28 15:00:14 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded because this study was not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>RCT</B>: randomised controlled trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2016-04-29 10:17:58 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2016-04-29 10:17:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pather-2006">
<CHAR_METHODS MODIFIED="2016-04-28 15:00:36 +0100" MODIFIED_BY="[Empty name]">
<P>Single-blinded, randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-28 15:00:58 +0100" MODIFIED_BY="[Empty name]">
<P>64 children with tinea capitis aged 4-12 years randomised to 3 treatment groups. 5 participants lost to follow-up.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-28 15:01:28 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Group 1: griseofulvin (10 mg/kg; daily dose for 6 weeks)</LI>
<LI>Group 2: griseofulvin (50 mg/kg; 2 doses 1 month apart)</LI>
<LI>Group 3: griseofulvin (50 mg/kg; weekly dose for 6 weeks)</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 10:17:58 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: mycological cure rate at week 6</P>
<P>Secondary outcomes: clinical improvement according to clinical symptom score; mycological cure rate at month 6; the type and frequency of adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-28 15:02:08 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-05-03 16:20:51 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-04-28 14:29:04 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dastghaib-2005">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Deng-2011">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 12:49:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elewski-2008">
<DESCRIPTION>
<P>Quote (page 43): "Eligible patients were randomized in a 2:1 ratio to terbinafine and griseofulvin treatment arms, respectively (Fig 1). Patients were randomized to the lowest available randomization number at each site based on treatment allocation cards received by a pharmacist or designee at the site after they had fulfilled the inclusion/exclusion criteria".</P>
<P>Comment: Standared randomisation method was applied</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Foster-2005">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Friedlander-2002">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 13:04:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fuller-2001">
<DESCRIPTION>
<P>Quote (page 323): "Computer generated", "participants randomised in blocks of four"</P>
<P>Comment: standard methods of randomisation performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-19 03:04:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gan-1987">
<DESCRIPTION>
<P>Quote (page 47): "Table of random numbers" was used.</P>
<P>Comment: A standard method of randomisation was performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gupta-2001">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hamm-1999">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haroon-1995">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haroon-1996">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jahangir-1998">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khan-2011">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kullavanijaya-1997">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:51:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lipozencic-2002">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:51:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:29:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mart_x00ed_nez_x002d_Roig-1988">
<DESCRIPTION>
<P>Quote (page 38): "Computer generated random number table"</P>
<P>Comment: A standard method of randomisation was done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:51:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Memisoglu-1999">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:51:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rademaker-1998">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:51:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Solomon-1997">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:51:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Talarico-Filho-1998">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:51:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tanz-1985">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:51:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tanz-1988">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:49:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ungpakorn-2004">
<DESCRIPTION>
<P>Comment: There was no information on the method of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-04-28 12:49:15 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dastghaib-2005">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Deng-2011">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 12:49:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elewski-2008">
<DESCRIPTION>
<P>Quote (page 43): "Randomization data were accessible only to the dispenser of medication and were kept confidential until database lock."</P>
<P>Comment: The method for allocation concealment seemed to be adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-19 03:01:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Foster-2005">
<DESCRIPTION>
<P>Quote (page 799): "Sealed envelopes containing randomly assigned treatments" were applied.</P>
<P>Comment: A standard method of location concealment was done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Friedlander-2002">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fuller-2001">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gan-1987">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gupta-2001">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hamm-1999">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haroon-1995">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haroon-1996">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jahangir-1998">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:50:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khan-2011">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:51:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kullavanijaya-1997">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:51:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lipozencic-2002">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:51:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:51:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mart_x00ed_nez_x002d_Roig-1988">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:51:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Memisoglu-1999">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:51:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rademaker-1998">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:51:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Solomon-1997">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:51:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Talarico-Filho-1998">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:51:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tanz-1985">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:51:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tanz-1988">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-01 16:49:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ungpakorn-2004">
<DESCRIPTION>
<P>Comment: There was no information on the method of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-02-18 15:37:14 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-04-28 14:54:37 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-01 16:17:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000">
<DESCRIPTION>
<P>Comment: Participants and clinicians were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-01 16:23:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dastghaib-2005">
<DESCRIPTION>
<P>Comment: Participants were not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-01 16:24:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Deng-2011">
<DESCRIPTION>
<P>Comment: Whether the participants and personnel were blinded was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-28 12:49:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Elewski-2008">
<DESCRIPTION>
<P>Quote (page 45): "Investigators and others performing assessments, recording data, or analysing data were blinded to treatment identity from the time of randomisation until database lock."</P>
<P>Comment: The method of blinding was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-18 17:37:49 +0100" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Foster-2005">
<DESCRIPTION>
<P>Comment: Whether the participants and personnel were blinded was not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-01 16:40:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Friedlander-2002">
<DESCRIPTION>
<P>Comment: Participants and clinicians were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-28 13:04:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fuller-2001">
<DESCRIPTION>
<P>Comment: no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-28 13:09:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gan-1987">
<DESCRIPTION>
<P>Comment: no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-01 16:44:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gupta-2001">
<DESCRIPTION>
<P>Comment: Clinicians were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-01 16:45:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hamm-1999">
<DESCRIPTION>
<P>Comment: Participants and clinicians were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-28 13:54:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haroon-1995">
<DESCRIPTION>
<P>Comment: insufficient information although stated to be a "double-blind comparative study of terbinafine and griseofulvin in tinea capitis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-01 16:45:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haroon-1996">
<DESCRIPTION>
<P>Comment: Participants and clinicians were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-01 16:45:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jahangir-1998">
<DESCRIPTION>
<P>Comment: Participants and clinicians were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-28 14:12:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khan-2011">
<DESCRIPTION>
<P>Comment: unclear, although the author stated this was a "third party blind" study in the abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-28 14:17:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kullavanijaya-1997">
<DESCRIPTION>
<P>Comment: study was described as "single blind and open trial study" but no mention of which one (participant or observers), and the method of blinding was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-28 14:21:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lipozencic-2002">
<DESCRIPTION>
<P>Quote: "Participants, clinicians and outcome assessors blinded, except for the arm taking griseofulvin, where both participants and investigators were informed from day 1"</P>
<P>Comment: The method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-01 16:46:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994">
<DESCRIPTION>
<P>Comment: Participants and clinicians were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-01 16:47:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mart_x00ed_nez_x002d_Roig-1988">
<DESCRIPTION>
<P>Comment: Participants and clinicians were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-01 16:47:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Memisoglu-1999">
<DESCRIPTION>
<P>Comment: Participants and clinicians were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-28 14:35:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rademaker-1998">
<DESCRIPTION>
<P>Comment: no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-01 16:48:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Solomon-1997">
<DESCRIPTION>
<P>Comment: Participants were not blinded, but the outcomes were unlikely to be influenced; clinicians were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-28 14:44:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Talarico-Filho-1998">
<DESCRIPTION>
<P>Comment: Only participants blinded, but the method of blinding was not stated. The outcomes were likely to be influenced if the clinicians were not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-01 16:48:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tanz-1985">
<DESCRIPTION>
<P>Comment: Participants and clinicians were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-01 16:48:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tanz-1988">
<DESCRIPTION>
<P>Comment: Participants and clinicians were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-28 14:54:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ungpakorn-2004">
<DESCRIPTION>
<P>Comment: Participants and clinicians were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-04-28 14:35:29 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-01 16:17:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000">
<DESCRIPTION>
<P>Comment: Outcome assessors were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-01 16:23:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dastghaib-2005">
<DESCRIPTION>
<P>Comment: Investigators were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-01 16:24:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Deng-2011">
<DESCRIPTION>
<P>Comment: Investigators were not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-28 12:49:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Elewski-2008">
<DESCRIPTION>
<P>Quote (page 45): "Investigators and others performing assessments, recording data, or analysing data were blinded to treatment identity from the time of randomisation until database lock."</P>
<P>Comment: The method of blinding was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-01 16:40:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Foster-2005">
<DESCRIPTION>
<P>Comment: Investigators were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-01 16:40:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Friedlander-2002">
<DESCRIPTION>
<P>Comment: Outcome assessors were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-28 13:04:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fuller-2001">
<DESCRIPTION>
<P>Comment: no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-28 13:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gan-1987">
<DESCRIPTION>
<P>Comment: no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-01 16:44:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gupta-2001">
<DESCRIPTION>
<P>Comment: Outcome assessors were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-01 16:45:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hamm-1999">
<DESCRIPTION>
<P>Comment: Outcome assessors were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-28 13:54:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haroon-1995">
<DESCRIPTION>
<P>Comment: insufficient information although stated to be a "double-blind comparative study of terbinafine and griseofulvin in tinea capitis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-01 16:45:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haroon-1996">
<DESCRIPTION>
<P>Comment: Outcome assessors were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-01 16:45:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jahangir-1998">
<DESCRIPTION>
<P>Comment: Outcome assessors were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-28 14:12:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khan-2011">
<DESCRIPTION>
<P>Comment: unclear, although the author stated this was a "third party blind" study in the abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-28 14:17:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kullavanijaya-1997">
<DESCRIPTION>
<P>Comment: study was described as "single blind and open trial study" but no mention of which one (participant or observers), and the method of blinding was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-28 14:21:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lipozencic-2002">
<DESCRIPTION>
<P>Quote: "Participants, clinicians and outcome assessors blinded, except for the arm taking griseofulvin, where both participants and investigators were informed from day 1"</P>
<P>Comment: The method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-01 16:46:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994">
<DESCRIPTION>
<P>Comment: Outcome assessors were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-01 16:47:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mart_x00ed_nez_x002d_Roig-1988">
<DESCRIPTION>
<P>Comment: Outcome assessors were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-01 16:47:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Memisoglu-1999">
<DESCRIPTION>
<P>Comment: Outcome assessors were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-28 14:35:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rademaker-1998">
<DESCRIPTION>
<P>Comment: no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-01 16:48:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Solomon-1997">
<DESCRIPTION>
<P>Comment: Outcome assessors were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-01 16:48:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Talarico-Filho-1998">
<DESCRIPTION>
<P>Comment: Outcome assessors were not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-01 16:48:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tanz-1985">
<DESCRIPTION>
<P>Comment: Outcome assessors were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-01 16:48:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tanz-1988">
<DESCRIPTION>
<P>Comment: Outcome assessors were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-01 16:49:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ungpakorn-2004">
<DESCRIPTION>
<P>Comment: Outcome assessors were blinded, but the method of blinding was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-04-28 14:54:46 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-03 03:04:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000">
<DESCRIPTION>
<P>Comment: There was only one drop-out (2%, 1/50). Although which group this drop-out belonged to was unclear and ITT analysis was not performed, the proportion of missing outcomes compared with the observed event risk seemed to be not enough to have a clinically relevant impact on the intervention effect estimate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 12:37:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dastghaib-2005">
<DESCRIPTION>
<P>Comment: 5 participants (12.5%, 5/40) were lost to follow-up. It was unclear which group these drop-outs belonged to. ITT analysis was not performed. The reason for drop-outs was not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 13:11:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Deng-2011">
<DESCRIPTION>
<P>Comment: 12.5% (11/88) participants lost to follow-up. It was unclear which group these drop-outs belonged to. ITT analysis was not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 13:11:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elewski-2008">
<DESCRIPTION>
<P>Comment: 3.6% (56/1549) participants lost to follow-up. Among them, 40 participants were in the terbinafine group and 16 participants in the griseofulvin group. ITT analyses were performed. The proportion of missing outcomes compared with the observed event risk didn't seem to be enough to have a clinically relevant impact on the intervention effect estimate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 13:12:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Foster-2005">
<DESCRIPTION>
<P>Comment: 9.3% (82/880) participants lost to follow-up. Among them, 37 participants were in the fluconazole 3 weeks group; 24 participants were in the fluconazole 6 weeks group; and 21 participants were in the griseofulvin group. ITT analyses were performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 13:12:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Friedlander-2002">
<DESCRIPTION>
<P>Comment: 23.2% (41/177) participants lost to follow-up. Among them, 14 patents were in the terbinafine for 1 week group; 15 participants were in the terbinafine for 2 weeks group; 12 participants were in the terbinafine for 4 weeks group. ITT analyses were performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 13:12:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fuller-2001">
<DESCRIPTION>
<P>Comment: 54.8% (115/210) participants lost to follow-up. Among them, 62 participants were in the terbinafine group; 53 participants were in the griseofulvin group. ITT analyses were performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 13:09:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gan-1987">
<DESCRIPTION>
<P>Comment: 21.3% (17/80) participants lost to follow-up. Among them, 11 participants were in the griseofulvin group, whereas 6 were in the ketoconazole group. ITT analysis was not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 13:10:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gupta-2001">
<DESCRIPTION>
<P>Comment: 7% (14/200) participants lost to follow-up. Among them, 4 were in the griseofulvin group, 2 were in the terbinafine group, 4 were in the itraconazole group, 4 were in the fluconazole group. ITT analysis was not performed. The proportion of missing outcomes compared with the observed event risk seemed to be not enough to have a clinically relevant impact on the intervention effect estimate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 13:51:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hamm-1999">
<DESCRIPTION>
<P>Comment: no drop-outs reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 13:54:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haroon-1995">
<DESCRIPTION>
<P>Comment: no drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 13:58:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haroon-1996">
<DESCRIPTION>
<P>Comment: no drop-outs reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 14:07:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jahangir-1998">
<DESCRIPTION>
<P>Comment: no drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 14:12:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khan-2011">
<DESCRIPTION>
<P>Comment: no drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 14:17:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kullavanijaya-1997">
<DESCRIPTION>
<P>Comment: 8.5% (7/82) participants lost to follow-up. It was unclear which group these lost participants belonged to. ITT analysis was not performed. The proportion of missing outcomes compared with the observed event risk seemed insufficient to have a clinically relevant impact on the intervention effect estimate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 14:22:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lipozencic-2002">
<DESCRIPTION>
<P>Comment: 21.8% (36/165) participants lost to follow-up. Among them, 7 were in the terbinafine for 6 weeks group, 4 were in the terbinafine for 8 weeks group, 6 were in the terbinafine for 10 weeks group, 12 were in the terbinafine for 12 weeks group, 7 were in the griseofulvin group. ITT analyses were performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 13:11:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994">
<DESCRIPTION>
<P>Comment: 8.6% (3/35) participants lost to follow-up. Among them, 1 was in the itraconazole group, 2 were in the griseofulvin group. ITT analysis was not performed. The proportion of missing outcomes compared with the observed event risk seemed to be not enough to have a clinically relevant impact on the intervention effect estimate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 14:29:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mart_x00ed_nez_x002d_Roig-1988">
<DESCRIPTION>
<P>Comment: no drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 13:11:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Memisoglu-1999">
<DESCRIPTION>
<P>Comment: 14.1% (11/78) participants lost to follow-up. Among them, 7 were in the griseofulvin group, whereas 4 were in the terbinafine group. ITT analysis was not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 14:35:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rademaker-1998">
<DESCRIPTION>
<P>Comment: not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 13:11:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Solomon-1997">
<DESCRIPTION>
<P>Comment: 51.8% (14/27) participants lost to follow-up. It was unclear which group these lost participants belonged to. ITT analysis was not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 14:45:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Talarico-Filho-1998">
<DESCRIPTION>
<P>Comment: 18.2% (24/132) participants lost to follow-up. Among them, 6 were in the terbinafine for 1 week group, 6 were in the terbinafine for 2 weeks group, and 12 were in the terbinafine for 4 weeks group. ITT analyses were performed. The reasons for drop-outs were not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 13:11:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tanz-1985">
<DESCRIPTION>
<P>Comment: 36.4% (8/22) participants lost to follow-up. Among them, 3 were in the griseofulvin group, whereas 5 were in the ketoconazole group. ITT analysis was not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 13:11:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tanz-1988">
<DESCRIPTION>
<P>Comment: 39.2% (31/79) participants lost to follow-up. Among them, 20 were in the griseofulvin group, whereas 11 were in the ketoconazole group. ITT analysis was not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-28 14:54:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ungpakorn-2004">
<DESCRIPTION>
<P>Comment: no drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-04-28 14:57:16 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:57:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:57:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dastghaib-2005">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:57:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Deng-2011">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:57:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elewski-2008">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:57:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Foster-2005">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 12:57:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Friedlander-2002">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 13:05:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fuller-2001">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 13:09:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gan-1987">
<DESCRIPTION>
<P>Comment: publication reported findings on all outcomes listed in the Methods section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:57:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gupta-2001">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:57:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hamm-1999">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 13:55:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haroon-1995">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 13:58:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haroon-1996">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:07:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jahangir-1998">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:12:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khan-2011">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:17:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kullavanijaya-1997">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:57:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lipozencic-2002">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:24:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:29:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mart_x00ed_nez_x002d_Roig-1988">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:57:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Memisoglu-1999">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:35:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rademaker-1998">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:57:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Solomon-1997">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:57:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Talarico-Filho-1998">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:57:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tanz-1985">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:52:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tanz-1988">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:54:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ungpakorn-2004">
<DESCRIPTION>
<P>Comment: The publication reported findings on all outcomes listed in the Methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-05-03 16:20:51 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 13:59:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: no</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability</LI>
<UL>
<LI>Severity of infection: griseofulvin group: black dot 32% (8/25); white-greyish hair 68% (17/25); terbinafine group: black dot 8% (2/25); white-greyish hair 92% (23/25)</LI>
<LI>Age: griseofulvin group: 6.72; terbinafine group: 6.84</LI>
<LI>Sex: griseofulvin group: males: 10; females: 15; terbinafine group: males: 13; females: 12</LI>
<LI>Duration of complaint: from 1 week to 4 years</LI>
</UL>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 12:41:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dastghaib-2005">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: not mentioned</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability:</LI>
<UL>
<LI>Mean age: griseofulvin (8.66); fluconazole (7.71)</LI>
<LI>Sex: griseofulvin (males: 17; females: 4), fluconazole (males: 15; females: 4)</LI>
<LI>Mean weight (kg): griseofulvin (23.61); fluconazole (21.60)</LI>
<LI>Severity of disease: similar in both groups at first examination</LI>
</UL>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 12:46:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Deng-2011">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: no</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability: yes, there were no significant differences regarding to gender, weight, age, and severity of signs and symptoms</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 12:50:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Elewski-2008">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: yes</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability: yes, there were no significant differences with regard to baseline demographic and disease characteristics, including infection severity</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 12:55:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Foster-2005">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: yes</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability: yes. There was no significant difference between groups regarding age, gender, weight or height. However, baseline information about severity of infection was not stated.</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:03:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Friedlander-2002">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: no</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type fungi involved: yes</LI>
<LI>Baseline comparability</LI>
<UL>
<LI>Severity of infection: not stated</LI>
<LI>Age: terbinafine for 1 week: 7.1 years; terbinafine for 2 weeks: 8.5 years; terbinafine for 4 weeks: 6.6 years</LI>
<LI>Sex: terbinafine for 1 week (males 28, females 28); terbinafine for 2 weeks: (males 32, females 27); terbinafine for 4 weeks: (males 31, females 31)</LI>
</UL>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 13:05:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fuller-2001">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: yes</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability</LI>
<UL>
<LI>Severity of infection: not reported</LI>
<LI>Age: group terbinafine: 5.6; group griseofulvin: 6</LI>
<LI>Sex: group terbinafine: males:69%, females: 31%; group griseofulvin: males:64%, females: 36%</LI>
<LI>Duration of complaint: unknown</LI>
</UL>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 13:10:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gan-1987">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: no</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria : yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability</LI>
<UL>
<LI>Severity of infection: not reported</LI>
<LI>Age (in months): griseofulvin group (63); ketoconazole group (62)</LI>
<LI>Sex: griseofulvin group (males: 13, females: 15); ketoconazole group (males: 16, females: 20)</LI>
<LI>Duration of complaint (in weeks): griseofulvin group (5.6); ketoconazole group (5.8)</LI>
</UL>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:05:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gupta-2001">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: no</LI>
<LI>Inclusion criteria: yes (only culture positive)</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability</LI>
<UL>
<LI>Severity of infection</LI>
<UL>
<LI>Mild: griseofulvin group: 18; terbinafine group: 20; itraconazole group: 9; fluconazole group: 9</LI>
<LI>Moderate: griseofulvin group: 28; terbinafine group: 27; itraconazole group: 36; fluconazole group: 28</LI>
<LI>Severe: griseofulvin group: 4; terbinafine group: 2; itraconazole group: 4; fluconazole group: 11</LI>
<LI>Kerion: griseofulvin group: 0; terbinafine group: 1: itraconazole group: 1; fluconazole group: 2</LI>
</UL>
<LI>Age: griseofulvin group: 5.9; terbinafine group: 5.6; itraconazole group: 5.2; fluconazole group: 5.9</LI>
<LI>Sex: griseofulvin group: males: 38, females: 12; terbinafine group: males: 37, females: 13; itraconazole group: males: 27, females: 23; fluconazole group: males: 32, females: 18</LI>
<LI>Duration of complaint: not mentioned</LI>
</UL>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 13:52:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hamm-1999">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: no</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: no</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability</LI>
<UL>
<LI>Severity of infection: not stated</LI>
<LI>Age: we are unaware of the mean age for each group</LI>
<LI>Sex: we are unaware of the number of females and males in each group</LI>
<LI>Duration of complaint: not stated</LI>
</UL>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 13:55:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haroon-1995">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: no</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability</LI>
<UL>
<LI>Severity of infection: not known</LI>
<LI>Age: terbinafine: 8.6; griseofulvin: 9.1</LI>
<LI>Sex: terbinafine: male: 24, female: 32; griseofulvin: male: 25, female: 24</LI>
<LI>Duration of complaint: not known</LI>
</UL>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 13:58:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haroon-1996">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: no</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability</LI>
<UL>
<LI>Severity of infection: not mentioned</LI>
<LI>Age: we are unaware of the mean age in each group</LI>
<LI>Sex: we are unaware of the number of females and males in each group, only the total stated</LI>
<LI>Duration of complaint: not stated</LI>
</UL>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-03 16:20:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jahangir-1998">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: no</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability</LI>
<UL>
<LI>Severity of infection: not declared</LI>
<LI>Age: itraconazole group: 7.9 ± 4.58; terbinafine group: 7.8 ± 4.58.</LI>
<LI>Sex: male to female ratio itraconazole group: 1:1; terbinafine group: 1:1.3</LI>
<LI>Duration of complaint: not stated</LI>
</UL>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:12:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khan-2011">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: yes</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability: not mentioned</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:17:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kullavanijaya-1997">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: no</LI>
<LI>Inclusion criteria: very poor</LI>
<LI>Exclusion criteria: not mentioned</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability: yes, though no statistical differences were noted either reported, among the 3 groups with regard to age, weight and sex ratio</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:22:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lipozencic-2002">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: yes</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability</LI>
<UL>
<LI>Severity of infection: not reported</LI>
<LI>Age: terbinafine for 6 weeks: 9.5; terbinafine for 8 weeks: 7; terbinafine for 10 weeks: 6.8; terbinafine for 12 weeks: 8.8; griseofulvin group: 6.3</LI>
<LI>Sex: % of males: terbinafine for 6 weeks: 66%; terbinafine for 8 weeks: 73%; terbinafine for 10 weeks: 70%; terbinafine for 12 weeks: 53%; griseofulvin group: 50%</LI>
</UL>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:25:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: no</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: not mentioned</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability</LI>
<UL>
<LI>Severity of infection: not reported</LI>
<LI>Age: itraconazole group: 2 to 11; griseofulvin group: 2 to 10</LI>
<LI>Sex: itraconazole group: males: 12, females: 6; griseofulvin group: males: 11, females: 6</LI>
<LI>Duration of complaint: not reported</LI>
</UL>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:29:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mart_x00ed_nez_x002d_Roig-1988">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: no</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability: not reported</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:33:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Memisoglu-1999">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: no</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability</LI>
<UL>
<LI>Severity of infection: not stated</LI>
<LI>Age: griseofulvin group: 6.6; terbinafine group: 7</LI>
<LI>Sex: griseofulvin group: males 26, females 9 ; terbinafine group: males 21, females 11</LI>
<LI>Duration of complaint: not stated</LI>
</UL>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:36:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rademaker-1998">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: no</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: no</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability</LI>
<UL>
<LI>Severity of infection: only total stated</LI>
<LI>Age: only total stated</LI>
<LI>Sex: only total stated</LI>
<LI>Duration of complaint: not stated</LI>
</UL>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:39:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Solomon-1997">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: no</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability</LI>
<UL>
<LI>Severity of infection: not reported</LI>
<LI>Age: not reported</LI>
<LI>Sex: not reported</LI>
<LI>Duration of complaint: not reported</LI>
</UL>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:46:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Talarico-Filho-1998">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: no</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability</LI>
<UL>
<LI>Severity of infection: studied but not shown</LI>
<LI>Age: terbinafine for 1 week: 6.5 years; terbinafine for 2 weeks: 6.5 years; terbinafine for 4 weeks: 6.1 years</LI>
<LI>Sex: terbinafine for 1 week: males 26, females 16; terbinafine for 2 weeks: males 17, females 27; terbinafine for 4 weeks: males 26, females 20</LI>
<LI>Duration of complaint: studied but not shown</LI>
</UL>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:50:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tanz-1985">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: no</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability</LI>
<UL>
<LI>Severity of infection: (minimum score = 0, maximum score = 21): griseofulvin group: 9.3; ketoconazole group: 8.3</LI>
<LI>Age: griseofulvin group: 6.4; ketoconazole group: 5.7</LI>
<LI>Sex: (male: female): griseofulvin group: 0:7; ketoconazole group: 2:5</LI>
<LI>Duration of complaint: (weeks): griseofulvin group: 16.5; ketoconazole group: 24</LI>
</UL>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:53:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tanz-1988">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: no</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability: taken into account but not reported</LI>
</UL>
<P>There were no statistically significant differences between the groups in terms of age, sex, weight or duration of infection</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-28 14:54:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ungpakorn-2004">
<DESCRIPTION>
<UL>
<LI>Sample size calculation declared: yes</LI>
<LI>Inclusion criteria: yes</LI>
<LI>Exclusion criteria: yes</LI>
<LI>Reporting of type of fungi involved: yes</LI>
<LI>Baseline comparability: not mentioned</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-05-04 15:36:23 +0100" MODIFIED_BY="Laura Prescott ">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-05-04 15:33:43 +0100" MODIFIED_BY="Laura Prescott " NO="1" READONLY="YES">
<TITLE MODIFIED="2016-04-29 10:18:11 +0100" MODIFIED_BY="[Empty name]">Complete cure and adverse events for terbinafine versus griseofulvin in children with tinea capitis</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>Terbinafine versus griseofulvin for children with tinea capitis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: children with tinea capitis<BR/>
<B>Intervention</B>: terbinafine<BR/>
<B>Comparison</B>: griseofulvin</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Griseofulvin</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Terbinafine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Proportion of participants with complete cure</B>
<BR/>Follow-up: 6-24 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>790 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>837 per 1000</B>
<BR/>(774 to 908)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.06 </B>
<BR/>(0.98 to 1.15)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>328<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>Low<SUP>a,b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>This outcome was for children infected with Trichophyton, terbinafine (2-4 weeks) versus griseofulvin (6-8 weeks); short treatment duration</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Proportion of participants with complete cure</B>
<BR/>Follow-up: 10 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>378 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>446 per 1000</B>
<BR/>(279 to 710)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.18 </B>
<BR/>(0.74 to 1.88)</P>
</TD>
<TD VALIGN="TOP">
<P>1006<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>Low<SUP>c,d</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>This outcome was for children infected with <I>Trichophyton</I> (<I>T. tonsurans and T. violaceum</I>)</P>
<P>Terbinafine (6 weeks) versus griseofulvin (6 weeks) in <I>Trichophyton</I> infections; medium treatment duration</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Proportion of participants with complete cure</B>
<BR/>Follow-up: 10 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>354 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>521 per 1000</B>
<BR/>(432 to 627)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.47</B>
<BR/>(1.22 to 1.77)</P>
</TD>
<TD VALIGN="TOP">
<P>764<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate<SUP>c</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>This outcome was for children infected with <I>T. tonsurans</I>
</P>
<P>Terbinafine (6 weeks) versus griseofulvin (6 weeks) in <I>Trichophyton</I> infections; medium treatment duration</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Proportion of participants with complete cure</B>
<BR/>Follow-up: 10 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>451 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>411 per 1000</B>
<BR/>(307 to 560)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.91</B>
<BR/>(0.68 to 1.24)</P>
</TD>
<TD VALIGN="TOP">
<P>242<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>Low<SUP>c,e</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>This outcome was for children infected with <I>T. violaceum</I>
</P>
<P>Terbinafine (6 weeks) versus griseofulvin (6 weeks) in <I>Trichophyton</I> infections; medium treatment duration</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Proportion of participants with complete cure</B>
<BR/>Follow-up: 10-16 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>509 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>346 per 1000</B>
<BR/>(270 to 438)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.68 </B>
<BR/>(0.53 to 0.86)</P>
</TD>
<TD VALIGN="TOP">
<P>334<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate<SUP>f</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>This outcome was for children infected with <I>Microsporum</I>. Terbinafine medium- (6 to 8 weeks) and long-term (10 to 12 weeks) treatment versus griseofulvin</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Proportion of participants with complete cure</B>
<BR/>Follow-up: 24 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>600 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>270 per 1000</B>
</P>
<P>(90 to 810)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.45</B> (0.15 to 1.35)</P>
</TD>
<TD VALIGN="TOP">
<P>21</P>
<P>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>Low<SUP>e,g</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>This outcome was for children infected with <I>Microsporum</I>. Terbinafine short-term (4 weeks) versus griseofulvin</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse events attributed to the study drugs</B>
<BR/>Follow-up: mean 10 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>83 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>92 per 1000</B>
<BR/>(65 to 130)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.11 </B>
<BR/>(0.79 to 1.57)</P>
</TD>
<TD VALIGN="TOP">
<P>1549<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate<SUP>c</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>This outcome was for children infected with <I>Trichophyton</I> and <I>Microsporum</I>
</P>
<P>Terbinafine (6 weeks) versus griseofulvin (6 weeks), medium treatment duration</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Severe adverse events</B>
<BR/>Follow-up: mean 10 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>6 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>6 per 1000</B>
<BR/>(1 to 23)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.97 </B>
<BR/>(0.24 to 3.88)</P>
</TD>
<TD VALIGN="TOP">
<P>1549<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate<SUP>c</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>This outcome was for children infected with <I>Trichophyton</I> and <I>Microsporum</I>
</P>
<P>Terbinafine (6 weeks) versus griseofulvin (6 weeks), medium treatment duration</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality</B>: Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality</B>: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality</B>: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality</B>: We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded one level because 1 of the 3 studies was at high risk of bias, the other two studies were at unclear risk of bias.<BR/>
<SUP>b</SUP>Downgraded one level for imprecision because the 95% confidence interval around the pooled effect includes both 'no effect' and 'appreciable benefit' (1.25).<BR/>
<SUP>c</SUP>Downgraded one level because the study was at unclear risk of bias.<BR/>
<SUP>d</SUP>Downgraded one level because I<SUP>2</SUP> = 86% which indicated substantial heterogeneity.<BR/>
<SUP>e</SUP>Downgraded one level for imprecision because total number of events was less than 300.<BR/>
<SUP>f</SUP>Downgraded one level because one of the two included studies was at high risk of bias.<BR/>
<SUP>g</SUP>Downgraded one level because the study was at high risk of bias.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2016-05-04 15:36:23 +0100" MODIFIED_BY="Laura Prescott " NO="2" READONLY="YES">
<TITLE MODIFIED="2016-04-29 08:47:11 +0100" MODIFIED_BY="[Empty name]">Complete cure for itraconazole versus griseofulvin in children infected with <I>Trichophyton</I> and <I>Microsporum</I>
</TITLE>
<TABLE COLS="6" ROWS="8">
<TR>
<TD COLSPAN="6">
<P>
<B>Itraconazole versus griseofulvin for children infected with <I>Trichophyton</I> and <I>Microsporum</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population</B>: children infected with <I>Trichophyton</I> and <I>Microsporum</I>
<BR/>
<B>Intervention</B>: itraconazole (2-6 weeks duration)<BR/>
<B>Comparison</B>: griseofulvin (6 weeks duration)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Griseofulvin</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Itraconazole</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Proportion of participants with complete cure</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>910 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>838 per 1000</B>
<BR/>(737 to 956)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.92 </B>
<BR/>(0.81 to 1.05)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>134<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>Very low<SUP>a,b,c</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality</B>: Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality</B>: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality</B>: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality</B>: We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded one level because both studies were at unclear risk of bias.<BR/>
<SUP>b</SUP>Downgraded one level because the treatment duration of itraconazole was significantly heterogenous between the two included studies.<BR/>
<SUP>c</SUP>Downgraded one level because total number of events was less than 300.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2016-04-29 09:09:47 +0100" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2016-04-29 08:47:21 +0100" MODIFIED_BY="[Empty name]">Complete cure for itraconazole versus terbinafine in children infected with <I>Trichophyton</I>
</TITLE>
<TABLE COLS="6" ROWS="8">
<TR>
<TD COLSPAN="6">
<P>
<B>Itraconazole versus terbinafine in children infected with <I>Trichophyton</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population</B>: children infected with <I>Trichophyton</I>
<BR/>
<B>Intervention</B>: itraconazole (2 weeks duration)<BR/>
<B>Comparison</B>: terbinafine (2 weeks duration)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Terbinafine</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Itraconazole</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Proportion of participants with complete cure</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>788 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>732 per 1000</B>
<BR/>(567 to 937)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.93 </B>
<BR/>(0.72 to 1.19)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>160<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>Low<SUP>a,b</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality</B>: Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality</B>: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality</B>: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality</B>: We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded one level because both studies were at unclear risk to bias.<BR/>
<SUP>b</SUP>Downgraded one level because total number of events was less than 300.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2016-04-29 09:09:53 +0100" MODIFIED_BY="[Empty name]" NO="4" READONLY="YES">
<TITLE MODIFIED="2016-04-29 08:50:39 +0100" MODIFIED_BY="[Empty name]">Complete cure for ketoconazole versus griseofulvin in children infected with <I>Trichophyton</I>
</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>Ketoconazole versus griseofulvin in children infected with <I>Trichophyton</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: children infected with <I>Trichophyton</I>
<BR/>
<B>Intervention</B>: ketoconazole (12-26 weeks duration)<BR/>
<B>Comparison</B>: griseofulvin (12-26 weeks duration)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Griseofulvin</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Ketoconazole</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Proportion of participants with complete cure</B>
</P>
<P>Follow-up: 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>964 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>733 per 1000</B>
</P>
<P>(598 to 906)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.76 </B>
</P>
<P>(0.62 to 0.94&#65289;</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>62</B>
<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>Low<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Ketoconazole (12 weeks) versus griseofulvin (12 weeks)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Proportion of participants with complete cure</B>
</P>
<P>Follow-up: 26 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>1000 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>920 per 1000</B>
</P>
<P>(810 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.92</B>
</P>
<P>(0.81 to 1.03)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>62</B>
</P>
<P>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>Low<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Ketoconazole (up to 26 weeks) versus griseofulvin (up to 26 weeks)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Proportion of participants with complete cure</B>
</P>
<P>Follow-up: 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>543 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>484 per 1000</B>
</P>
<P>(310 to 755)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.89</B>
</P>
<P>(0.57 to 1.39)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>79 </B>
</P>
<P>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>Low<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Ketoconazole (12 weeks) versus griseofulvin (12 weeks)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality</B>: Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality</B>: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality</B>: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality</B>: We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded one level because the study was at high risk of bias.<BR/>
<SUP>b</SUP>Downgraded one level because total number of events was less than 300.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2016-04-29 10:19:35 +0100" MODIFIED_BY="[Empty name]" NO="5" READONLY="YES">
<TITLE MODIFIED="2016-04-29 08:55:18 +0100" MODIFIED_BY="[Empty name]">Complete cure for fluconazole versus griseofulvin in children with tinea capitis</TITLE>
<TABLE COLS="6" ROWS="9">
<TR>
<TD COLSPAN="6">
<P>
<B>Fluconazole versus griseofulvin in children with tinea capitis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population</B>: children with tinea capitis<BR/>
<B>Intervention</B>: fluconazole (for the first outcome: 2-4 weeks duration; for the second outcome: 6 weeks duration)<BR/>
<B>Comparison</B>: griseofulvin (6 weeks duration)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Griseofulvin</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Fluconazole</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Proportion of participants with complete cure</B>
<BR/>Follow-up: 2-4 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>449 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>413 per 1000</B>
<BR/>(368 to 466)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.92 </B>
<BR/>(0.81 to 1.05)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>615<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate<SUP>a</SUP>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Proportion of participants with complete cure</B>
<BR/>Follow-up: 8-12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>322 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>341 per 1000</B>
<BR/>(248 to 470)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.06 </B>
<BR/>(0.77 to 1.46)</P>
</TD>
<TD VALIGN="TOP">
<P>361<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>Low<SUP>b,c</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality</B>: Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality</B>: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality</B>: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality</B>: We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded one level because one of the three studies was at high risk of bias, the other two were at unclear risk of bias.<BR/>
<SUP>b</SUP>Downgraded one level because the study was at unclear risk of bias.<BR/>
<SUP>c</SUP>Downgraded one level because total number of events was less than 300.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-06" MODIFIED="2016-04-29 09:02:53 +0100" MODIFIED_BY="[Empty name]" NO="6" READONLY="YES">
<TITLE MODIFIED="2016-04-29 09:00:07 +0100" MODIFIED_BY="[Empty name]">Complete cure for fluconazole versus terbinafine in children infected with <I>Trichophyton</I>
</TITLE>
<TABLE COLS="6" ROWS="8">
<TR>
<TD COLSPAN="6">
<P>
<B>Fluconazole versus terbinafine for children infected with <I>Trichophyton</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population</B>: children infected with <I>Trichophyton</I>
<BR/>
<B>Intervention</B>: fluconazole (2-3 weeks duration)<BR/>
<B>Comparison</B>: terbinafine (2-3 weeks duration)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Terbinafine</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Fluconazole</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>The proportion of participants with complete cure</B>
<BR/>Follow-up: 12 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>940 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>818 per 1000</B>
<BR/>(705 to 949)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.87 </B>
<BR/>(0.75 to 1.01)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>100<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>Low<SUP>a,b</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality</B>: Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality</B>: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality</B>: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality</B>: We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP> Downgraded one level because the study was at unclear risk of bias.<BR/>
<SUP>b</SUP>Downgraded one level because total number of events was less than 300.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-07" MODIFIED="2016-04-29 10:19:44 +0100" MODIFIED_BY="[Empty name]" NO="7" READONLY="YES">
<TITLE MODIFIED="2016-04-29 09:03:35 +0100" MODIFIED_BY="[Empty name]">Complete cure for fluconazole versus itraconazole in children infected with <I>Trichophyton</I>
</TITLE>
<TABLE COLS="6" ROWS="8">
<TR>
<TD COLSPAN="6">
<P>
<B>Fluconazole versus itraconazole in children infected with <I>Trichophyton</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population</B>: children infected with <I>Trichophyton</I>
<BR/>
<B>Intervention</B>: fluconazole (2-3 weeks duration)<BR/>
<B>Comparison</B>: itraconazole (2-3 weeks duration)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Itraconazole</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Fluconazole</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Proportion of participants with complete cure</B>
</P>
<P>Follow-up:12 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>820 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>820 per 1000</B>
<BR/>(681 to 984)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.00 </B>
<BR/>(0.83 to 1.20)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>100<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>Low<SUP>a,b</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality</B>: Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality</B>: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality</B>: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality</B>: We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a </SUP>Downgraded one level because the study was at unclear risk of bias.<BR/>
<SUP>b</SUP>Downgraded one level because total number of events was less than 300.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-08" MODIFIED="2016-04-29 10:19:48 +0100" MODIFIED_BY="[Empty name]" NO="8" READONLY="YES">
<TITLE MODIFIED="2016-04-29 09:05:57 +0100" MODIFIED_BY="[Empty name]">Complete cure for different durations of fluconazole in children infected with <I>T. tonsurans</I> and <I>M. canis</I>
</TITLE>
<TABLE COLS="6" ROWS="8">
<TR>
<TD COLSPAN="6">
<P>
<B>Different durations of fluconazole in children infected with <I>T. tonsurans</I> and <I>M. canis</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population</B>: children infected with <I>T. tonsurans</I> and <I>M. canis</I>
<BR/>
<B>Intervention</B>: fluconazole (3 weeks duration)</P>
<P>
<B>Comparison</B>: fluconazole (6 weeks duration)<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Fluconazole ( 6 weeks duration)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Fluconazole ( 3 weeks duration)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Proportion of participants with complete cure</B>
</P>
<P>Follow-up: 8-12 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>341 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
<BR/>(232 to 389)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.88 </B>
<BR/>(0.68 to 1.14)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>491<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>Low<SUP>a,b</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality</B>: Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality</B>: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality</B>: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality</B>: We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a </SUP>Downgraded one level because the study was at unclear risk of bias.<BR/>
<SUP>b</SUP>Downgraded one level because the total number of events was less than 300.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-02-04 10:27:05 +0000" MODIFIED_BY="Cathy Bennett"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-05-03 13:53:26 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-05-03 13:51:36 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Terbinafine (2-4 weeks) versus griseofulvin (6-8 weeks); short treatment duration; 6-24 weeks follow-up</NAME>
<DICH_OUTCOME CHI2="8.42826398012236" CI_END="1.2367114072399343" CI_START="0.9409793332206488" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0787584879717071" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="158" I2="40.675802136807164" I2_Q="21.335154844861762" ID="CMP-001.01" LOG_CI_END="0.09226836667377628" LOG_CI_START="-0.026419914900898865" LOG_EFFECT_SIZE="0.03292422588643874" METHOD="MH" MODIFIED="2016-04-29 09:47:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13415933513243583" P_Q="0.2804904829974022" P_Z="0.2768639717462751" Q="2.5424317508738703" RANDOM="YES" SCALE="19.402382459391458" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.009960158098786195" TOTALS="YES" TOTAL_1="246" TOTAL_2="231" WEIGHT="100.0" Z="1.0873912083002168">
<NAME>Primary outcome: complete cure, i.e. clinical and mycological cure</NAME>
<GROUP_LABEL_1>Terbinafine</GROUP_LABEL_1>
<GROUP_LABEL_2>Griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours griseofulvin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours terbinafine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9457944146701949" CI_END="1.1533849051345135" CI_START="0.9756416411779285" DF="2" EFFECT_SIZE="1.0607970313661734" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="124" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.06197426330542837" LOG_CI_START="-0.010709671921388685" LOG_EFFECT_SIZE="0.025632295692019875" MODIFIED="2016-04-29 09:47:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3779864321349964" P_Z="0.16685533066682834" STUDIES="3" TAU2="0.0" TOTAL_1="171" TOTAL_2="157" WEIGHT="86.08866785497312" Z="1.3823790976827681">
<NAME>
<I>Trichophyton</I> infections</NAME>
<DICH_DATA CI_END="1.3681468494724731" CI_START="0.99485746843325" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="39" LOG_CI_END="0.13613271470336813" LOG_CI_START="-0.0022391354421416806" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="1" O_E="0.0" SE="0.08128030972717744" STUDY_ID="STD-Haroon-1995" TOTAL_1="56" TOTAL_2="49" VAR="0.006606488749345895" WEIGHT="29.339740848014795"/>
<DICH_DATA CI_END="1.311397163780627" CI_START="0.8083340016297893" EFFECT_SIZE="1.029585798816568" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="39" LOG_CI_END="0.11773424006272533" LOG_CI_START="-0.09240915272487302" LOG_EFFECT_SIZE="0.01266254366892615" MODIFIED="2015-12-16 14:28:41 +0000" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.1234392691500061" STUDY_ID="STD-Fuller-2001" TOTAL_1="65" TOTAL_2="58" VAR="0.015237253168287647" WEIGHT="19.290121516567307"/>
<DICH_DATA CI_END="1.1378481124496944" CI_START="0.9174782110540963" EFFECT_SIZE="1.0217391304347827" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="46" LOG_CI_END="0.05608429340578011" LOG_CI_START="-0.03740424089749327" LOG_EFFECT_SIZE="0.009340026254143432" ORDER="3" O_E="0.0" SE="0.05491562782545112" STUDY_ID="STD-Gupta-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.0030157261794634613" WEIGHT="37.458805490391015"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.987807884848865E-32" CI_END="1.3514838497870887" CI_START="0.1528775725144501" DF="0" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="100.00000000000001" ID="CMP-001.01.02" LOG_CI_END="0.13081086025283" LOG_CI_START="-0.8156562218972425" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2016-04-29 09:47:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.15613465535419974" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="1.52345870373091" Z="1.4181922109252243">
<NAME>
<I>Microsporum</I> infections</NAME>
<DICH_DATA CI_END="1.3514838497870887" CI_START="0.1528775725144501" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.13081086025283" LOG_CI_START="-0.8156562218972425" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2015-12-16 14:49:01 +0000" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.5559594491425693" STUDY_ID="STD-Fuller-2001" TOTAL_1="11" TOTAL_2="10" VAR="0.3090909090909091" WEIGHT="1.52345870373091"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.3283298192068163" CI_END="2.41543029493063" CI_START="0.640908852435186" DF="1" EFFECT_SIZE="1.2442148763220815" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="28" I2="69.95490067633042" ID="CMP-001.01.03" LOG_CI_END="0.38299450902858706" LOG_CI_START="-0.19320372976216288" LOG_EFFECT_SIZE="0.09489538963321204" MODIFIED="2016-04-29 09:47:47 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.06809606523200895" P_Z="0.5185502357933052" STUDIES="2" TAU2="0.1603623363582994" TOTAL_1="64" TOTAL_2="64" WEIGHT="12.387873441295966" Z="0.6455817927188607">
<NAME>Mixed <I>Trichophyton</I>/<I>Microsporum</I> infections</NAME>
<DICH_DATA CI_END="1.5049414831010597" CI_START="0.5173269004443326" EFFECT_SIZE="0.8823529411764706" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.177519613511004" LOG_CI_START="-0.2862349381561894" LOG_EFFECT_SIZE="-0.0543576623225927" ORDER="1" O_E="0.0" SE="0.27241171927136343" STUDY_ID="STD-Memisoglu-1999" TOTAL_1="39" TOTAL_2="39" VAR="0.0742081447963801" WEIGHT="5.774871400819115"/>
<DICH_DATA CI_END="2.8309071621021844" CI_START="1.0538922343764496" EFFECT_SIZE="1.7272727272727273" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.4519256271722934" LOG_CI_START="0.022796204416914455" LOG_EFFECT_SIZE="0.23736091579460392" ORDER="2" O_E="0.0" SE="0.25207274715141126" STUDY_ID="STD-C_x00e1_ceres_x002d_R_x00ed_os-2000" TOTAL_1="25" TOTAL_2="25" VAR="0.06354066985645931" WEIGHT="6.613002040476852"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-02-02 17:08:35 +0000" MODIFIED_BY="Finola  M Delamere" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="77" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Primary outcome: adverse events</NAME>
<GROUP_LABEL_1>Terbinafine</GROUP_LABEL_1>
<GROUP_LABEL_2>Griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours terbinafine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours griseofulvin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="17" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-01-18 10:51:39 +0000" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Drug-related adverse events</NAME>
<DICH_DATA CI_END="2.3353842759097487" CI_START="0.8277613246677723" EFFECT_SIZE="1.3903743315508021" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="17" LOG_CI_END="0.3683583517869309" LOG_CI_START="-0.08209486891829287" LOG_EFFECT_SIZE="0.143131741434319" MODIFIED="2015-12-18 06:57:53 +0000" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.26459845162165235" STUDY_ID="STD-Fuller-2001" TOTAL_1="77" TOTAL_2="70" VAR="0.07001234060057589" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="103" EVENTS_2="100" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-04-29 09:48:58 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="160" TOTAL_2="148" WEIGHT="0.0" Z="0.0">
<NAME>Secondary outcome: proportion of participants with clinical cure only</NAME>
<GROUP_LABEL_1>Terbinafine</GROUP_LABEL_1>
<GROUP_LABEL_2>Griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours griseofulvin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours terbinafine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="16" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-01-19 01:03:05 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>2-week terbinafine</NAME>
<DICH_DATA CI_END="1.2992836558597212" CI_START="0.7875740626181635" EFFECT_SIZE="1.0115740740740742" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="0.11370397534277071" LOG_CI_START="-0.10370859503175114" LOG_EFFECT_SIZE="0.004997690155509793" MODIFIED="2016-01-19 01:03:05 +0000" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.12770922004757435" STUDY_ID="STD-Deng-2011" TOTAL_1="27" TOTAL_2="19" VAR="0.016309644885159763" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="2" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="80" EVENTS_2="84" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-01-19 01:19:53 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="133" TOTAL_2="129" WEIGHT="0.0" Z="0.0">
<NAME>4-week terbinafine</NAME>
<DICH_DATA CI_END="1.2424417020114067" CI_START="0.6951532457855497" EFFECT_SIZE="0.9293478260869565" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.09427601986915929" LOG_CI_START="-0.1579194451039245" LOG_EFFECT_SIZE="-0.03182171261738262" MODIFIED="2016-01-19 01:04:32 +0000" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.14814086451287475" STUDY_ID="STD-Deng-2011" TOTAL_1="23" TOTAL_2="19" VAR="0.021945715738621918" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.8397202294039496" CI_START="0.38885643195314695" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="35" LOG_CI_END="-0.07586538425292444" LOG_CI_START="-0.41021071311966456" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2016-01-19 01:19:53 +0000" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.19639610121239312" STUDY_ID="STD-Gupta-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.03857142857142856" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.688247238054069" CI_START="0.9594771868905161" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="33" LOG_CI_END="0.2274360478938588" LOG_CI_START="-0.017965346853832866" LOG_EFFECT_SIZE="0.10473535052001298" MODIFIED="2016-01-19 01:16:30 +0000" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.14414999403128945" STUDY_ID="STD-Khan-2011" TOTAL_1="60" TOTAL_2="60" VAR="0.020779220779220783" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="43" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-05-03 13:51:36 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="448.13" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="242" TOTAL_2="215" WEIGHT="0.0" Z="0.0">
<NAME>Secondary outcome: percentage of drop-outs as a surrogate for participant adherence</NAME>
<GROUP_LABEL_1>Terbinafine</GROUP_LABEL_1>
<GROUP_LABEL_2>Griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours terbinafine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours griseofulvin</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0766867391883848" CI_START="0.0055538462145463645" EFFECT_SIZE="0.13071895424836602" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.48808327968338405" LOG_CI_START="-2.2554061499906193" LOG_EFFECT_SIZE="-0.8836614351536176" MODIFIED="2016-03-24 13:57:02 +0000" MODIFIED_BY="[Empty name]" ORDER="194" O_E="0.0" SE="1.6115392714822099" STUDY_ID="STD-Deng-2011" TOTAL_1="50" TOTAL_2="19" VAR="2.597058823529412" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.255259824776234" CI_START="0.9690658175426906" EFFECT_SIZE="1.4783420463032113" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="26" LOG_CI_END="0.35319658344956617" LOG_CI_START="-0.013646725297137187" LOG_EFFECT_SIZE="0.16977492907621444" MODIFIED="2016-01-19 01:36:14 +0000" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.2154855754614783" STUDY_ID="STD-Fuller-2001" TOTAL_1="103" TOTAL_2="107" VAR="0.04643403323196446" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.6073850637346965" CI_START="0.09588150345615298" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4162051733647412" LOG_CI_START="-1.0182651646927037" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2016-01-19 01:35:39 +0000" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.8426149773176358" STUDY_ID="STD-Gupta-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.71" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.7965603321473593" CI_START="0.18175321273770334" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2544418062769431" LOG_CI_START="-0.740517903649532" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2016-01-19 01:35:20 +0000" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.5844442587408072" STUDY_ID="STD-Memisoglu-1999" TOTAL_1="39" TOTAL_2="39" VAR="0.3415750915750915" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-04-29 09:50:38 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Terbinafine (6 weeks) versus griseofulvin (6 weeks) in <I>Trichophyton</I> infections; medium treatment duration; 10 weeks follow-up</NAME>
<DICH_OUTCOME CHI2="6.953434820111969" CI_END="1.8764943241105363" CI_START="0.73901711638068" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.177608349286333" ESTIMABLE="YES" EVENTS_1="330" EVENTS_2="128" I2="85.61861833941951" I2_Q="85.55313444544336" ID="CMP-002.01" LOG_CI_END="0.2733472551273575" LOG_CI_START="-0.13134550279110854" LOG_EFFECT_SIZE="0.07100087616812455" METHOD="MH" MODIFIED="2016-04-29 09:50:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.008365920533957683" P_Q="0.008514636820917687" P_Z="0.4916244322590303" Q="6.921916703825028" RANDOM="YES" SCALE="52.16" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09718051474523083" TOTALS="YES" TOTAL_1="667" TOTAL_2="339" WEIGHT="100.0" Z="0.6877274546551135">
<NAME>Primary outcome: complete cure, i.e. clinical and mycological cure</NAME>
<GROUP_LABEL_1>Terbinafine</GROUP_LABEL_1>
<GROUP_LABEL_2>Griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours griseofulvin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours terbinafine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7694999640410543" CI_START="1.2221509197635858" DF="0" EFFECT_SIZE="1.470576760517589" ESTIMABLE="YES" EVENTS_1="264" EVENTS_2="91" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.24785055814800563" LOG_CI_START="0.08712483894538649" LOG_EFFECT_SIZE="0.16748769854669604" MODIFIED="2016-04-29 09:49:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="4.4106173786459115E-5" STUDIES="1" TAU2="0.0" TOTAL_1="507" TOTAL_2="257" WEIGHT="53.26419641567344" Z="4.084845395417917">
<NAME>
<I>T. tonsurans</I> infections</NAME>
<DICH_DATA CI_END="1.7694999640410543" CI_START="1.2221509197635858" EFFECT_SIZE="1.470576760517589" ESTIMABLE="YES" EVENTS_1="264" EVENTS_2="91" LOG_CI_END="0.24785055814800563" LOG_CI_START="0.08712483894538649" LOG_EFFECT_SIZE="0.16748769854669604" MODIFIED="2015-02-21 16:20:29 +0000" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="0.09441108306475987" STUDY_ID="STD-Elewski-2008" TOTAL_1="507" TOTAL_2="257" VAR="0.008913452605460987" WEIGHT="53.26419641567344"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.57302335698643E-31" CI_END="1.236429200851163" CI_START="0.6759318471733432" DF="0" EFFECT_SIZE="0.9141891891891892" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="37" I2="100.0" ID="CMP-002.01.02" LOG_CI_END="0.0921692532812484" LOG_CI_START="-0.1700970908759172" LOG_EFFECT_SIZE="-0.03896391879733439" MODIFIED="2016-04-29 09:50:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.5603182466787534" STUDIES="1" TAU2="0.0" TOTAL_1="160" TOTAL_2="82" WEIGHT="46.735803584326554" Z="0.5823688722602887">
<NAME>
<I>T. violaceum</I> infections</NAME>
<DICH_DATA CI_END="1.236429200851163" CI_START="0.6759318471733432" EFFECT_SIZE="0.9141891891891892" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="37" LOG_CI_END="0.0921692532812484" LOG_CI_START="-0.1700970908759172" LOG_EFFECT_SIZE="-0.03896391879733439" MODIFIED="2015-02-21 16:26:31 +0000" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="0.15405654879726038" STUDY_ID="STD-Elewski-2008" TOTAL_1="160" TOTAL_2="82" VAR="0.02373342022732267" WEIGHT="46.735803584326554"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="96" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-02-02 17:09:10 +0000" MODIFIED_BY="Finola  M Delamere" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="1042" TOTAL_2="507" WEIGHT="0.0" Z="0.0">
<NAME>Primary outcome: drug-related adverse events</NAME>
<GROUP_LABEL_1>Terbinafine</GROUP_LABEL_1>
<GROUP_LABEL_2>Griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours terbinafine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours griseofulvin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5730442563499476" CI_START="0.7862912172606273" EFFECT_SIZE="1.1121469701124211" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="42" LOG_CI_END="0.1967409413252545" LOG_CI_START="-0.104416575302258" LOG_EFFECT_SIZE="0.04616218301149824" MODIFIED="2015-12-17 06:38:15 +0000" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.1769014160207507" STUDY_ID="STD-Elewski-2008" TOTAL_1="1042" TOTAL_2="507" VAR="0.031294110990146715" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-02-02 17:09:27 +0000" MODIFIED_BY="Finola  M Delamere" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="1042" TOTAL_2="507" WEIGHT="0.0" Z="0.0">
<NAME>Primary outcome: severe adverse events</NAME>
<GROUP_LABEL_1>Terbinafine</GROUP_LABEL_1>
<GROUP_LABEL_2>Griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours terbinafine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours griseofulvin</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.875192081951645" CI_START="0.2443696337807509" EFFECT_SIZE="0.9731285988483686" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.5882932340847014" LOG_CI_START="-0.6119527620170782" LOG_EFFECT_SIZE="-0.011829763966188485" MODIFIED="2015-12-17 06:57:02 +0000" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.7050304394236863" STUDY_ID="STD-Elewski-2008" TOTAL_1="1042" TOTAL_2="507" VAR="0.4970679205139562" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="459" EVENTS_2="200" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-04-29 09:50:38 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="667" TOTAL_2="339" WEIGHT="0.0" Z="0.0">
<NAME>Secondary outcomes: proportion of participants with clinical cure only</NAME>
<GROUP_LABEL_1>Terbinafine</GROUP_LABEL_1>
<GROUP_LABEL_2>Griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours griseofulvin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours terbinafine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="355" EVENTS_2="147" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-04-29 09:50:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="507" TOTAL_2="257" WEIGHT="0.0" Z="0.0">
<NAME>
<I>T. tonsurans </I>infections</NAME>
<DICH_DATA CI_END="1.3803982149907241" CI_START="1.0855953529169855" EFFECT_SIZE="1.224154356022488" ESTIMABLE="YES" EVENTS_1="355" EVENTS_2="147" LOG_CI_END="0.1400043890284757" LOG_CI_START="0.0356679755812774" LOG_EFFECT_SIZE="0.08783618230487655" MODIFIED="2016-01-19 01:54:12 +0000" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="0.0612877257324604" STUDY_ID="STD-Elewski-2008" TOTAL_1="507" TOTAL_2="257" VAR="0.0037561853254572883" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="104" EVENTS_2="53" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-01-19 01:54:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="160" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>T. <I>violaceum </I>infections</NAME>
<DICH_DATA CI_END="1.2238659830167833" CI_START="0.8263591019139821" EFFECT_SIZE="1.0056603773584907" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="53" LOG_CI_END="0.08773386386929051" LOG_CI_START="-0.08283118501772396" LOG_EFFECT_SIZE="0.0024513394257832653" MODIFIED="2016-01-19 01:54:39 +0000" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.10019075402684116" STUDY_ID="STD-Elewski-2008" TOTAL_1="160" TOTAL_2="82" VAR="0.010038187192466987" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2016-04-29 09:52:54 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Terbinafine, medium- (6-8 weeks) and long-term (10-12 weeks) treatment versus griseofulvin in <I>Microsporum</I> infections; 10-16 weeks follow-up</NAME>
<DICH_OUTCOME CHI2="2.029721690053592" CI_END="0.7714299040956667" CI_START="0.5097873025661357" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.627108579057712" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="78" I2="1.4643234192766188" I2_Q="32.84378101663815" ID="CMP-003.01" LOG_CI_END="-0.11270352993457344" LOG_CI_START="-0.2926109858423021" LOG_EFFECT_SIZE="-0.2026572578884378" METHOD="MH" MODIFIED="2016-04-29 09:52:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3624529908596319" P_Q="0.22236188148083447" P_Z="1.007237516000104E-5" Q="1.489065368983553" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="5.051670511109536E-4" TOTALS="SUB" TOTAL_1="287" TOTAL_2="142" WEIGHT="200.0" Z="4.415613846162118">
<NAME>Primary outcome: complete cure, i.e. clinical and mycological cure</NAME>
<GROUP_LABEL_1>Terbinafine</GROUP_LABEL_1>
<GROUP_LABEL_2>Griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours griseofulvin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours terbinafine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5630841578795376" CI_END="0.8623085319361373" CI_START="0.5321386980234485" DF="1" EFFECT_SIZE="0.6773977705004699" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="57" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-0.06433731683981198" LOG_CI_START="-0.2739751572997903" LOG_EFFECT_SIZE="-0.16915623706980115" MODIFIED="2016-04-29 09:52:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4530203614885151" P_Z="0.0015616314096910703" STUDIES="2" TAU2="0.0" TOTAL_1="222" TOTAL_2="112" WEIGHT="100.0" Z="3.1629798483868985">
<NAME>Medium terbinafine treatment duration (6-8 weeks)</NAME>
<DICH_DATA CI_END="0.8790231132010036" CI_START="0.4294404469322688" EFFECT_SIZE="0.6144005847953217" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="36" LOG_CI_END="-0.055999705354346285" LOG_CI_START="-0.3670970538628689" LOG_EFFECT_SIZE="-0.21154837960860762" MODIFIED="2015-02-18 14:29:05 +0000" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.18274012247061738" STUDY_ID="STD-Elewski-2008" TOTAL_1="152" TOTAL_2="82" VAR="0.03339395236057624" WEIGHT="45.40950160303118"/>
<DICH_DATA CI_END="1.018528872593393" CI_START="0.529955613665198" EFFECT_SIZE="0.7346938775510204" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="21" LOG_CI_END="0.00797334460791633" LOG_CI_START="-0.27576050313036904" LOG_EFFECT_SIZE="-0.1338935792612264" MODIFIED="2015-02-18 14:04:42 +0000" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.16666666666666666" STUDY_ID="STD-Lipozencic-2002" TOTAL_1="70" TOTAL_2="30" VAR="0.027777777777777776" WEIGHT="54.59049839696881"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7567403615872248" CI_START="0.3376649483175238" DF="0" EFFECT_SIZE="0.5054945054945055" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="-0.12105310183639095" LOG_CI_START="-0.47151401944264826" LOG_EFFECT_SIZE="-0.29628356063951955" MODIFIED="2016-04-29 09:52:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="9.198771255130041E-4" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="30" WEIGHT="100.00000000000001" Z="3.313950736824638">
<NAME>Long terbinafine treatment duration (10-12 weeks)</NAME>
<DICH_DATA CI_END="0.7567403615872248" CI_START="0.3376649483175238" EFFECT_SIZE="0.5054945054945055" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="-0.12105310183639095" LOG_CI_START="-0.47151401944264826" LOG_EFFECT_SIZE="-0.29628356063951955" ORDER="8" O_E="0.0" SE="0.20586247781143632" STUDY_ID="STD-Lipozencic-2002" TOTAL_1="65" TOTAL_2="30" VAR="0.042379359770664114" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.23153793280609" CI_END="0.8606367052043705" CI_START="0.633558353243907" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7384196460621445" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="95" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.06518013567877097" LOG_CI_START="-0.19821337868942387" LOG_EFFECT_SIZE="-0.13169675718409743" METHOD="MH" MODIFIED="2016-04-29 09:52:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5402256175578269" P_Q="0.5938323285997928" P_Z="1.0422164090513067E-4" Q="0.2843991299600168" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="287" TOTAL_2="142" WEIGHT="200.0" Z="3.8805473747772665">
<NAME>Secondary outcome: clinical cure only</NAME>
<GROUP_LABEL_1>Terbinafine</GROUP_LABEL_1>
<GROUP_LABEL_2>Griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours griseofulvin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours terbinafine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9960084832589842" CI_END="0.9103307980500427" CI_START="0.6321222311965491" DF="1" EFFECT_SIZE="0.7585778372654504" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="71" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="-0.040800764094110466" LOG_CI_START="-0.19919893563931798" LOG_EFFECT_SIZE="-0.11999984986671423" MODIFIED="2016-04-29 09:52:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3182785159826089" P_Z="0.002981169327227533" STUDIES="2" TAU2="0.0" TOTAL_1="222" TOTAL_2="112" WEIGHT="100.0" Z="2.969672965219144">
<NAME>Medium terbinafine treatment duration (6-8 weeks)</NAME>
<DICH_DATA CI_END="0.9033892968416927" CI_START="0.5250157994421666" EFFECT_SIZE="0.6886898096304591" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="47" LOG_CI_END="-0.04412505916993992" LOG_CI_START="-0.2798276270563195" LOG_EFFECT_SIZE="-0.1619763431131297" MODIFIED="2015-02-17 07:46:25 +0000" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.13845285512298744" STUDY_ID="STD-Elewski-2008" TOTAL_1="152" TOTAL_2="82" VAR="0.019169193091706952" WEIGHT="45.16184751400379"/>
<DICH_DATA CI_END="1.0507981639351422" CI_START="0.6421260724631704" EFFECT_SIZE="0.8214285714285714" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="24" LOG_CI_END="0.021519305269787545" LOG_CI_START="-0.19237969591904028" LOG_EFFECT_SIZE="-0.08543019532462635" ORDER="9" O_E="0.0" SE="0.12564533211544973" STUDY_ID="STD-Lipozencic-2002" TOTAL_1="70" TOTAL_2="30" VAR="0.015786749482401663" WEIGHT="54.83815248599622"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9180029687470814" CI_START="0.5221006436205233" DF="0" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="24" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="-0.037155914323386253" LOG_CI_START="-0.28224577141163754" LOG_EFFECT_SIZE="-0.1597008428675119" MODIFIED="2016-04-29 09:52:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.010642301305823726" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="30" WEIGHT="99.99999999999999" Z="2.5542297346748764">
<NAME>Long terbinafine treatment duration (10-12 weeks)</NAME>
<DICH_DATA CI_END="0.9180029687470814" CI_START="0.5221006436205233" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="24" LOG_CI_END="-0.037155914323386253" LOG_CI_START="-0.28224577141163754" LOG_EFFECT_SIZE="-0.1597008428675119" ORDER="10" O_E="0.0" SE="0.1439669952679979" STUDY_ID="STD-Lipozencic-2002" TOTAL_1="65" TOTAL_2="30" VAR="0.02072649572649573" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2016-04-29 09:55:12 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Terbinafine, short-term versus long-term for treating <I>Trichophyton</I> and <I>Microsporum</I> infections; 12-20 weeks follow-up</NAME>
<DICH_OUTCOME CHI2="14.232029807736838" CI_END="0.9329725175337211" CI_START="0.6931693418302577" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8041815379157669" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="148" I2="71.89438151804943" I2_Q="89.76792781130676" ID="CMP-004.01" LOG_CI_END="-0.030131149028680526" LOG_CI_START="-0.15916065393328965" LOG_EFFECT_SIZE="-0.09464590148098512" METHOD="MH" MODIFIED="2016-04-29 09:54:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.006590183421286144" P_Q="0.001770753831573768" P_Z="0.004035785723590694" Q="9.773191407944044" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0630072536480898" TOTALS="SUB" TOTAL_1="430" TOTAL_2="257" WEIGHT="200.0" Z="2.8753510032329137">
<NAME>Primary outcome: complete cure, i.e. clinical and mycological cure</NAME>
<GROUP_LABEL_1>Shorter terbinafine</GROUP_LABEL_1>
<GROUP_LABEL_2>Longer terbinafine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours longer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours shorter</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.640778968240906" CI_END="0.8583215261628199" CI_START="0.6232530215616621" DF="3" EFFECT_SIZE="0.7314037767556267" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="125" I2="17.60005135797924" ID="CMP-004.01.01" LOG_CI_END="-0.06634999550665063" LOG_CI_START="-0.20533560733782613" LOG_EFFECT_SIZE="-0.13584280142223837" MODIFIED="2015-09-03 16:18:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3029574868838386" P_Z="1.2747385017142248E-4" STUDIES="4" TAU2="0.004729809897931153" TOTAL_1="360" TOTAL_2="192" WEIGHT="100.0" Z="3.831288646914349">
<NAME>1-2 weeks versus 4 weeks</NAME>
<DICH_DATA CI_END="1.05909176271084" CI_START="0.638163499536001" EFFECT_SIZE="0.8221153846153846" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="38" LOG_CI_END="0.024933590242013495" LOG_CI_START="-0.19506803938322897" LOG_EFFECT_SIZE="-0.08506722457060774" MODIFIED="2015-09-03 16:17:23 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.12923004626749768" STUDY_ID="STD-Haroon-1996" TOTAL_1="104" TOTAL_2="57" VAR="0.016700404858299593" WEIGHT="31.10200359894908"/>
<DICH_DATA CI_END="0.9092094582081205" CI_START="0.471211279423412" EFFECT_SIZE="0.6545454545454545" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="21" LOG_CI_END="-0.0413360551003553" LOG_CI_START="-0.32678432235355787" LOG_EFFECT_SIZE="-0.1840601887269566" MODIFIED="2015-09-03 16:17:44 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.16767372517624257" STUDY_ID="STD-Kullavanijaya-1997" TOTAL_1="55" TOTAL_2="27" VAR="0.02811447811447812" WEIGHT="20.29341041653008"/>
<DICH_DATA CI_END="0.8130241523386417" CI_START="0.4789706400674058" EFFECT_SIZE="0.624031007751938" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="36" LOG_CI_END="-0.08989655271885318" LOG_CI_START="-0.31969110714390775" LOG_EFFECT_SIZE="-0.20479382993138046" MODIFIED="2015-09-03 16:18:09 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.1349824587706669" STUDY_ID="STD-Talarico-Filho-1998" TOTAL_1="86" TOTAL_2="46" VAR="0.01822026417577479" WEIGHT="29.042286065567858"/>
<DICH_DATA CI_END="1.2067586293862238" CI_START="0.6166052959515214" EFFECT_SIZE="0.8626086956521739" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="30" LOG_CI_END="0.08162041308958563" LOG_CI_START="-0.20999274948845167" LOG_EFFECT_SIZE="-0.06418616819943303" MODIFIED="2015-09-03 16:18:35 +0100" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.1712950152067745" STUDY_ID="STD-Friedlander-2002" TOTAL_1="115" TOTAL_2="62" VAR="0.02934198223468911" WEIGHT="19.562299918952984"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.963987376262247E-31" CI_END="2.1675637992072" CI_START="0.9745588587266608" DF="0" EFFECT_SIZE="1.4534161490683228" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="23" I2="100.0" ID="CMP-004.01.02" LOG_CI_END="0.33597188918670917" LOG_CI_START="-0.011191926430122928" LOG_EFFECT_SIZE="0.16238998137829308" MODIFIED="2016-04-29 09:54:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.06671448013030332" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="65" WEIGHT="99.99999999999999" Z="1.8335926766219872">
<NAME>Medium term (6-8 weeks) versus long term (10-12 weeks)</NAME>
<DICH_DATA CI_END="2.1675637992072" CI_START="0.9745588587266609" EFFECT_SIZE="1.453416149068323" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="23" LOG_CI_END="0.33597188918670917" LOG_CI_START="-0.011191926430122878" LOG_EFFECT_SIZE="0.16238998137829316" MODIFIED="2015-09-03 16:19:50 +0100" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.2039257437819299" STUDY_ID="STD-Lipozencic-2002" TOTAL_1="70" TOTAL_2="65" VAR="0.04158570897701332" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.11279044166049" CI_END="1.1567564287310357" CI_START="0.8117430106025634" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.969014419909219" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="160" I2="73.00408015656114" I2_Q="71.50828246620485" ID="CMP-004.02" LOG_CI_END="0.06324192179169365" LOG_CI_START="-0.09058144211656727" LOG_EFFECT_SIZE="-0.013669760162436869" METHOD="MH" MODIFIED="2016-04-29 09:55:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.011131363193097932" P_Q="0.06100724846921668" P_Z="0.7275768292211793" Q="3.5097919204549903" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03255172820373047" TOTALS="SUB" TOTAL_1="375" TOTAL_2="230" WEIGHT="200.0" Z="0.3483506915328586">
<NAME>Secondary outcome: clinical cure only</NAME>
<GROUP_LABEL_1>shorter terbinafine</GROUP_LABEL_1>
<GROUP_LABEL_2>longer terbinafine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours longer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours shorter</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.583120224572056" CI_END="1.0595437413899547" CI_START="0.6677667126335842" DF="2" EFFECT_SIZE="0.8411468605894328" ESTIMABLE="YES" EVENTS_1="195" EVENTS_2="124" I2="73.62563244719138" ID="CMP-004.02.01" LOG_CI_END="0.025118890496706025" LOG_CI_START="-0.17537523379896688" LOG_EFFECT_SIZE="-0.0751281716511304" MODIFIED="2015-09-03 16:26:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.02256040035775353" P_Z="0.14187181878874458" STUDIES="3" TAU2="0.03014769215399186" TOTAL_1="305" TOTAL_2="165" WEIGHT="100.0" Z="1.4688561191290395">
<NAME>1-2 weeks versus 4 weeks</NAME>
<DICH_DATA CI_END="1.113749510479561" CI_START="0.8502406245922272" EFFECT_SIZE="0.973116169544741" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="49" LOG_CI_END="0.04678752616181365" LOG_CI_START="-0.0704581482341818" LOG_EFFECT_SIZE="-0.011835311036184078" MODIFIED="2015-09-03 16:25:38 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.06887068951565618" STUDY_ID="STD-Haroon-1996" TOTAL_1="104" TOTAL_2="57" VAR="0.004743171874361914" WEIGHT="39.75271352595437"/>
<DICH_DATA CI_END="0.8520551824619351" CI_START="0.5519018288380511" EFFECT_SIZE="0.6857483601669648" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="39" LOG_CI_END="-0.06953227769497684" LOG_CI_START="-0.25813816680997126" LOG_EFFECT_SIZE="-0.16383522225247404" MODIFIED="2015-09-03 16:25:53 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.110788032880356" STUDY_ID="STD-Talarico-Filho-1998" TOTAL_1="86" TOTAL_2="46" VAR="0.012273988229498843" WEIGHT="32.695699695383986"/>
<DICH_DATA CI_END="1.1475754765553974" CI_START="0.6574419695787275" EFFECT_SIZE="0.8685990338164251" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="36" LOG_CI_END="0.059781258892132864" LOG_CI_START="-0.18214257501154843" LOG_EFFECT_SIZE="-0.06118065805970779" MODIFIED="2015-09-03 16:26:15 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.14210725757731393" STUDY_ID="STD-Friedlander-2002" TOTAL_1="115" TOTAL_2="62" VAR="0.020194472656145046" WEIGHT="27.551586778661644"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5638176873154812" CI_START="0.9002335085575194" DF="0" EFFECT_SIZE="1.1865079365079365" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="36" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="0.19418612084147005" LOG_CI_START="-0.04564482575569896" LOG_EFFECT_SIZE="0.07427064754288555" MODIFIED="2016-04-29 09:55:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.22477828791301246" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="65" WEIGHT="100.0" Z="1.2139200245665231">
<NAME>Medium term (6-8 weeks) versus long term (10-12 weeks)</NAME>
<DICH_DATA CI_END="1.5638176873154812" CI_START="0.9002335085575194" EFFECT_SIZE="1.1865079365079365" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="36" LOG_CI_END="0.19418612084147005" LOG_CI_START="-0.04564482575569896" LOG_EFFECT_SIZE="0.07427064754288555" MODIFIED="2015-09-03 17:06:53 +0100" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.14087788521350936" STUDY_ID="STD-Lipozencic-2002" TOTAL_1="70" TOTAL_2="65" VAR="0.019846578542230715" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2016-04-29 10:06:22 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Terbinafine standard dose versus double dose in <I>Microsporum</I> infections; 20 weeks follow-up</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-04-29 10:06:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="19" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Primary outcome: complete cure, i.e. clinical and mycological cure</NAME>
<GROUP_LABEL_1>double dose</GROUP_LABEL_1>
<GROUP_LABEL_2>standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours standard</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours double</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7593172130422572" CI_START="0.7181827201464617" EFFECT_SIZE="1.1240601503759398" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.24534415182435226" LOG_CI_START="-0.143765048437627" LOG_EFFECT_SIZE="0.050789551693362626" ORDER="44" O_E="0.0" SE="0.228564670355492" STUDY_ID="STD-Ungpakorn-2004" TOTAL_1="19" TOTAL_2="23" VAR="0.05224180853471472" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2016-04-29 09:57:20 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Itraconazole (6 and 2 weeks) versus griseofulvin (6 weeks) in <I>Trichophyton</I> and <I>Microsporum</I> infections</NAME>
<DICH_OUTCOME CHI2="0.6087046999472681" CI_END="1.0485174351666202" CI_START="0.8082728611386193" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9205912161626629" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.0205756564834788" LOG_CI_START="-0.09244200298495812" LOG_EFFECT_SIZE="-0.035933173250739685" METHOD="MH" MODIFIED="2016-04-29 09:56:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.43527611082967643" P_Q="1.0" P_Z="0.21264929534415622" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="67" WEIGHT="100.0" Z="1.246313642539316">
<NAME>Primary outcome: complete cure, i.e. clinical and mycological cure</NAME>
<GROUP_LABEL_1>itraconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours griseofulvin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours itraconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0391227830608467" CI_START="0.7645135429651801" EFFECT_SIZE="0.8913043478260869" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="46" LOG_CI_END="0.016666866955909403" LOG_CI_START="-0.11661481687958657" LOG_EFFECT_SIZE="-0.0499739749618386" ORDER="45" O_E="0.0" SE="0.07829032083994568" STUDY_ID="STD-Gupta-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.0061293743372216325" WEIGHT="71.9037724699289"/>
<DICH_DATA CI_END="1.2782288532878412" CI_START="0.7823325200552427" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.10660861659406164" LOG_CI_START="-0.10660861659406169" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-17 08:38:45 +0000" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.1252448582170299" STUDY_ID="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TOTAL_1="17" TOTAL_2="17" VAR="0.01568627450980392" WEIGHT="28.0962275300711"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-01-19 02:00:29 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Secondary outcome: proportion of participants with clinical cure only</NAME>
<GROUP_LABEL_1>itraconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours griseofulvin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours itraconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9023362113048469" CI_START="0.4378656601234909" EFFECT_SIZE="0.6285714285714286" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="35" LOG_CI_END="-0.044631613779055355" LOG_CI_START="-0.35865911327708344" LOG_EFFECT_SIZE="-0.20164536352806942" MODIFIED="2016-01-19 02:00:29 +0000" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.18446130766633423" STUDY_ID="STD-Gupta-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.034025974025974015" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-04-29 09:57:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="68" TOTAL_2="67" WEIGHT="0.0" Z="0.0">
<NAME>Secondary outcome: percentage of drop-outs as a surrogate for participant adherence</NAME>
<GROUP_LABEL_1>itraconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours itraconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours griseofulvin</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.7784438683076322" CI_START="0.2646592181473641" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5773129748228616" LOG_CI_START="-0.5773129748228617" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-19 02:02:41 +0000" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.6782329983125268" STUDY_ID="STD-Gupta-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.45999999999999996" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.74368876721774" CI_START="0.04700852819466987" EFFECT_SIZE="0.4722222222222222" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6761161872883394" LOG_CI_START="-1.327823346066366" LOG_EFFECT_SIZE="-0.3258535793890133" MODIFIED="2016-01-19 02:03:28 +0000" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="1.1771240015532263" STUDY_ID="STD-L_x00f3_pez_x002d_G_x00f3_mez-1994" TOTAL_1="18" TOTAL_2="17" VAR="1.3856209150326797" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2016-05-03 13:52:31 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Itraconazole versus terbinafine (both 2 weeks) in <I>Trichophyton</I> infections</NAME>
<DICH_OUTCOME CHI2="1.5434055543885798" CI_END="1.1889953242395281" CI_START="0.7232735972294748" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.927345095016817" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="63" I2="35.208215549272786" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.07518014674571898" LOG_CI_START="-0.14069738833414971" LOG_EFFECT_SIZE="-0.03275862079421538" METHOD="MH" MODIFIED="2016-04-29 09:58:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.21411207184513947" P_Q="1.0" P_Z="0.5519540194179757" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.015502199898077086" TOTALS="YES" TOTAL_1="80" TOTAL_2="80" WEIGHT="100.0" Z="0.5948346308115172">
<NAME>Primary outcome: complete cure, i.e. clinical and mycological cure</NAME>
<GROUP_LABEL_1>itraconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>terbinafine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours terbinafine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours itraconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7543344856697909" CI_START="0.7214274189661127" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.24411240056449734" LOG_CI_START="-0.1418073556697347" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="1" O_E="0.0" SE="0.22669117514559073" STUDY_ID="STD-Jahangir-1998" TOTAL_1="30" TOTAL_2="30" VAR="0.051388888888888894" WEIGHT="24.03930126622949"/>
<DICH_DATA CI_END="1.0110278085801796" CI_START="0.752677435337678" EFFECT_SIZE="0.8723404255319149" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="47" LOG_CI_END="0.004763101136824991" LOG_CI_START="-0.12339110356878892" LOG_EFFECT_SIZE="-0.05931400121598195" ORDER="2" O_E="0.0" SE="0.07527841421762198" STUDY_ID="STD-Gupta-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.0056668396471198715" WEIGHT="75.96069873377051"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-01-18 17:32:59 +0000" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Secondary outcome: clinical cure only</NAME>
<GROUP_LABEL_1>itraconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>terbinafine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours terbinafine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours itraconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.745180448741165" CI_START="0.6933380447121089" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" LOG_CI_END="0.24184033894039078" LOG_CI_START="-0.15905496862394064" LOG_EFFECT_SIZE="0.04139268515822508" ORDER="49" O_E="0.0" SE="0.23548788812706578" STUDY_ID="STD-Gupta-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.05545454545454545" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-05-03 13:52:31 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Secondary outcome: percentage of drop-outs as a surrogate for participant adherence</NAME>
<GROUP_LABEL_1>itraconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>terbinafine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours itraconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tervinafine</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.429540254938788" CI_START="0.38352601382461193" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0182651646927037" LOG_CI_START="-0.4162051733647413" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2016-01-19 02:12:27 +0000" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.8426149773176358" STUDY_ID="STD-Gupta-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.71" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2016-05-03 13:53:08 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Ketoconazole (2-26 weeks) versus griseofulvin (2 to 26 weeks) in <I>Trichophyton</I> infections; 12-26 weeks follow-up</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="72" EVENTS_2="80" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-04-29 09:59:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.65" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="101" TOTAL_2="102" WEIGHT="0.0" Z="0.0">
<NAME>Primary outcome: complete cure, i.e. clinical and mycological cure</NAME>
<GROUP_LABEL_1>Ketoconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours griseofulvin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ketoconazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="27" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-04-29 09:58:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Ketoconazole (12 weeks) versus griseofulvin (12 weeks) assessed at 12 weeks</NAME>
<DICH_DATA CI_END="0.9443942600511781" CI_START="0.6156833071086459" EFFECT_SIZE="0.7625272331154684" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="-0.024846661190594966" LOG_CI_START="-0.21064262118337623" LOG_EFFECT_SIZE="-0.11774464118698559" MODIFIED="2016-03-25 06:07:23 +0000" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.10913746660459449" STUDY_ID="STD-Gan-1987" TOTAL_1="34" TOTAL_2="28" VAR="0.011910986616868978" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="31" EVENTS_2="28" I2="0.0" ID="CMP-008.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-04-29 09:59:03 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Ketoconazole (up to 26 weeks) versus griseofulvin (up to 26 weeks) assessed at 26 weeks</NAME>
<DICH_DATA CI_END="1.03306096067125" CI_START="0.8118304650345727" EFFECT_SIZE="0.9157894736842105" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="28" LOG_CI_END="0.014125949885529069" LOG_CI_START="-0.09053465522598758" LOG_EFFECT_SIZE="-0.03820435267022926" MODIFIED="2016-03-25 06:55:19 +0000" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.06147815752085561" STUDY_ID="STD-Gan-1987" TOTAL_1="34" TOTAL_2="28" VAR="0.0037795638521591346" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="25" I2="0.0" ID="CMP-008.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-04-29 09:59:13 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Ketoconazole (12 weeks) versus griseofulvin (12 weeks)</NAME>
<DICH_DATA CI_END="1.3855677208665744" CI_START="0.5744073314719356" EFFECT_SIZE="0.8921212121212121" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="25" LOG_CI_END="0.1416277571697927" LOG_CI_START="-0.2407800255946452" LOG_EFFECT_SIZE="-0.049576134212426244" MODIFIED="2016-03-25 06:54:49 +0000" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.2246282245448846" STUDY_ID="STD-Tanz-1988" TOTAL_1="33" TOTAL_2="46" VAR="0.050457839262187096" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-01-19 02:22:47 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="8" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Secondary outcome: proportion of participants with clinical cure only</NAME>
<GROUP_LABEL_1>Ketoconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours griseofulvin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ketoconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0521966415428805" CI_START="0.772700749007168" EFFECT_SIZE="1.2592592592592593" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.31221897254373765" LOG_CI_START="-0.111988666777202" LOG_EFFECT_SIZE="0.10011515288326783" MODIFIED="2016-01-19 02:22:47 +0000" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.24918166719880072" STUDY_ID="STD-Mart_x00ed_nez_x002d_Roig-1988" TOTAL_1="8" TOTAL_2="5" VAR="0.062091503267973885" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-05-03 13:53:08 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="43" TOTAL_2="58" WEIGHT="0.0" Z="0.0">
<NAME>Secondary outcome: percentage of drop-outs as a surrogate for participant adherence</NAME>
<GROUP_LABEL_1>Ketoconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ketoconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours griseofulvin</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2956734976340756" CI_START="0.22581608427080935" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3609101205469288" LOG_CI_START="-0.6462451276843918" LOG_EFFECT_SIZE="-0.14266750356873156" MODIFIED="2016-01-19 02:25:54 +0000" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Tanz-1985" TOTAL_1="10" TOTAL_2="12" VAR="0.35000000000000003" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6736341546795996" CI_START="0.8312390152201162" EFFECT_SIZE="1.1794871794871795" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" LOG_CI_END="0.22366053013981296" LOG_CI_START="-0.08027408082966318" LOG_EFFECT_SIZE="0.07169322465507488" MODIFIED="2016-01-19 02:29:17 +0000" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.17853269498405888" STUDY_ID="STD-Tanz-1988" TOTAL_1="33" TOTAL_2="46" VAR="0.03187392317827101" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2016-05-03 13:53:26 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Fluconazole (2-6 weeks) versus griseofulvin (6 weeks); 8-12 weeks follow-up</NAME>
<DICH_OUTCOME CHI2="1.8456755041340251" CI_END="1.0597993962197165" CI_START="0.8352421096067292" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9408448774683815" ESTIMABLE="YES" EVENTS_1="214" EVENTS_2="135" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.025223667755664918" LOG_CI_START="-0.07818761837818008" LOG_EFFECT_SIZE="-0.02648197531125759" METHOD="MH" MODIFIED="2016-04-29 10:00:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.605046408673913" P_Q="0.42167922149501047" P_Z="0.3154601819100622" Q="0.645631261908365" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="560" TOTAL_2="301" WEIGHT="200.0" Z="1.0038308155720044">
<NAME>Primary outcome: complete cure, i.e. clinical and mycological cure</NAME>
<GROUP_LABEL_1>Fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours griseofulvin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fluconazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8551539920342711" CI_END="1.0488613114061758" CI_START="0.8112272882737915" DF="2" EFFECT_SIZE="0.9224233937988155" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="98" I2="0.0" ID="CMP-009.01.01" LOG_CI_END="0.02071806619834679" LOG_CI_START="-0.090857448854674" LOG_EFFECT_SIZE="-0.03506969132816362" MODIFIED="2016-01-14 19:01:46 +0000" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="0.6520872109106894" P_Z="0.21791687053467812" STUDIES="3" TAU2="0.0" TOTAL_1="314" TOTAL_2="186" WEIGHT="100.00000000000001" Z="1.232086303513352">
<NAME>Short-term (2-4 weeks) fluconazole</NAME>
<DICH_DATA CI_END="1.4460435874196205" CI_START="0.7424933297204124" EFFECT_SIZE="1.0361842105263157" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.16018138389248365" LOG_CI_START="-0.12930744353079016" LOG_EFFECT_SIZE="0.015436970180846733" ORDER="52" O_E="0.0" SE="0.17004717022123778" STUDY_ID="STD-Dastghaib-2005" TOTAL_1="19" TOTAL_2="21" VAR="0.028916040100250617" WEIGHT="14.855052338516396"/>
<DICH_DATA CI_END="1.343369986136927" CI_START="0.6929889488460084" EFFECT_SIZE="0.9648526077097506" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="36" LOG_CI_END="0.12819564096972624" LOG_CI_START="-0.15927369106418993" LOG_EFFECT_SIZE="-0.015539025047231857" MODIFIED="2015-09-06 10:06:49 +0100" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.1688609086328657" STUDY_ID="STD-Foster-2005" TOTAL_1="245" TOTAL_2="115" VAR="0.028514006464317024" WEIGHT="15.06450135828538"/>
<DICH_DATA CI_END="1.0391227830608467" CI_START="0.7645135429651801" EFFECT_SIZE="0.8913043478260869" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="46" LOG_CI_END="0.016666866955909403" LOG_CI_START="-0.11661481687958657" LOG_EFFECT_SIZE="-0.0499739749618386" ORDER="53" O_E="0.0" SE="0.07829032083994568" STUDY_ID="STD-Gupta-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.0061293743372216325" WEIGHT="70.08044630319823"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4572809290535456" CI_START="0.7729249188140286" DF="0" EFFECT_SIZE="1.0613052076466711" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="37" I2="0.0" ID="CMP-009.01.02" LOG_CI_END="0.16354328147286315" LOG_CI_START="-0.11186269098262461" LOG_EFFECT_SIZE="0.025840295245119247" MODIFIED="2016-01-18 13:51:33 +0000" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="1.0" P_Z="0.7130283824075213" STUDIES="1" TAU2="0.0" TOTAL_1="246" TOTAL_2="115" WEIGHT="100.0" Z="0.3677919369631752">
<NAME>Medium-term (6 weeks) fluconazole</NAME>
<DICH_DATA CI_END="1.4572809290535456" CI_START="0.7729249188140286" EFFECT_SIZE="1.0613052076466711" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="37" LOG_CI_END="0.16354328147286315" LOG_CI_START="-0.11186269098262461" LOG_EFFECT_SIZE="0.025840295245119247" MODIFIED="2015-09-06 10:06:51 +0100" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="0.16177483150190386" STUDY_ID="STD-Foster-2005" TOTAL_1="246" TOTAL_2="115" VAR="0.026171096107469385" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-01-19 02:35:27 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Secondary outcome: proportion of participants with clinical cure only</NAME>
<GROUP_LABEL_1>Fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours griseofulvin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fluconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6133578209564581" CI_START="0.22492447142573085" EFFECT_SIZE="0.37142857142857144" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="35" LOG_CI_END="-0.21228609264387083" LOG_CI_START="-0.6479632914430069" LOG_EFFECT_SIZE="-0.43012469204343884" MODIFIED="2016-01-19 02:35:27 +0000" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.25591894321152836" STUDY_ID="STD-Gupta-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.06549450549450549" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-05-03 13:53:26 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Secondary outcome: percentage of drop-outs as a surrogate for participant adherence</NAME>
<GROUP_LABEL_1>Fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Griseofulvin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours griseofulvin</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.7784438683076322" CI_START="0.2646592181473641" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5773129748228616" LOG_CI_START="-0.5773129748228617" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-19 02:38:29 +0000" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.6782329983125268" STUDY_ID="STD-Gupta-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.45999999999999996" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2016-04-29 10:01:10 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Fluconazole (2-3 weeks) versus terbinafine (2-3 weeks) in <I>Trichophyton</I> infections; 12 weeks follow-up</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0110278085801796" CI_START="0.752677435337678" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8723404255319149" ESTIMABLE="NO" EVENTS_1="41" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.004763101136824991" LOG_CI_START="-0.12339110356878892" LOG_EFFECT_SIZE="-0.05931400121598195" METHOD="MH" MODIFIED="2016-04-29 10:01:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.06963582762916311" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="1.8142722110341647">
<NAME>Primary outcome: complete cure, i.e. clinical and mycological cure</NAME>
<GROUP_LABEL_1>fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>terbinafine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours terbinafine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fluconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0110278085801796" CI_START="0.752677435337678" EFFECT_SIZE="0.8723404255319149" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="47" LOG_CI_END="0.004763101136824991" LOG_CI_START="-0.12339110356878892" LOG_EFFECT_SIZE="-0.05931400121598195" ORDER="54" O_E="0.0" SE="0.07527841421762198" STUDY_ID="STD-Gupta-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.0056668396471198715" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2016-04-29 10:07:20 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Fluconazole (2-3 weeks) versus itraconazole (2-3 weeks) in <I>Trichophyton</I> infections; 12 weeks follow-up</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="41" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-04-29 10:07:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Primary outcome: complete cure, i.e. clinical and mycological cure</NAME>
<GROUP_LABEL_1>fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>itraconazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours itraconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fluconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.201603565334349" CI_START="0.8322212324010103" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="41" LOG_CI_END="0.07976120827755054" LOG_CI_START="-0.07976120827755058" LOG_EFFECT_SIZE="0.0" ORDER="55" O_E="0.0" SE="0.09370425713316365" STUDY_ID="STD-Gupta-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.00878048780487805" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-01-19 02:43:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Secondary outcome: proportion of participants with clinical cure only</NAME>
<GROUP_LABEL_1>itraconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>fluconazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours itraconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9702086426965595" CI_START="0.9642101515278527" EFFECT_SIZE="1.6923076923076923" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" LOG_CI_END="0.47278695746172134" LOG_CI_START="-0.015828300430982347" LOG_EFFECT_SIZE="0.22847932851536945" MODIFIED="2016-01-19 02:43:59 +0000" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.2870150211707087" STUDY_ID="STD-Gupta-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.08237762237762238" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-04-29 10:02:17 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Secondary outcome: percentage of drop-outs as a surrogate for participant adherence</NAME>
<GROUP_LABEL_1>fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>itraconazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours itraconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.7784438683076322" CI_START="0.2646592181473641" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5773129748228616" LOG_CI_START="-0.5773129748228617" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-19 02:47:30 +0000" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.6782329983125268" STUDY_ID="STD-Gupta-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.45999999999999996" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2016-04-29 10:03:53 +0100" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Fluconazole low dose versus higher dose (1.5, 3.0 and 6.0 mg/kg/d) in <I>Trichophyton</I> infections; 4 months follow-up</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-04-29 10:03:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="481.5572857651611" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="43" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Primary outcome: complete cure, i.e. clinical and mycological cure</NAME>
<GROUP_LABEL_1>high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-012.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-04-29 10:03:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>1.5 mg versus 3.0 mg</NAME>
<DICH_DATA CI_END="9.818630132534022" CI_START="0.5866398797235721" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.9920509004773091" LOG_CI_START="-0.23162841705409712" LOG_EFFECT_SIZE="0.38021124171160603" ORDER="56" O_E="0.0" SE="0.7187952884282608" STUDY_ID="STD-Solomon-1997" TOTAL_1="15" TOTAL_2="12" VAR="0.5166666666666666" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="2" I2="0.0" ID="CMP-012.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-04-29 10:03:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>1.5 mg versus 6.0 mg</NAME>
<DICH_DATA CI_END="13.146658164059165" CI_START="0.8941513420462147" EFFECT_SIZE="3.4285714285714284" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.1188153706694366" LOG_CI_START="-0.04858896727473815" LOG_EFFECT_SIZE="0.5351132016973492" ORDER="57" O_E="0.0" SE="0.6857390868530795" STUDY_ID="STD-Solomon-1997" TOTAL_1="14" TOTAL_2="12" VAR="0.4702380952380953" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="6" I2="0.0" ID="CMP-012.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-04-29 10:03:53 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>3.0 mg versus 6.0 mg</NAME>
<DICH_DATA CI_END="3.0794449407259386" CI_START="0.662722135259063" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.4884724434797983" LOG_CI_START="-0.17866852350831186" LOG_EFFECT_SIZE="0.1549019599857432" ORDER="58" O_E="0.0" SE="0.39188190640986287" STUDY_ID="STD-Solomon-1997" TOTAL_1="14" TOTAL_2="15" VAR="0.15357142857142853" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2016-04-29 10:04:59 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Fluconazole 3 weeks versus 6 weeks; 10 weeks follow-up</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="74" EVENTS_2="84" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-04-29 10:04:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="245" TOTAL_2="246" WEIGHT="0.0" Z="0.0">
<NAME>Primary outcome: complete cure, i.e. clinical and mycological cure</NAME>
<GROUP_LABEL_1>3 weeks</GROUP_LABEL_1>
<GROUP_LABEL_2>6 weeks</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 6 weeks regimen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3 weeks regimen</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1444257271020661" CI_START="0.6836838175274125" EFFECT_SIZE="0.8845481049562682" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="84" LOG_CI_END="0.05858761233916147" LOG_CI_START="-0.16514469952327906" LOG_EFFECT_SIZE="-0.0532785435920588" MODIFIED="2015-02-13 09:36:58 +0000" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.13142146748080272" STUDY_ID="STD-Foster-2005" TOTAL_1="245" TOTAL_2="246" VAR="0.017271602114807688" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-05-03 16:20:52 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-04-13 14:49:52 +0100" MODIFIED_BY="Cathy Bennett" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArcAAAK/CAYAAABzzuUaAABggklEQVR42uzdDcQV+fs/8B9JkmRJ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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-05-03 16:20:52 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-05-03 16:20:52 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVcAAARDCAIAAABTLPVlAAA2lElEQVR42u3dsY4lyXWt4QIECDLa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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-04-13 14:50:35 +0100" MODIFIED_BY="Cathy Bennett">
<APPENDIX ID="APP-01" MODIFIED="2016-04-13 14:50:35 +0100" MODIFIED_BY="Cathy Bennett" NO="1">
<TITLE MODIFIED="2016-04-13 14:50:35 +0100" MODIFIED_BY="Cathy Bennett">Cochrane Skin Group Specialized Register (CRS) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-10-16 14:02:53 +0100" MODIFIED_BY="[Empty name]">
<P>(tinea and (capitis or tonsurans)) or kerion or (ringworm near (hair or scalp or head))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-10-16 14:03:25 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-10-16 14:01:04 +0100" MODIFIED_BY="[Empty name]">CENTRAL (Cochrane Library) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-10-16 14:03:25 +0100" MODIFIED_BY="[Empty name]">
<P>#1 MeSH descriptor: [Tinea Capitis] explode all trees<BR/>#2 tinea tonsurans:ti,ab,kw<BR/>#3 (ringworm near/3 (hair or scalp or head))<BR/>#4 tinea capitis:ti,ab,kw<BR/>#5 herpes tonsurans:ti,ab,kw<BR/>#6 kerion:ti,ab,kw<BR/>#7 {or #1-#6}<BR/>#8 MeSH descriptor: [Antifungal Agents] explode all trees<BR/>#9 MeSH descriptor: [Griseofulvin] explode all trees<BR/>#10 MeSH descriptor: [Itraconazole] explode all trees<BR/>#11 MeSH descriptor: [Fluconazole] explode all trees<BR/>#12 (griseofulvin or terbinafine or itraconazole or fluconazole):ti,ab,kw<BR/>#13 {or #8-#12}<BR/>#14 #7 and #13</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2015-06-18 13:28:12 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2015-06-18 13:03:14 +0100" MODIFIED_BY="[Empty name]">MEDLINE (Ovid) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-06-18 13:28:12 +0100" MODIFIED_BY="[Empty name]">
<P>1. tinea tonsurans.mp.<BR/>2. exp Tinea Capitis/<BR/>3. (ringworm adj3 (hair or scalp or head)).mp.<BR/>4. tinea capitis.mp.<BR/>5. herpes tonsurans.mp.<BR/>6. kerion.mp.<BR/>7. or/1-6<BR/>8. Antifungal Agents/<BR/>9. Griseofulvin/<BR/>10. Itraconazole/<BR/>11. Fluconazole/<BR/>12. (griseofulvin or terbinafine or itraconazole or fluconazole).mp.<BR/>13. or/8-12<BR/>14. randomized controlled trial.pt.<BR/>15. controlled clinical trial.pt.<BR/>16. randomized.ab.<BR/>17. placebo.ab.<BR/>18. clinical trials as topic.sh.<BR/>19. randomly.ab.<BR/>20. trial.ti.<BR/>21. 14 or 15 or 16 or 17 or 18 or 19 or 20<BR/>22. exp animals/ not humans.sh.<BR/>23. 21 not 22<BR/>24. 7 and 13 and 23</P>
<P>[Lines 14-23: Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and precision-maximizing version (2008 revision)]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2015-06-18 13:03:22 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2015-06-18 13:03:22 +0100" MODIFIED_BY="[Empty name]">Embase (Ovid) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-10-16 14:04:15 +0100" MODIFIED_BY="[Empty name]">
<P>1. tinea capitis/<BR/>2. tinea tonsurans.mp.<BR/>3. (ringworm adj3 (head or hair or scalp)).mp.<BR/>4. tinea capitis.mp.<BR/>5. herpes tonsurans.mp.<BR/>6. kerion/<BR/>7. kerion.mp.<BR/>8. or/1-7<BR/>9. antifungal agent/<BR/>10. griseofulvin/<BR/>11. itraconazole/<BR/>12. fluconazole/<BR/>13. terbinafine/<BR/>14. (griseofulvin or terbinafine or itraconazole or fluconazole).mp.<BR/>15. or/9-14<BR/>16. crossover procedure.sh.<BR/>17. double-blind procedure.sh.<BR/>18. single-blind procedure.sh.<BR/>19. (crossover$ or cross over$).tw.<BR/>20. placebo$.tw.<BR/>21. (doubl$ adj blind$).tw.<BR/>22. allocat$.tw.<BR/>23. trial.ti.<BR/>24. randomized controlled trial.sh.<BR/>25. random$.tw.<BR/>26. or/16-25<BR/>27. exp animal/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/<BR/>28. human/ or normal human/<BR/>29. 27 and 28<BR/>30. 27 not 29<BR/>31. 26 not 30<BR/>32. 8 and 15 and 31</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2015-06-18 13:29:05 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2014-10-16 14:01:33 +0100" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-06-18 13:29:05 +0100" MODIFIED_BY="[Empty name]">
<P>((tinea or tina) and (capitis or tonsurans or tonsurante)) or kerion or querion or (ringworm near (hair or scalp or head))</P>
<P>These terms were combined with the Controlled clinical trials topic-specific query filter in the LILACS database.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2015-06-18 13:40:09 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2014-10-16 14:02:24 +0100" MODIFIED_BY="[Empty name]">CINAHL (EBSCO) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-06-18 13:40:09 +0100" MODIFIED_BY="[Empty name]">
<P>S1 TI ( (tinea and (capitis or tonsurans)) or kerion or (ringworm near3 (hair or scalp or head)) ) OR AB ( (tinea and (capitis or tonsurans)) or kerion or (ringworm near3 (hair or scalp or head)) )<BR/>S2 (MH "Clinical Trials+")<BR/>S3 PT clinical trial<BR/>S4 TX (clinic* n1 trial*)<BR/>S5 (MH "Random Assignment")<BR/>S6 TX random* allocat*<BR/>S7 TX placebo*<BR/>S8 (MH "Placebos")<BR/>S9 (MH "Quantitative Studies")<BR/>S10 TX allocat* random*<BR/>S11 "randomi#ed control* trial*"<BR/>S12 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )<BR/>S13 S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12<BR/>S14 S1 AND S13</P>
<P>[Lines S2-S13 are the SIGN filter for RCTs adapted for CINAHL via EBSCO].</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2015-08-06 06:01:34 +0100" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2015-08-06 05:59:25 +0100" MODIFIED_BY="[Empty name]">Trials registers search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-08-06 06:01:34 +0100" MODIFIED_BY="[Empty name]">
<P>((tinea or tina) and (capitis or tonsurans or tonsurante)) or kerion or querion or (ringworm and (hair or scalp or head))</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;17 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;TOTAL 25 studies included in qualitative synthesis&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;21 studies included in previous version of this review&lt;/p&gt;" WIDTH="140"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;4 NEW studies included&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 full-text articles assessed for eligibility&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;85 records screened&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;85 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;85 records identified through database searching (2007-2015)&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;No additional records identified through other sources&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;79 records excluded&lt;/p&gt;" WIDTH="113"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;2 full-text articles excluded because they were not RCTs&lt;/p&gt;" WIDTH="113"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>